Letter to Stockholders
Š
2015 Annual Meeting of Stockholders
Notice and Proxy Statement
Š
2014 Annual Report on Form 10-K
Dear Fellow Stockholders,
2014 was an exciting year for Ardelyx. In June, we completed an initial public offering on the NASDAQ Global
Market, raising $61.2 million in net proceeds. We also reported data from two clinical trials for tenapanor, our
lead clinical program that we licensed to AstraZeneca in October 2012. We strengthened our leadership team
with the addition of Jeremy S. Caldwell, Ph.D., our new Chief Scientific Officer, and we received a $25 million
milestone payment from AstraZeneca in connection with the development of tenapanor.
At Ardelyx, we are focused on the discovery, development and commercialization of innovative, minimally-
systemic small molecule therapeutics that work exclusively in the gastrointestinal tract. Our lead clinical program
is tenapanor, a minimally-absorbed sodium-proton exchanger (NHE3) inhibitor, which we and our partner,
AstraZeneca, have evaluated in patients with constipation-predominant irritable bowel syndrome (IBS-C),
chronic kidney disease patients on dialysis (CKD-5D) with hyperphosphatemia, and in chronic kidney disease
(CKD) patients. We have announced data from two Phase 2b clinical trials for tenapanor in patients with IBS-C
and in CKD-5D patients with hyperphosphatemia. In addition, a Phase 2a clinical trial in CKD patients is nearing
completion, and results are expected in the second quarter of 2015.
Tenapanor has been administered to over 1,000 individuals to date including 347 healthy volunteers, 417 IBS-C
patients and about 255 patients with CKD. As expected due to it pharmacological actions, the most common side
effects generally observed in all clinical trials were loose stools and diarrhea.
In October 2014, we reported data from a 371–patient double-blind placebo controlled Phase 2b clinical trial
evaluating tenapanor for the treatment of IBS-C. At the 50 mg twice daily dose, tenapanor met the primary
endpoint of an increase in the complete spontaneous bowel movement responder rate. In addition, tenapanor at
50mg twice daily also produced statistically significant effects on abdominal pain and overall responder rates.
Most secondary endpoints, including abdominal pain and other abdominal and IBS-C symptoms, demonstrated
statistically significant and clinically meaningful improvements also at 50mg twice daily.
In February 2015, we reported results from a 161-patient Phase 2b trial evaluating tenapanor in CKD-5D patients
with hyperphosphatemia. The study met the primary endpoint, with tenapanor-treated patients demonstrating a
dose-related decrease in serum phosphate levels compared to patients receiving placebo. In this trial,
discontinuation rates due to diarrhea were higher than previously observed in tenapanor trials, with the higher
rates observed primarily in the 30mg once daily and 30mg twice daily dose groups.
Current treatments for IBS-C and elevated phosphorus in CKD-5D patients are limited due to modest efficacy.
Based upon its novel mechanism of action, we believe tenapanor has the potential to offer a new treatment
paradigm for these diseases. Patients with CKD-5D, the most advanced form of CKD, may be required to
consume 10-14 oral medications daily, which is a challenge since these patients are highly fluid-restricted. We
believe that tenapanor, if approved, has the potential to have the lowest pill burden among any of the marketed
hyperphosphatemia drugs. Additionally, we believe that tenapanor may have the appropriate profile to allow its
titration in both IBS-C patients and hyperphosphatemic CKD-5D patients in order to optimize its efficacy and
minimize loose stools or diarrhea.
In February of 2014, we licensed to Sanofi our RDX002 program aimed at discovering and evaluating small
molecule inhibitors of the intestinal phosphate transporter NaP2b for the treatment of hyperphosphatemia in
CKD-5D patients. In preclinical studies, NaP2b inhibitors that we identified generated an equal or better response
rate to sevelamer, the current standard of care, but at one-tenth of the administered dose. Sanofi is responsible for
completing discovery and preclinical development, and if it exercises its option to continue the development of
the program, Sanofi will be responsible for developing and commercializing at least one NaP2b inhibitor
resulting from the program.
During 2014, our balance sheet was further strengthened by the addition of a $25 million development milestone
received from AstraZeneca and a $1.25M upfront payment received from Sanofi. Those proceeds, coupled with
the capital that we raised in our IPO, provide sufficient capital to advance and augment our own R&D clinical
programs toward IND filings. We are also looking to augment our pipeline with external opportunities that may
fit our strategy and commercialization plans.
We continue to enhance the tools that comprise our proprietary drug discovery platform. This platform enables
us to design novel drug candidates, optimize their drug properties, make them minimally systemic, and monitor
their effects in the GI tract of animals prior to testing them in humans. Part of this platform includes the Ardelyx
Primary Enterocyte and Colonocyte Culture System, or APECCS, which allows us to emulate gut tissue in a two-
dimensional miniaturized format to screen drug candidates and improve our understanding of gut physiology.
Using these tools, we discovered and are developing RDX009, a TGR5 agonist with potential applications in
inflammatory bowel disease (IBD), short bowel, and nonalcoholic steatohepatitis (NASH), and RDX013, a novel
potassium secretagogue to treat hyperkalemia (elevated serum potassium). We plan to accelerate the
development of these two programs in 2015.
In December, we strengthened our R&D clinical team with the appointment of Jeremy S. Caldwell, Ph.D., who
assumed the role of Executive Vice President, Chief Scientific Officer, replacing Dominique Charmot, Ph.D.,
who retired at year-end. Jeremy is a highly accomplished scientist and entrepreneur with a strong biology
background who has demonstrated a highly innovative approach to drug discovery that aligns well with
Ardelyx’s research goals.
As we look ahead, we expect 2015 to be another transformative year as we advance our lead programs, and
further strengthen our proprietary research efforts to build a sustainable product development pipeline. I am
incredibly lucky to be a part of such a driven, dedicated and creative team. Our passion for innovation will drive
us towards our goal to bring effective and novel treatments to transform the lives millions of patients worldwide.
We appreciate your continued support in Ardelyx, and I look forward to sharing our progress with you
throughout the year.
Sincerely,
Mike Raab
President and Chief Executive Officer
P
r
o
x
y
S
t
a
t
e
m
e
n
t
ARDELYX, INC.
34175 Ardenwood Blvd.
Suite 200
Fremont, CA 94555
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 11, 2015
To the Stockholders of Ardelyx, Inc.:
The 2015 Annual Meeting of Stockholders, or the 2015 Annual Meeting, of Ardelyx, Inc., a Delaware
corporation, or the Company, will be held on June 11, 2015 at 8:30 a.m. local time at the Company’s
headquarters at 34175 Ardenwood Blvd., Suite 200 (2nd Floor), Fremont, CA 94555 for the following purposes:
1.
2.
3.
To elect two Class I directors to hold office until the 2018 Annual Meeting of Stockholders and until
their successors are elected and qualified;
To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young LLP as
the independent registered public accounting firm of the Company for the fiscal year ending
December 31, 2015; and
To transact such other business as may properly come before the 2015 Annual Meeting or any
adjournment or postponement thereof.
The foregoing items of business are more fully described in the proxy statement accompanying this Notice of
Annual Meeting of Stockholders. Only stockholders who owned the Company’s common stock at the close of
business on April 21, 2015 may vote at the 2015 Annual Meeting or any adjournments that take place.
We have elected to provide our proxy materials to our stockholders over the internet as permitted by the rules of
the U.S. Securities and Exchange Commission. As a result, we are mailing most of our stockholders a paper copy
of the Notice of Internet Availability of Proxy Materials, or the Notice, but not a paper copy of our proxy
statement and our 2014 Annual Report to Stockholders. This process allows us to provide our proxy materials to
our stockholders in a timelier and more readily accessible manner, while reducing the environmental impact and
lowering the costs of printing and distributing our proxy materials. The Notice contains instructions on how to
access those documents over the internet. The Notice also contains instructions on how to request a paper copy of
our proxy materials, including this proxy statement, our 2014 Annual Report to Stockholders and a form of proxy
card or voting instruction card. All stockholders who have previously requested a paper copy of our proxy
materials will continue to receive a paper copy of the proxy materials by mail.
You are cordially invited to attend the 2015 Annual Meeting in person. Whether or not you plan to attend the
2015 Annual Meeting, please vote as soon as possible. You may vote over the internet or by a toll-free telephone
number. If, however, you requested to receive paper proxy materials, then you may also vote by mailing a
complete, signed and dated proxy card or voting instruction card in the envelope provided. Please note that any
stockholder attending the 2015 Annual Meeting may vote in person, even if the stockholder has already voted
over the internet or by phone or returned a proxy card or voting instruction card by mail.
Our board of directors recommends that you vote “FOR” the election of the director nominees named in
Proposal No. 1 of the proxy statement and “FOR” the ratification of the appointment of Ernst & Young LLP as
our independent registered public accounting firm as described in Proposal No. 2 of the proxy statement.
Fremont, California
April 24, 2015
By Order of the Board of Directors:
/s/ Elizabeth Grammer
Elizabeth Grammer
Vice President and General Counsel
TABLE OF CONTENTS
QUESTIONS AND ANSWERS REGARDING THESE PROXY MATERIALS AND THE VOTING
PROCESS
PROPOSAL NO. 1: ELECTION OF DIRECTORS
PROPOSAL NO. 2: RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS
CORPORATE GOVERNANCE
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
NON-EMPLOYEE DIRECTOR COMPENSATION
EXECUTIVE OFFICERS
EXECUTIVE COMPENSATION
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
ADDITIONAL INFORMATION
t
n
e
m
e
t
a
t
S
y
x
o
r
P
Page
1
6
9
10
11
16
17
19
21
28
31
31
P
r
o
x
y
S
t
a
t
e
m
e
n
t
ARDELYX, INC.
34175 Ardenwood Blvd.
Suite 200
Fremont, CA 94555
PROXY STATEMENT
FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 11, 2015
IMPORTANT NOTICE REGARDING THE INTERNET AVAILABILITY OF PROXY MATERIALS
FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 11, 2015
This proxy statement and our 2014 Annual Report to Stockholders, which includes our Annual Report on
Form 10-K for the fiscal year ended December 31, 2014, are available at our website at www.ardelyx.com and at
www.astproxyportal.com/ast/19476.
Unless the context requires otherwise, in this proxy statement the terms “Ardelyx,” “we,” “us,” “our” and “the
Company” refer to Ardelyx, Inc.
QUESTIONS AND ANSWERS REGARDING THE PROXY MATERIALS AND THE VOTING
PROCESS
Why am I receiving these proxy materials?
We have made these proxy materials available to you on the internet or, upon your request, have delivered paper
proxy materials to you, because the board of directors of Ardelyx, Inc., or the Company, is soliciting your proxy
to vote at the 2015 Annual Meeting of Stockholders, or the 2015 Annual Meeting, or any adjournments that take
place. The 2015 Annual Meeting will be held on June 11, 2015 at 8:30 a.m. local time at the Company’s
headquarters at 34175 Ardenwood Blvd., Suite 200 (2nd Floor), Fremont, CA 94555. As a stockholder, you are
invited to attend the 2015 Annual Meeting and are requested to vote on the proposals described in this proxy
statement. However, you do not need to attend the 2015 Annual Meeting to vote.
What is included in the proxy materials?
The proxy materials include:
• This proxy statement, which includes information regarding the proposals to be voted on at the 2015
Annual Meeting, the voting process, corporate governance, the compensation of our directors and
certain executive officers, and other required information;
• Our 2014 Annual Report to Stockholders, which includes our Annual Report on Form 10-K for the
fiscal year ended December 31, 2014; and
• The proxy card or a voting instruction card for the 2015 Annual Meeting.
The proxy materials are being mailed or made available to stockholders on or about April 24, 2015.
Why did I receive a Notice of Internet Availability of Proxy Materials, or the Notice, in the mail instead of
a complete set of paper proxy materials?
We have elected to provide our proxy materials to our stockholders over the internet as permitted by the rules of
the U.S. Securities and Exchange Commission, or SEC. As a result, we are mailing most of our stockholders a
paper copy of the Notice, but not a paper copy of the proxy materials. This process allows us to provide our
proxy materials to our stockholders in a timelier and more readily accessible manner, while reducing the
environmental impact and lowering the costs of printing and distributing our proxy materials. The Notice
1
t
n
e
m
e
t
a
t
S
y
x
o
r
P
contains instructions on how to access the proxy materials over the internet, and how to request a paper copy of
the proxy materials. All stockholders who have previously elected to receive a paper copy of our proxy materials
will continue to receive a paper copy of the proxy materials by mail until the stockholder terminates such
election.
Why did I receive a complete set of paper proxy materials in the mail instead of a Notice of Internet
Availability of Proxy Materials?
We are providing stockholders who have previously requested to receive paper copies of the proxy materials with
paper copies of the proxy materials instead of the Notice. If you would like to reduce the environmental impact
and the costs incurred by us in printing and distributing the proxy materials, you may elect to receive all future
proxy materials electronically via email or the internet. To sign up for electronic delivery, please follow the
instructions provided with your proxy materials and on your proxy card or voting instruction card.
Who can vote at the 2015 Annual Meeting?
Only stockholders of record at the close of business on April 21, 2015 will be entitled to vote at the 2015 Annual
Meeting. On this record date, there were 18,642,752 shares of common stock outstanding and entitled to vote.
Stockholder of Record: Shares Registered in Your Name
If, at the close of business on April 21, 2015, your shares were registered directly in your name with our transfer
agent, American Stock Transfer & Trust Company, LLC, then you are a stockholder of record. As a stockholder
of record, you may vote in person at the 2015 Annual Meeting or vote by proxy. Whether or not you plan to
attend the 2015 Annual Meeting, please vote as soon as possible by internet, telephone or by mail as instructed
below to ensure your vote is counted.
Beneficial Owner: Shares Registered in the Name of a Broker or Bank
If, at the close of business on April 21, 2015, your shares were not held in your name, but rather in an account at
a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in
“street name” and these proxy materials are being forwarded to you by that organization. The organization
holding your account is considered to be the stockholder of record for purposes of voting at the 2015 Annual
Meeting. As a beneficial owner, you have the right to direct your broker or other agent how to vote the shares in
your account. You are also invited to attend the 2015 Annual Meeting. However, because you are not the
stockholder of record, you may not vote your shares in person at the 2015 Annual Meeting unless you request
and obtain a valid proxy from your broker or other agent.
What proposals are scheduled for a vote?
There are two proposals scheduled for a vote at the 2015 Annual Meeting:
•
•
Proposal No. 1 — To elect two Class I directors to hold office until the 2018 Annual Meeting of
Stockholders and until their successors are elected and qualified; and
Proposal No. 2 — To ratify the selection, by the Audit Committee of our Board of Directors, of
Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal
year ending December 31, 2015.
How do I vote?
For Proposal No. 1, you may either vote “FOR” all nominees to the board of directors or you may
“WITHHOLD” your vote for any nominee you specify. For Proposal No. 2, you may either vote “FOR” or
“AGAINST” or you may abstain from voting.
2
P
r
o
x
y
S
t
a
t
e
m
e
n
t
The procedures for voting are as follows:
Stockholder of Record: Shares Registered in Your Name
If you are a stockholder of record, you may vote in person at the 2015 Annual Meeting or vote by internet,
telephone or by mail. Whether or not you plan to attend the 2015 Annual Meeting, please vote as soon as
possible to ensure your vote is counted. You may still attend the 2015 Annual Meeting and vote in person even if
you have already voted by proxy.
• To vote in person. You may attend the 2015 Annual Meeting and we will give you a ballot when
you arrive. If you need directions to the meeting, please visit www.ardelyx.com/contact.
• To vote by proxy by internet or telephone. If you have internet or telephone access, you may
submit your proxy by following the instructions provided in the Notice, or if you received paper
proxy materials by mail, by following the instructions provided with your proxy materials and on
your proxy card or voting instruction card.
• To vote by proxy by mail. If you received paper proxy materials, you may submit your proxy by
mail by completing and signing your proxy card and mailing it in the enclosed envelope. Your
shares will be voted as you have instructed.
Beneficial Owner: Shares Registered in the Name of Broker or Bank
If you are a beneficial owner of shares registered in the name of your broker, bank, dealer or other similar
organization, you should have received a proxy card and voting instructions with these proxy materials from that
organization rather than from us. Simply complete and mail the proxy card to ensure that your vote is counted.
Alternatively, you may vote by internet or telephone as instructed by your broker or other agent. To vote in
person at the 2015 Annual Meeting, you must obtain a valid proxy from your broker or other agent. Follow the
instructions from your broker or other agent included with these proxy materials, or contact your broker or bank
to request a proxy form.
Can I vote my shares by completing and returning the Notice?
No. The Notice will, however, provide instructions on how to vote by internet, by telephone, by requesting and
returning a paper proxy card or voting instruction card, or by submitting a ballot in person at the 2015 Annual
Meeting.
How many votes do I have?
On each matter to be voted upon, you have one vote for each share of the Company’s common stock you owned
as of April 21, 2015.
What if I return a proxy card but do not make specific choices?
If you return a signed and dated proxy card without marking any voting selections, your shares will be voted
“FOR” the election of each nominee for director (Proposal No. 1) and “FOR” the ratification of the selection of
Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year
ending December 31, 2015 (Proposal No. 2). If any other matter is properly presented at the 2015 Annual
Meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his or
her best judgment.
3
Who is paying for this proxy solicitation?
We will pay for the entire cost of soliciting proxies. In addition to these mailed proxy materials, our directors,
officers and employees may also solicit proxies in person, by telephone, or by other means of communication.
Directors, officers and employees will not be paid any additional compensation for soliciting proxies.
What does it mean if I receive more than one Notice or proxy card?
If you receive more than one Notice or proxy card, your shares are registered in more than one name or are
registered in different accounts. In order to vote all the shares you own, you must vote pursuant to the
instructions on each Notice or return each proxy card.
t
n
e
m
e
t
a
t
S
y
x
o
r
P
Can I change my vote after submitting my proxy?
Yes. You can revoke your proxy at any time before the final vote at the 2015 Annual Meeting. If you are the
stockholder of record of your shares, you may revoke your proxy in any one of three ways:
• You may submit another properly completed proxy with a later date.
• You may send a timely written notice that you are revoking your proxy to the Company’s General
Counsel at Ardelyx, Inc., 34175 Ardenwood Blvd., Suite 200, Fremont, CA 94555.
• You may attend the 2015 Annual Meeting and vote in person. Simply attending the 2015 Annual
Meeting will not, by itself, revoke your proxy.
If your shares are held by your broker or other agent, you should follow the instructions provided by your broker
or agent.
What is the quorum requirement?
A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding
at least a majority of the outstanding shares entitled to vote are present at the 2015 Annual Meeting. On the
record date, there were 18,642,752 shares outstanding and entitled to vote. Accordingly, the holders of
9,321,377 shares must be present at the 2015 Annual Meeting to have a quorum. Your shares will be counted
toward the quorum at the 2015 Annual Meeting only if you vote in person at the meeting, or you submit a valid
proxy vote.
Abstentions and broker non-votes (as described below) will be counted towards the quorum requirement. If there
is no quorum, the chairperson of the meeting or the holders of a majority of shares present and entitled to vote at
the meeting in person or represented by proxy may adjourn the 2015 Annual Meeting to another date.
How are votes counted?
Votes will be counted by the Inspector of Elections appointed for the 2015 Annual Meeting. The Inspector of
Elections will separately count “FOR,” “WITHHOLD” and broker non-votes for the election of directors
(Proposal 1) and “FOR” and “AGAINST” votes, abstentions and, if any, broker non-votes for the ratification of
the selection of Ernst & Young LLP as the independent registered accounting firm of the Company for the fiscal
year ending December 31, 2015 (Proposal 2).
If your shares are held by your broker or other agent as your nominee (that is, held beneficially in “street name”),
you will need to obtain a proxy form from the institution that holds your shares and follow the instructions
included on that form regarding how to instruct your broker or other agent to vote your shares. If you do not give
voting instructions to your broker or other agent, your broker or other agent can only vote your shares with
respect to “routine” matters (as described below).
4
What are “broker non-votes”?
If you hold shares beneficially in street name and do not provide your broker with voting instructions, your
shares may constitute “broker non-votes.” Broker non-votes occur on a matter when a broker is not permitted to
vote on that matter without instructions from the beneficial owner and instructions are not given. These matters
are referred to as “non-routine” matters. Proposal No. 1 to elect directors is a non-routine matter, but Proposal
No. 2 to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for the
Company for the fiscal year ending December 31, 2015 is a “routine” matter.
How many votes are needed to approve each proposal?
•
•
Proposal No. 1 — To elect two Class I directors to hold office until the 2018 Annual Meeting of
Stockholders and until their successors are elected and qualified. The two nominees receiving the most
“FOR” votes (from the votes of shares present in person or represented by proxy and entitled to vote
on the election of directors) will be elected. Broker non-votes will not be counted towards the vote total
for this proposal.
Proposal No. 2 — To ratify the selection of Ernst & Young LLP as the independent registered public
accounting firm of the Company for the fiscal year ending December 31, 2015. “FOR” votes from the
holders of a majority of the shares cast (excluding abstentions and broker non-votes) are required to
approve this proposal. Because Proposal No. 2 is considered a “routine” matter, no broker non-votes
are expected in connection with this proposal.
P
r
o
x
y
S
t
a
t
e
m
e
n
t
How can I find out the results of the voting at the 2015 Annual Meeting?
We will disclose final voting results in a Current Report on Form 8-K filed with the SEC within four business
days after the 2015 Annual Meeting. If final voting results are unavailable at that time, then we intend to file a
Current Report on Form 8-K to disclose preliminary voting results and file an amended Current Report on
Form 8-K within four business days after the date the final voting results are available.
When are stockholder proposals due for next year’s annual meeting?
To be considered for inclusion in the proxy materials for the 2016 Annual Meeting of Stockholders, your
proposal must be submitted in writing by January 6, 2016, to the Company’s Corporate Secretary at Ardelyx,
Inc., 34175 Ardenwood Blvd., Suite 200, Fremont, CA 94555. However, if the meeting is not held between
May 12, 2016 and July 11, 2016, then the deadline will be a reasonable time before we begin to print and mail
our proxy materials for that meeting.
If you wish to submit a proposal before the stockholders or nominate a director at the 2016 Annual Meeting of
Stockholders, but you are not requesting that your proposal or nomination be included in the proxy materials for
that meeting, then you must follow the procedures set forth in our bylaws and, among other things, notify the
Company’s Corporate Secretary in writing between February 12, 2016 and March 14, 2016. However, if the date
of the 2016 Annual Meeting of Stockholders is more than 30 days before or more than 60 days after June 11,
2016, then you must give notice not later than the 90th day prior to that meeting or, if later, the 10th day following
the day on which public disclosure of that annual meeting date is first made. You are also advised to review our
bylaws, which contain additional requirements regarding advance notice of stockholder proposals and director
nominations.
5
t
n
e
m
e
t
a
t
S
y
x
o
r
P
PROPOSAL NO. 1
ELECTION OF DIRECTORS
Our board of directors is divided into three classes. Each class consists, as nearly as possible, of one-third of the
total number of directors, and each class has a three-year term. Except as otherwise provided by law, vacancies
on the board of directors may be filled only by individuals elected by a majority of the remaining directors. A
director elected by the board of directors to fill a vacancy in a particular class, including a vacancy created by an
increase in the number of directors, shall serve for the remainder of the full term of that class and until such
director’s successor is elected and qualified, or until such director’s earlier death, resignation or removal.
Our board of directors currently consists of six directors and no vacancies, divided into the three following
classes:
• The Class I directors are Annalisa Jenkins, MMBS, MRCP and Peter Schultz, Ph.D., and their terms
will expire at the 2015 Annual Meeting;
• The Class II directors are Michael Raab and David Mott, and their terms will expire at the 2016 Annual
Meeting of Stockholders; and
• The Class III directors are Gordon Ringold, Ph.D. and Richard Rodgers, and their terms will expire at
the 2017 Annual Meeting of Stockholders.
Our current Class I directors, Annalisa Jenkins, MMBS, MRCP and Peter Schultz, Ph.D., and have been
nominated to serve as Class I directors and have agreed to stand for election. If the nominees for Class I are
elected at the 2015 Annual Meeting, then each nominee will serve for a three-year term expiring at the 2018
Annual Meeting of Stockholders, and until his or her successor is elected and qualified, or until his or her earlier
death, resignation or removal.
Our directors are elected by a plurality of the votes cast. If a choice is specified on the proxy card by a
stockholder, the shares will be voted as specified. If a choice is not specified on the proxy card, and authority to
do so is not withheld, the shares will be voted “FOR” the election of the two nominees for Class I above. If any
of the nominees becomes unavailable for election as a result of an unexpected occurrence, shares that would have
been voted for the nominee will instead be voted for the election of a substitute nominee proposed by our
management or the board of directors. Each person nominated for election has agreed to serve if elected. Our
management has no reason to believe that any nominee will be unable to serve.
The following is a brief biography and discussion of the specific attributes, qualifications, experience and skills
of each nominee for director and each director whose term will continue after the 2015 Annual Meeting. Our
board of directors and management encourage each nominee for director and each continuing director to attend
the 2015 Annual Meeting.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” EACH OF THE TWO CLASS I
NOMINEES FOR DIRECTOR.
CLASS I NOMINEES FOR DIRECTOR — To be elected for a three-year term expiring at the 2018 Annual
Meeting of Stockholders
Annalisa Jenkins, MMBS, MRCP was appointed to our board of directors in April 2015. Dr. Jenkins has served
as the Chief Executive Officer at Dimension Therapeutics, Inc., a biopharmaceutical company since September
2014. From October 2013 to March 2014, Dr. Jenkins served as Executive Vice President, head of Global
Research and Development for Merck Serono Pharmaceuticals, a biopharmaceutical company. Previously, from
September 2011 to October 2013, she served as Merck Serono’s Executive Vice President Global Development
6
and Medical, and was a member of Merck Serono’s Executive Committee. Prior to that, Dr. Jenkins pursued a
15 year career at Bristol-Myers Squibb Company, a biopharmaceutical company, where, from July 2009 to June
2011, she was a Senior Vice President and head of Global Medical Affairs at Bristol-Myers Squibb. Dr. Jenkins
is currently a committee member of the Science Board to the U.S. Food & Drug Administration, which advises
FDA leadership on complex scientific and technical issues. Dr. Jenkins is also a member of the European
Commission’s Scientific Panel for Health, a science-led expert group tasked with helping to achieve better health
and wellbeing for all. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the
University of London and subsequently trained in cardiovascular medicine in the UK National Health Service.
Earlier in her career, Dr. Jenkins served as a medical officer in the British Royal Navy. We believe Dr. Jenkins is
qualified to serve on our board of directors based on her extensive scientific background and deep industry
experience.
Peter Schultz, Ph.D. is our co-founder and has served on our board of directors since April 2010. In 1985, after
postdoctoral studies at the Massachusetts Institute of Technology, he joined the faculty of the University of
California, Berkeley, where he was Professor of Chemistry, Principal Investigator at Lawrence Berkeley National
Laboratory and an Investigator of the Howard Hughes Medical Institute. Dr. Schultz joined the faculty of Scripps in
1999, where he is currently the Scripps Professor of Chemistry. He founded and was the Institute Director of the
Genomics Institute of the Novartis Research Foundation in San Diego, CA from 1999 to 2010, and he is currently the
President of the California Institute for Biomedical Research, or Calibr, a not-for-profit biomedical research institute.
His awards include the Waterman Award of the National Science Foundation, membership in the National Academy
of Sciences and National Institute of Medicine, the 1994 Wolf Prize in Chemistry, the 2003 Paul Ehrlich Prize, and
the 2005 Arthur C. Cope Award of the American Chemical Society. Dr. Schultz received a B.S. in Chemistry and a
Ph.D. in Organic Chemistry, both from the California Institute of Technology. We believe that Dr. Schultz is
qualified to serve on our board of directors due to his extensive scientific background and deep industry experience.
P
r
o
x
y
S
t
a
t
e
m
e
n
t
CLASS II DIRECTORS — To continue in office until the 2016 Annual Meeting of Stockholders
David Mott has served on our board of directors since March 2009 and as chairman of the board of directors
since March 2014. Mr. Mott has served as a general partner of NEA since September 2008, where he leads the
healthcare investing practice. From 1992 until 2008, Mr. Mott worked at MedImmune, LLC, a biotechnology
company and subsidiary of AstraZeneca Plc, where he served in roles of increasing responsibility including Chief
Operating Officer, Chief Financial Officer, President and from 2000, Chief Executive Officer. During that time,
Mr. Mott also served as Executive Vice President of AstraZeneca Plc from June 2007 to July 2008. In 2002,
Mr. Mott founded MedImmune Ventures and chaired its investment committee through his departure from
MedImmune. Prior to joining MedImmune, he was a Vice President in the Health Care Investment Banking
Group at Smith Barney, Harris Upham & Co. Inc. where he focused on public and private equity and debt
financings as well as merger and acquisition work for biotechnology, healthcare services, and medical product
and device companies. Mr. Mott is currently Chairman of TESARO, Inc., a biopharmaceutical company, and a
director of Epizyme, Inc., a biopharmaceutical company. Mr. Mott received a B.A. in Economics and
Government from Dartmouth College. We believe that Mr. Mott is qualified to serve on our board of directors
due to his extensive experience in the life sciences industry as a senior executive, his investment experience,
strategic leadership track record and service on other boards of directors of life sciences companies.
Michael Raab has served as our President and Chief Executive Officer and a director since March 2009. From
2002 to 2009, Mr. Raab was a partner at New Enterprise Associates, or NEA, a venture capital firm, specializing in
healthcare investments focusing on the biotechnology and pharmaceutical sectors. Prior to joining NEA, Mr. Raab
spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He was
Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation, a
biotechnology company. Mr. Raab also spent two years with Genzyme’s Diagnostic products and services division.
Before Genzyme, Mr. Raab held business development and sales and marketing positions at Repligen Corporation,
a life sciences company, and Bristol-Myers Squibb Company. Mr. Raab is currently a director of Amicus
7
t
n
e
m
e
t
a
t
S
y
x
o
r
P
Therapeutics, Inc., a biopharmaceutical company. Mr. Raab currently serves as a member of the board of directors
of BayBio, a non-profit trade association serving the life science industry in Northern California, and as a member
of the Emerging Companies Section Governing Board of the Biotechnology Industry Organization. Mr. Raab
received a B.A. from DePauw University. We believe Mr. Raab is qualified to serve on our board of directors based
on his role as our President and Chief Executive Officer, his senior management experience in the life sciences
sector, his investment experience and his current and past service on other boards of directors of public companies.
CLASS III DIRECTORS — To continue in office until the 2017 Annual Meeting of Stockholders
Gordon Ringold, Ph.D. was appointed to our board of directors in June 2014. Dr. Ringold has served as the
President and CEO of Quadriga BioSciences, Inc., a biotechnology company, since January 2015. From March
2000 to December 2013, Dr. Ringold served as Chairman and Chief Executive Officer of Alavita, Inc., a
biotechnology company. From March 1995 to February 2000, Dr. Ringold served as Chief Executive Officer and
Scientific Director of Affymax Research Institute where he managed the development of novel technologies to
accelerate the pace of drug discovery. Dr. Ringold is currently also a director of Alexza Pharmaceuticals, Inc., a
pharmaceutical company. From 1997 to 2013, Dr. Ringold served as a member of the board of directors of
Maxygen, Inc., a publicly-traded biopharmaceutical company. Dr. Ringold received a Ph.D. in microbiology
from University of California, San Francisco, in the laboratory of Dr. Harold Varmus before joining the Stanford
University School of Medicine, Department of Pharmacology. Dr. Ringold also received a B.S. in biology from
the University of California, Santa Cruz. We believe that Dr. Ringold is qualified to serve on our board of
directors due to his significant industry experience, including as a chief executive officer, and service on other
boards of directors of publicly-traded life sciences companies.
Richard Rodgers has served on our board of directors since March 2014. From March 2010 until August 2013,
Mr. Rodgers was co-founder, Executive Vice President, Chief Financial Officer, Secretary and Treasurer of
TESARO, Inc., a biopharmaceutical company. Mr. Rodgers previously served as the Chief Financial Officer
from June 2009 to February 2010 of Abraxis BioScience, Inc., a biotechnology company. Prior to that,
Mr. Rodgers served as Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA, Inc.,
a biopharmaceutical company, from 2004 until its acquisition by Eisai Co. Ltd., a pharmaceutical company, in
January 2008. Mr. Rodgers has held finance and accounting positions at several private and public companies,
including Arthur Anderson & Co. Mr. Rodgers currently serves as a director of Rexahn Pharmaceuticals, Inc., a
biopharmaceutical company. Mr. Rodgers received a B.S. in Financial Accounting from St. Cloud State
University and his M.B.A. in Finance from the University of Minnesota, Carlson School of Business. We believe
that Mr. Rodgers is qualified to serve on our board of directors due to his financial background, significant
industry experience, and service on other boards of directors of publicly-traded life sciences companies.
8
PROPOSAL NO. 2
RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The audit committee of our board of directors has selected Ernst & Young LLP, or EY, as our independent
registered public accounting firm for the year ending December 31, 2015, and is seeking ratification of such
selection by our stockholders at the 2015 Annual Meeting. EY has audited our financial statements for the fiscal
years ended December 31, 2014, 2013 and 2012. Representatives of EY are expected to be present at the 2015
Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to
respond to appropriate questions.
Neither our bylaws nor other governing documents or law require stockholder ratification of the selection of EY as
our independent registered public accounting firm. However, the audit committee is submitting the selection of EY
to our stockholders for ratification as a matter of good corporate practice. If our stockholders fail to ratify the
selection, the audit committee will reconsider whether or not to retain EY. Even if the selection is ratified, the audit
committee in its discretion may select a different independent registered public accounting firm at any time during
the year if they determine that such a change would be in the best interests of the Company and our stockholders.
The affirmative vote of a majority of the shares cast at the 2015 Annual Meeting will be required to ratify the
selection of EY.
THE BOARD OF DIRECTORS RECOMMENDS
A VOTE “FOR” PROPOSAL NO. 2.
For the fiscal years ended December 31, 2014 and 2013, EY billed the approximate fees set forth below. All fees
included below were approved by the audit committee.
P
r
o
x
y
S
t
a
t
e
m
e
n
t
Year Ended December 31,
2014
2013
Audit Fees(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . .
Audit-Related Fees(2)
Tax Fees(3)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
All Other Fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$1,377,232
—
35,500
—
$369,774
—
—
—
Total All Fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$1,412,732
$369,744
(1) This category consists of fees for professional services rendered for the audit of our financial statements,
review of interim financial statements, assistance with registration statements filed with the SEC and
services that are normally provided by EY in connection with statutory and regulatory filings or
engagements. Related to the years ended December 31, 2014 and 2013, fees of $879,982 and $0,
respectively were billed in connection with the filing of our Registration Statements on Form S-1 in
connection with the initial public offering of our common stock, or IPO.
(2) This category consists of fees for assurance and related services reasonably related to the performance of the
audit or review of financial statements and that are not reported under the Audit Fees category. We did not
incur any fees in this category in the years ended December 31, 2014 or 2013.
(3) This category consists of fees for professional services rendered for tax compliance, tax advice and tax
planning.
Pre-Approval Policies and Procedures
The audit committee has adopted a policy for the pre-approval of all audit and non-audit services to be performed
for the Company by the independent registered public accounting firm. This policy is set forth in the charter of
the audit committee and available at http://ir.ardelyx.com /corporate-governance.cfm. The audit committee has
considered the role of EY in providing audit and audit-related services to the Company and has concluded that
such services are compatible with EY’s role as the Company’s independent registered public accounting firm.
9
REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS
The material in this report is not “soliciting material,” is not deemed “filed” with the SEC, and is not to be
incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended.
The primary purpose of the audit committee is to oversee our financial reporting processes on behalf of our board
of directors. The audit committee’s functions are more fully described in its charter, which is available on our
website at http://ir.ardelyx.com /corporate-governance.cfm.
In fulfilling its oversight responsibilities, the audit committee reviewed and discussed with management the
Company’s audited financial statements for the fiscal year ended December 31, 2014. The audit committee has
discussed with EY, the Company’s independent registered public accounting firm, the matters required to be
discussed by Auditing Standard No. 16, “Communications with Audit Committees,” issued by the Public
Company Accounting Oversight Board, or PCAOB. In addition, the audit committee has discussed with EY their
independence, and received from EY the written disclosures and the letter required by Ethics and Independence
Rule 3526 of the PCAOB. Finally, the audit committee discussed with EY, with and without management
present, the scope and results of EY’s audit of the financial statements for the fiscal year ended December 31,
2014.
Based on these reviews and discussions, the audit committee has recommended to our board of directors that
such audited financial statements be included in our Annual Report on Form 10-K for the year ended
December 31, 2014 for filing with the SEC.
t
n
e
m
e
t
a
t
S
y
x
o
r
P
Audit Committee
Richard Rodgers
David Mott
Gordon Ringold, Ph.D.
10
CORPORATE GOVERNANCE
Board Composition
Director Independence
Our board of directors currently consists of six members. Our board of directors has determined that all of our
directors, as well as each individual nominated by our board of directors for election to our board of directors at
the 2015 Annual Meeting, other than Mr. Raab, qualify as “independent” directors in accordance with the
NASDAQ listing requirements. Mr. Raab is not considered independent because he is an employee of our
company.
The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and
has not been for at least three years, one of our employees and that neither the director nor any of his family
members has engaged in various types of business dealings with us. In addition, as required by NASDAQ rules,
our board of directors has made a subjective determination as to each independent director and director nominee
that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of
independent judgment in carrying out the responsibilities of a director. In making these determinations, our board
of directors reviewed and discussed information provided by the directors and us with regard to each director’s
and each nominee’s business and personal activities and relationships as they may relate to us and our
management. There are no family relationships among any of our directors, nominees for election to our board of
directors or our executive officers.
P
r
o
x
y
S
t
a
t
e
m
e
n
t
As described more fully below, the board of directors has also determined that each current member of the
compensation committee, the audit committee and the nominating and corporate governance committee, as well
as each director and director nominee that we expect to serve on such committees after the 2015 Annual Meeting,
meets the independence standards applicable to those committees prescribed by NASDAQ, the SEC, and the
Internal Revenue Service.
Classified Board of Directors
In accordance with our amended and restated certificate of incorporation, our board of directors is divided into
three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors
whose terms then expire will be elected to serve from the time of election and qualification until the third annual
meeting following election.
Leadership Structure of the Board
Our amended and restated bylaws and corporate governance guidelines provide our board of directors with
flexibility to combine or separate the positions of Chairman of the Board and Chief Executive Officer and/or the
implementation of a lead director in accordance with its determination that utilizing one or the other structure
would be in the best interests of our company. Mr. Mott currently serves as the Chairman of the Board. In that
role, Mr. Mott presides over the executive sessions of the board of directors in which Mr. Raab does not
participate and serves as a liaison to Mr. Raab and management on behalf of the board of directors.
Our board of directors has concluded that our current leadership structure is appropriate at this time. However,
our board of directors will continue to periodically review our leadership structure and may make such changes
in the future as it deems appropriate.
Role of Board in Risk Oversight Process
Risk assessment and oversight are an integral part of our governance and management processes. Our board of
directors encourages management to promote a culture that incorporates risk management into our corporate
11
t
n
e
m
e
t
a
t
S
y
x
o
r
P
strategy and day-to-day business operations. Management discusses strategic and operational risks at regular
management meetings, and conducts specific strategic planning and review sessions during the year that include
a focused discussion and analysis of the risks facing us. Throughout the year, senior management reviews these
risks with the board of directors at regular board meetings as part of management presentations that focus on
particular business functions, operations or strategies, and presents the steps taken by management to mitigate or
eliminate such risks.
Our board of directors does not have a standing risk management committee, but rather administers this oversight
function directly through our board of directors as a whole, as well as through various standing committees of
our board of directors that address risks inherent in their respective areas of oversight. In particular, our board of
directors is responsible for monitoring and assessing strategic risk exposure and our audit committee is
responsible for overseeing our major financial risk exposures and the steps our management has taken to monitor
and control these exposures. The audit committee also monitors compliance with legal and regulatory
requirements. Our nominating and corporate governance committee monitors the effectiveness of our corporate
governance guidelines and considers and approves or disapproves any related-persons transactions. Our
compensation committee assesses and monitors whether any of our compensation policies and programs has the
potential to encourage excessive risk-taking.
Meetings of the Board of Directors and Committees
During 2014, the board of directors met 12 times, the audit committee met 2 times and the compensation
committee met 2 times. In that year, each current director attended at least 75% of the meetings of the board of
directors and the committees on which he served. In addition, one former director, Dr. Jean Frechet, who
resigned from our board of directors in March 2014 prior to the completion of our initial public offering in June
2014, attended one of the two board meetings held during the time he served on our board of directors from
January 2014 through March 2014. As required under NASDAQ rules and regulations, our independent directors
meet in regularly scheduled executive sessions at which only independent directors are present.
Board Committees
Audit Committee
Our audit committee oversees our corporate accounting and financial reporting process. Among other matters,
the audit committee:
•
•
•
•
•
•
appoints our independent registered public accounting firm;
evaluates the independent registered public accounting firm’s qualifications, independence and
performance;
determines the engagement of the independent registered public accounting firm;
reviews and approves the scope of the annual audit and the audit fee;
discusses with management and the independent registered public accounting firm the results of the
annual audit and the review of our quarterly financial statements;
approves the retention of the independent registered public accounting firm to perform any proposed
permissible audit and non-audit services;
• monitors the rotation of partners of the independent registered public accounting firm on our
engagement team as required by law;
•
is responsible for reviewing our consolidated financial statements and our management’s discussion
and analysis of financial condition and results of operations to be included in our annual and quarterly
reports to be filed with the SEC;
12
P
r
o
x
y
S
t
a
t
e
m
e
n
t
•
•
reviews our critical accounting policies and estimates; and
reviews the audit committee charter and the committee’s performance.
The current members of our audit committee are Messrs. Mott and Rodgers and Dr. Ringold. Mr. Rodgers serves
as the chairperson of the committee. After the 2015 Annual Meeting, we expect that our audit committee will be
composed of Mr. Rodgers, as chairman, Mr. Mott and Dr. Ringold.
Each of the current members of our audit committee, as well as the expected members of our audit committee
after the 2015 Annual Meeting, meets or will meet the requirements for financial literacy under the applicable
rules and regulations of the SEC and NASDAQ. Our board of directors has determined that Mr. Rodgers is an
audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial
sophistication as defined under the applicable rules and regulations of NASDAQ. Under the rules of the SEC,
members of the audit committee must also meet heightened independence standards. Our board of directors has
determined that each of Messrs. Mott and Rodgers and Dr. Ringold are independent under the heightened
independence standards under the applicable rules of NASDAQ. Our audit committee has been established in
accordance with the rules and regulations of the Exchange Act. The audit committee operates under a written
charter that satisfies the applicable standards of the SEC and NASDAQ. A copy of the audit committee charter is
available to security holders on the Company’s website at http://ir.ardelyx.com /corporate-governance.cfm.
Compensation Committee
Our compensation committee reviews and recommends policies relating to compensation and benefits of our
officers and employees. The compensation committee reviews and approves corporate goals and objectives
relevant to compensation of our Chief Executive Officer and other executive officers, evaluates the performance
of these officers in light of those goals and objectives, and sets the compensation of these officers, other than the
Chief Executive Officer, based on such evaluations. The board of directors retains the authority to determine and
approve, upon the recommendation of the compensation committee, the compensation of the Chief Executive
Officer, unless such authority has been delegated to the compensation committee. Our executive officers submit
proposals to the board of director and compensation committee regarding our executive and director
compensation. The compensation committee also approves grants of stock options and other awards under our
stock plans. The compensation committee has delegated authority to the Chief Executive Officer to grant stock
options to purchase shares of common stock to existing and new non-senior management team employees, with
such individual grants to be consistent with equity grant guidelines provided by our compensation consultant and
approved by the compensation committee and with the aggregate number of shares of common stock eligible for
purchase upon the exercise of stock options granted under this delegation to be no more than 65,000 shares. The
compensation committee will review and evaluate, at least annually, the performance of the compensation
committee and its members, including compliance of the compensation committee with its charter. The current
members of our compensation committee are Messrs. Mott and Rodgers and Dr. Schultz. Mr. Mott serves as the
chairman of the committee. After the 2015 Annual Meeting, and subject to election by our stockholders in the
case of Dr. Schultz, we expect that our compensation committee will be composed of Mr. Mott, as chairman,
Mr. Rodgers and Dr. Schultz.
Each of the current members of our compensation committee, as well as the expected members of our
compensation committee after the 2015 Annual Meeting, is or will be an independent under the applicable rules
and regulations of The NASDAQ Global Market, is or will be a “non-employee director” as defined in
Rule 16b-3 promulgated under the Exchange Act and is or will be an “outside director” as that term is defined in
Section 162(m) of the U.S. Internal Revenue Code of 1986, as amended, or Section 162(m). The compensation
committee operates under a written charter that satisfies the applicable standards of the SEC and NASDAQ. A
copy of the compensation committee charter is available to security holders on the Company’s website at
http://ir.ardelyx.com /corporate-governance.cfm.
13
t
n
e
m
e
t
a
t
S
y
x
o
r
P
For fiscal year 2014, the compensation committee retained Compensia, Inc., or Compensia, a national executive
compensation consulting firm, to conduct market research and analysis on our various executive positions, to
assist the committee in developing appropriate incentive plans for our executives on an annual basis, to provide
the committee with advice and ongoing recommendations regarding material executive compensation decisions,
and to review compensation proposals of management. In compliance with the disclosure requirements of the
SEC regarding the independence of compensation consultants, Compensia addressed each of the six
independence factors established by the SEC with the compensation committee. Its responses affirmed the
independence of Compensia on executive compensation matters. Based on this assessment, the compensation
committee determined that the engagement of Compensia did not raise any conflicts of interest or similar
concerns. The compensation committee also evaluated the independence of other outside advisors to the
compensation committee, including outside legal counsel, considering the same independence factors and
concluded their work for the compensation committee does not raise any conflicts of interest.
Nominating and Corporate Governance Committee
The nominating and corporate governance committee is responsible for making recommendations to our board of
directors regarding candidates for directorships and the size and composition of our board of directors. In
addition, the nominating and corporate governance committee is responsible for overseeing our corporate
governance policies and reporting and making recommendations to our board of directors concerning governance
matters. The current members of our nominating and corporate governance committee are Dr. Ringold and
Mr. Rodgers. Dr. Ringold serves as the chairman of the committee. After the 2015 Annual Meeting, we expect
that our nominating and corporate governance committee will be composed of Dr. Ringold, as chairman,
Dr. Jenkins and Mr. Rodgers.
Each of the current members of our nominating and corporate governance committee, as well as the expected
members of our nominating and corporate governance committee after the 2015 Annual Meeting, is or will be an
“independent director” under the applicable rules and regulations of NASDAQ relating to nominating and
corporate governance committee independence. Following the 2015 Annual Meeting, we will continue to comply
with NASDAQ’s rules regarding independent director oversight of director nominations under either NASDAQ
Rule 5605(e)(1)(A) or 5605(e)(1)(B). The nominating and corporate governance committee operates under a
written charter that satisfies the applicable standards of the SEC and NASDAQ. A copy of the nominating and
corporate governance committee charter is available to security holders on the Company’s website at
http://ir.ardelyx.com /corporate-governance.cfm.
Dr. Jenkins was recommended to our board of directors and our nominating and corporate governance committee
by our chief executive officer and by certain of our other existing directors.
Board Diversity
Our nominating and corporate governance committee is responsible for reviewing with the board of directors, on
an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a
whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and
current members), the nominating and corporate governance committee, in recommending candidates for
election, and the board of directors, in approving (and, in the case of vacancies, appointing) such candidates, will
take into account many factors, including the following:
•
•
•
•
personal and professional integrity;
ethics and values;
experience in corporate management, such as serving as an officer or former officer of a publicly held
company;
experience in the industries in which we compete;
14
•
•
•
•
experience as a board member or executive officer of another publicly held company;
diversity of expertise and experience in substantive matters pertaining to our business relative to other
board members;
conflicts of interest; and
practical and mature business judgment.
Currently, our board of directors evaluates each individual in the context of the board of directors as a whole,
with the objective of assembling a group that can best maximize the success of the business and represent
stockholder interests through the exercise of sound judgment using its diversity of experience in these various
areas.
Code of Business Conduct and Ethics
We have adopted a code of business conduct and ethics that applies to all of our employees, officers and
directors, including those officers responsible for financial reporting. The code of business conduct and ethics is
available on our website at http://ir.ardelyx.com/corporate-governance.cfm. We expect that any substantive
amendments to the code, or any waivers of its requirements, will be disclosed on our website. The reference to
our web address does not constitute incorporation by reference of the information contained at or available
through our website.
P
r
o
x
y
S
t
a
t
e
m
e
n
t
Director Attendance at Annual Meetings
Our board of directors has a policy of encouraging director attendance at our annual meetings of stockholders,
but attendance is not mandatory. Our board of directors and management team encourage all of our directors to
attend the 2015 Annual Meeting.
Stockholder Communications with the Board of Directors
A stockholder may communicate with the board of directors, or an individual director, by sending written
correspondence to the Company’s General Counsel at Ardelyx, Inc., 34175 Ardenwood Blvd., Fremont, CA
94555. The General Counsel will review such correspondence and forward it to the board of directors, or an
individual director, as appropriate.
Compensation Committee Interlocks and Insider Participation
Until March 2014, our compensation committee consisted of Drs. David Collier, Jean Frechet and Peter Schultz
and Mr. Mott. Mr. Mott served as chairman of the compensation committee. In March 2014, Drs. Collier and
Frechet resigned from our board of directors and Mr. Rodgers joined our board of directors and the compensation
committee. In addition to Mr. Rodgers, Dr. Schultz and Mr. Mott continued to serve on the compensation
committee, with Mr. Mott continuing to serve as chairman. None of the members of our compensation committee
has at any time been one of our officers or employees. None of our executive officers currently serves, or in the
past fiscal year has served, as a member of the board of directors or compensation committee of any entity that
has one or more executive officers on our board of directors or compensation committee.
15
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
The following is a description of transactions since January 1, 2014 to which we have been a party, in which the amount
involved exceeds $120,000, and in which any of our directors, executive officers or holders of more than 5% of our
capital stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest.
Sales and Purchases of Securities
Participation in our IPO
t
n
e
m
e
t
a
t
S
y
x
o
r
P
In connection with our IPO, the underwriters allocated an aggregate of 888,053 shares of our common stock in the
offering to certain of our principal stockholders and/or affiliates on the same terms as the other shares that were offered
and sold in our IPO. These allocations included allocations to the following owners of more than 5% of a class of our
capital stock: 510,442 shares to New Enterprise Associates 12, Limited Partnership; 308,905 shares to CMEA
Ventures II, LP; 7,921 shares to CMEA Ventures II (Parallel), LP; and 60,785 shares to Amgen Ventures LLC. All of
the shares allocated to our principal stockholders and/or affiliates were sold at $14.00, which was the IPO price.
Consulting Agreement with Dr. Susan Rosenbaum
In November 2012, we entered into a consulting agreement with Susan Rosenbaum, Ph.D., the wife of David
Rosenbaum, Ph.D, our Vice President, Drug Development. Dr. Susan Rosenbaum provides clinical operation
services to us, and she is compensated at a rate of $125 per hour for her services. For the year ended
December 31, 2014, Dr. Susan Rosenbaum was a paid a total of $229,000 for her services pursuant to the
consulting agreement. On January 5, 2015, Dr. Susan Rosenbaum became an employee of the Company.
Indemnification Agreements and Directors’ and Officers’ Liability Insurance
We have entered into indemnification agreements with each of our directors and executive officers. These
agreements, among other things, require us to indemnify each director and executive officer to the fullest extent
permitted by Delaware law, including indemnification of expenses such as attorneys’ fees, judgments, penalties
fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any
action or proceeding by or in right of us, arising out of the person’s services as a director or executive officer.
Investor Rights Agreement
We entered into an amended and restated investor rights agreement with the purchasers of our outstanding
convertible preferred stock and certain holders of common stock and warrants to purchase our convertible
preferred stock, including entities with which certain of our directors are affiliated. As of March 31, 2015, the
holders of approximately 9.7 million shares of our common stock are entitled to rights pursuant to the amended
and restated investor rights agreement to the registration of their shares under the Securities Act.
Policies and Procedures for Related Party Transactions
Our board of directors has adopted a written related person transaction policy setting forth the policies and
procedures for the review and approval or ratification of related person transactions. This policy covers, with
certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act of 1933, any transaction,
arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were
or are to be a participant, where the amount involved exceeds $120,000 and a related person had or will have a
direct or indirect material interest, including, without limitation, purchases of goods or services by or from the
related person or entities in which the related person has a material interest, indebtedness, guarantees of
indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our
audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether
the transaction is on terms comparable to those that could be obtained in an arm’s length transaction with an
unrelated third party and the extent of the related person’s interest in the transaction.
16
NON-EMPLOYEE DIRECTOR COMPENSATION
In May 2014, our board of directors approved a compensation policy for our non-employee directors, or the
Director Compensation Program. Pursuant to the Director Compensation Program, we do not pay director fees to
directors who are employees and our non-employee directors receive cash compensation as follows:
• Each non-employee director receives an annual cash retainer in the amount of $35,000 per year.
• The non-employee Chairman of the Board receives an additional annual cash retainer in the amount of
$25,000 per year.
• The chairperson of the audit committee receives additional annual cash compensation in the amount of
$20,000 per year for such chairperson’s service on the audit committee. Each non-chairperson member
of the audit committee receives additional annual cash compensation in the amount of $10,000 per year
for such member’s service on the audit committee.
• The chairperson of the compensation committee receives additional annual cash compensation in the
amount of $15,000 per year for such chairperson’s service on the compensation committee. Each non-
chairperson member of the compensation committee receives additional annual cash compensation in
the amount of $7,500 per year for such member’s service on the compensation committee.
• The chairperson of the nominating and corporate governance committee receives additional annual
cash compensation in the amount of $8,000 per year for such chairperson’s service on the nominating
and corporate governance committee. Each non-chairperson member of the nominating and corporate
governance committee receives additional annual cash compensation in the amount of $4,000 per year
for such member’s service on the nominating and corporate governance committee.
P
r
o
x
y
S
t
a
t
e
m
e
n
t
In lieu of a cash retainer, each non-employee director will also have the ability to elect to receive a stock award
consisting of that number of fully vested shares of common stock calculated by dividing the amount of the cash
retainer by the fair market value of the common stock on the date of our annual meeting of stockholders.
Members of our board of directors are also reimbursed for reasonable travel and other out-of-pocket expenses.
Under the Director Compensation Program, each non-employee director is automatically granted an option to
purchase 25,000 shares of our common stock upon initial appointment or election to our board of directors. In
addition, each continuing non-employee director who has been serving on our board of directors for at least six
months as of the date of any annual meeting of our stockholders and will continue to serve as a non-employee
director immediately following such meeting is automatically granted an option to purchase 15,000 shares of our
common stock on the date of each annual stockholders meeting. Each initial non-employee director stock option
vests with respect to 1/36th of the shares on each monthly anniversary of the grant date, subject to the non-
employee director’s continued service on our board of directors through such date. Each annual stock option
granted to our non-employee directors, vests with respect to 1/12th of the shares on each monthly anniversary of
the grant date, subject to acceleration in full immediately prior to the next annual stockholders meeting, subject
to the non-employee director’s continued service on our board of directors through such date. The Director
Compensation Program also provides that upon a “Change in Control” of Ardelyx (as defined in our equity
incentive plan), all outstanding equity awards granted under an equity incentive plan maintained by Ardelyx that
are held by a non-employee director will become fully vested and/or exercisable.
17
2014 Director Compensation Table
The following table sets forth information for the year ended December 31, 2014 regarding the compensation
awarded to, earned by or paid to our non-employee directors:
Name
David Mott
Gordon Ringold, Ph.D.
Richard Rodgers
Peter Schultz, Ph.D.
Fees Earned
or Paid in
Cash ($)
85,000
53,000
72,664(2)
42,500
Option
Awards(1) ($)
All Other
Compensation ($)
—
329,496
329,496
—
—
—
—
—
Total ($)
85,000
382,496
402,160
42,500
t
n
e
m
e
t
a
t
S
y
x
o
r
P
(1) The amounts reported in the Option Awards column represent the grant date fair value of the stock options
granted to the non-employee members of our board of directors during 2014 as computed in accordance
with ASC 718. The assumptions used in calculating the grant date fair value of the stock option reported in
the Option Awards column are set forth in Note 8 to the audited financial statements included in our Annual
Report on Form 10-K filed on March 5, 2015. The amounts reported in this column exclude the impact of
estimated forfeitures related to service-based vesting provisions. Note that amounts reported in this column
reflect the accounting for cost for these stock options, and do not correspond to the actual economic value
that may be received by the directors from the options.
Includes $6,164 paid to Mr. Rodgers in connection with his service as a member of our board of directors
prior to our IPO.
(2)
As of December 31, 2014, each of our non-employee directors held the following outstanding options:
Name
Gordon Ringold, Ph.D.
Richard Rodgers
Shares Subject to
Outstanding
Options
30,000
30,000
18
The following table sets forth information regarding our executive officers as of March 31, 2015.
EXECUTIVE OFFICERS
Name
Michael Raab
Jeremy Caldwell, Ph.D.
Mark Kaufmann
David Rosenbaum, Ph.D.
Elizabeth Grammer, Esq.
Age
Position(s)
50
President, Chief Executive Officer and Director
46 Executive Vice President and Chief Scientific Officer
47 Chief Financial Officer
54
51 Vice President and General Counsel
Senior Vice President, Drug Development
Michael Raab has served as our President and Chief Executive Officer and a director since March 2009. From
2002 to 2009, Mr. Raab was a partner at New Enterprise Associates, or NEA, a venture capital firm, specializing
in healthcare investments focusing on the biotechnology and pharmaceutical sectors. Prior to joining NEA,
Mr. Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical
industries. He was Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme
Corporation, a biotechnology company. Mr. Raab also spent two years with Genzyme’s Diagnostic products and
services division. Before Genzyme, Mr. Raab held business development and sales and marketing positions at
Repligen Corporation, a life sciences company, and Bristol-Myers Squibb Company, a biopharmaceutical
company. Mr. Raab received a B.A. from DePauw University.
P
r
o
x
y
S
t
a
t
e
m
e
n
t
Jeremy Caldwell, Ph.D., has served as our Chief Scientific Officer since December 2014. From January 2014 to
November 2014, Dr. Caldwell was an Entrepreneur-in-Residence at Third Rock Ventures focusing on the
formation and development of life science companies. Prior to joining Third Rock, Dr. Caldwell served as Vice
President, Head of RNA Therapeutics, Lead Discovery and Protein Sciences for Merck Research Laboratories, or
Merck, from November 2008 to November 2013. Prior to joining Merck, he was the Executive Director of
Molecular and Cellular Biology, Lead Discovery and Genomics at the Genomics Institute of the Novartis
Research Foundation, or GNF. Additionally, he was Chairman and Head of GNF’s Technology and Early
Research Committee, in which he was responsible for the novel target and new technology portfolio. Prior to
that, he was one of the first scientists at the biopharmaceutical company Rigel Inc. Dr. Caldwell received a B.S.
in Molecular and Cellular Biology from the University of California at Berkeley and a Ph.D. in Molecular
Pharmacology from Stanford University.
Mark Kaufmann has served as our Chief Financial Officer since May 2014 and formerly served as our Chief
Business Officer from August 2011 until May 2014. Mr. Kaufmann has over 20 years of experience in the
biopharmaceutical industry in both the U.S. and Canada in business and corporate development roles. From 2008
to 2010, Mr. Kaufmann was President and Chief Executive Officer of Allostera Pharma Inc., a preclinical
company focused on autoimmune diseases. Prior to joining Allostera, Mr. Kaufmann was President and Chief
Executive Officer of Celmed BioSciences, Inc., a biopharmaceutical company, and he started his career as
Director of Strategic Planning and Investor Relations at MedImmune in 1994. Mr. Kaufmann received a B.A. in
Biochemical Sciences from Harvard University and a M.B.A. from the University of Michigan School of
Business.
David Rosenbaum, Ph.D., has served as our Vice President of Drug Development since January 2010.
Dr. Rosenbaum has spent the past 20 years developing novel drugs for global registration. From 2003 to 2008, he
was Vice President of Drug Development for Trine Pharmaceuticals, Inc., a biopharmaceutical company, where
he was developing a novel non-systemic therapeutic for the treatment of IBS. In addition, Dr. Rosenbaum
previously served as Vice President of Preclinical Research and Development at GelTex Pharmaceuticals, a
biopharmaceutical company, where he was responsible for the preclinical development of Renagel and Welchol.
He received a B.A. in Biology from the University of Pennsylvania, a M.S. in Toxicology from Albany Medical
College and a Ph.D. in Pharmacology from Boston University School of Medicine.
19
Elizabeth Grammer, Esq., has served as our Vice President responsible for legal affairs since December 2012,
after serving as an independent outside corporate counsel for Ardelyx for three years. In May 2014,
Ms. Grammer was appointed as our Vice President, General Counsel. Ms. Grammer has over 20 years of
experience representing privately held and publicly traded life sciences companies. Prior to joining Ardelyx,
from 2001 to 2006, Ms. Grammer served as Vice President and General Counsel of Trine Pharmaceuticals, Inc.,
a biopharmaceutical company. In addition, Ms. Grammer previously served as independent outside corporate
counsel to GelTex Pharmaceuticals, a biopharmaceutical company. Ms. Grammer received a B.A. from Boston
University and a J.D. from Stanford Law School.
t
n
e
m
e
t
a
t
S
y
x
o
r
P
20
EXECUTIVE COMPENSATION
The following is a discussion and analysis of compensation arrangements of our named executive officers, or
NEOs. This discussion contains forward-looking statements that are based on our current plans, considerations,
expectations and determinations regarding future compensation programs. Actual compensation programs that
we adopt may differ materially from currently planned programs as summarized in this discussion. As an
“emerging growth company” as defined in the Jumpstart our Business Startups Act of 2012 we are not required
to include a Compensation Discussion and Analysis section and have elected to comply with the scaled
disclosure requirements applicable to emerging growth companies.
Our compensation committee, appointed by our board of directors, is responsible for establishing, implementing
and monitoring our compensation philosophy and objectives. We seek to ensure that the total compensation paid
to our executive officers is reasonable and competitive. Compensation of our executives is structured around the
achievement of individual performance and near-term corporate targets as well as long-term business objectives.
Our NEOs for fiscal year 2014 were as follows:
• Michael Raab, President and Chief Executive Officer;
•
Jeremy Caldwell, Ph.D., Executive Vice President and Chief Scientific Officer;
• Mark Kaufmann, Chief Financial Officer; and
• Dominique Charmot, former Chief Scientific Officer.
Dr. Charmot resigned as Chief Scientific Officer and a member of our board of directors, effective December 23,
2014. In connection with Dr. Charmot’s resignation, Dr. Caldwell was hired as our Executive Vice President,
Research effective December 1, 2014.
2014 Summary Compensation Table
The following table shows information regarding the compensation of our NEOs for services performed in the
year ended December 31, 2014.
P
r
o
x
y
S
t
a
t
e
m
e
n
t
Name and Principal Position
Year
Salary
($)
Bonus
($)(1)
Stock
Awards
($)(2)
Option
Awards
($)(3)
Non-Equity
Incentive Plan
Compensation
($)(4)
All Other
Compensation
($)(5)
2014 426,708
2013
39,338
—
—
—
— 130,662
57,449
—
—
—
Total ($)
596,708
473,749
2014
32,083 100,000
— 2,196,162
—
— 2,328,245
Michael Raab
President and Chief
Executive Officer
Jeremy Caldwell, Ph.D.
Executive Vice
President and Chief
Scientific Officer
Mark Kaufmann
2014 281,875
37,068
—
Chief Financial Officer
Dominique Charmot, Ph.D.
Former Chief
Scientific Officer
2014 311,130
2013 310,000
— 835,886
—
—
—
—
—
86,292
—
405,235
—
33,325
512,048
—
1,659,064
343,325
(1) The amount reported in the Bonus column for Dr. Caldwell represents a $100,000 signing bonus paid to
Dr. Caldwell, which signing bonus is subject to reimbursement in the event that Dr. Caldwell terminates his
employment without good reason, or we terminate his employment for cause, in either case before the first
21
t
n
e
m
e
t
a
t
S
y
x
o
r
P
anniversary of the commencement of his employment with us (100% to be reimbursed) or during the period
between the first and second anniversaries of the commencement of his employment (50% to be
reimbursed). Please see the description of Dr. Caldwell’s Change in Control Severance Agreement in
“— Narrative to 2014 Summary Compensation Table and Outstanding Equity Awards at 2014 Fiscal Year-
End — Terms and Conditions of Employee Arrangements with our NEOs” below. The amounts reported in
the Bonus column for Messrs. Raab and Kaufmann represents discretionary amounts paid to each executive
as the result of exceptional performance outside of the pre-established goals for our annual cash
performance-based bonus program. Please see the description of annual performance bonuses paid to our
NEOs in “— Narrative to 2014 Summary Compensation Table and Outstanding Equity Awards at 2014
Fiscal Year-End — Terms and Conditions of Annual Bonuses” below.
(2) Pursuant to his transition and separation agreement, 58,969 shares of common stock held by Dr. Charmot
pursuant to the early exercise of unvested options, vested and were released from our right of repurchase as
a result of Dr. Charmot’s separation on December 23, 2014. The amount reported for Dr. Charmot in the
Stock Awards column for 2014 includes the incremental fair value of the modified award, as computed in
accordance with ASC 718, which is the fair value at the date of modification minus the fair value of the
original award at the date of modification. See Note 8 to the audited financial statements included in our
Annual Report on Form 10-K filed on March 5, 2015. The amounts reported in this column exclude the
impact of forfeitures related to service-based vesting conditions. Note that the amount reported in this
column reflect the accounting cost for the stock award modification and do not correspond to the actual
economic value that may be received by Dr. Charmot from the stock award modification.
(3) The amount reported in the Option Awards column represents the grant date fair value of the stock options
granted to our NEOs during 2013 and 2014 as computed in accordance with ASC 718. The assumptions
used in calculating the grant date fair value of the stock options granted in 2014 reported in the Options
Column are set forth in Note 8 to the audited financial statements included in our Annual Report on Form
10-K filed on March 5, 2015. The amounts reported in this column exclude the impact of forfeitures related
to service-based vesting conditions. Note that the amounts reported in this column reflect the accounting
cost for these stock options and do not correspond to the actual economic value that may be received by the
NEOs from the options.
(4) The amounts reported in the Non-Equity Incentive Plan Compensation column represent the annual cash
performance-based bonuses earned by our NEOs pursuant to the achievement of certain company and
individual performance objectives. The amounts earned in 2014 were paid to our named executive officers
in January 2015. Drs. Charmot and Caldwell were not eligible to receive performance bonuses for 2014
because Dr. Charmot was no longer providing services to us through the end of 2014 as he resigned his
employment in December 2014 and Dr. Caldwell commenced employment with us in December 2104.
Please see the description of the annual performance bonuses paid to our NEOs in “— Narrative to 2014
Summary Compensation Table and Outstanding Equity Awards at 2014 Fiscal Year-End — Terms and
Conditions of Annual Bonuses” below.
(5) The amount reported in the All Other Compensation column for Dr. Charmot represents a lump sum cash
severance payment of $397,188, severance benefits of $85,812 consisting of payment of continued health,
dental and vision insurance premiums for himself and any covered dependents for 24 months, and accrued
paid time off cash out of $29,048. Please see the description of Dr. Charmot’s transition and separation
agreement in “— Narrative to 2014 Summary Compensation Table and Outstanding Equity Awards at 2014
Fiscal Year-End — Terms and Conditions of Transition and Separation Agreement with Dr. Charmot”
below.
22
P
r
o
x
y
S
t
a
t
e
m
e
n
t
Outstanding Equity Awards at 2014 Fiscal Year-End
The following table sets forth specified information concerning unexercised stock options for each of the NEOs
outstanding as of December 31, 2014.
Name
Michael Raab
Jeremy Caldwell, Ph.D.
Mark Kaufmann
Option Awards
Number of
Securities
Underlying
Unexercised
Options
(#)
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
Unexercisable
36,123
267,892
—
137,658
—
—
90,000
—
Vesting
Commencement
Date
9/15/2010(1)
8/1/2011(1)
12/1/2014(2)
8/8/2011(3)
Option
Exercise
Price ($)
Option
Expiration
Date
1.08
0.54
32.74
0.54
9/15/2020
8/1/2021
12/3/2024
8/8/2021
(1) The options are fully exercisable upon the date of grant, provided that the options vest monthly in
substantially equal installments until the fourth anniversary of the vesting commencement date, subject to
the holder continuing to provide services to us through each such date. Any shares that are purchased prior
to vesting are subject to a repurchase right in favor of the company, which repurchase right lapses in
accordance with the vesting schedule.
(2) The option vests and becomes exercisable as to 25% of the shares subject to the option on the first
anniversary of the vesting commencement date with the remaining 75% of the shares vesting and becoming
exercisable monthly thereafter in substantially equal installments until the fourth anniversary of the vesting
commencement date, subject to the holder continuing to provide services to us through each such date.
(3) The option is fully exercisable upon the date of grant, provided that the option vests as to 25% of the shares
subject to the option on the first anniversary of the vesting commencement date with the remaining 75% of
the shares vesting monthly thereafter in substantially equal installments until the fourth anniversary of the
vesting commencement date, subject to the holder continuing to provide services to us through each such
date. Any shares that are purchased prior to vesting are subject to a repurchase right in favor of the
company, which repurchase right lapses in accordance with the vesting schedule.
Narrative to 2014 Summary Compensation Table and Outstanding Equity Awards at 2014 Fiscal Year
End
Terms and Conditions of Employee Arrangements with our NEOs
We have entered into agreements with each of the NEOs in connection with his employment with us. These
agreements set forth the terms and conditions of employment of each named executive officer, including base
salary, initial equity award grants, and standard employee benefit plan participation. Our board of directors or the
compensation committee reviews each NEO’s base salary from time to time to ensure compensation adequately
reflects the NEO’s qualifications, experience, role and responsibilities. For fiscal year 2014, Mr. Raab’s annual
base salary was $426,708, Dr. Charmot’s annual base salary was $317,750 (which was pro-rated for his partial
service and resignation in December 2014), Mr. Kaufmann’s annual base salary was $281,875, and
Dr. Caldwell’s annual base salary was $385,000 (which was prorated for his partial service when he commenced
employment in December 2014). In addition, for 2014, Mr. Raab, Dr. Charmot and Mr. Kaufmann each had an
annual bonus target of 30%, 25% and 30%, respectively, of base salary awarded based on the achievement of
certain corporate and individual performance goals set by the board of directors. Dr. Caldwell was not eligible
for a performance bonus in 2014 because he commenced service in December 2014, but his annual bonus target
for 2015 will be 40%. The annual target bonus for 2015 for Mr. Raab and Mr. Kaufmann will be 50% and 40%,
respectively.
23
t
n
e
m
e
t
a
t
S
y
x
o
r
P
In June 2014, we entered into an amended and restated employment agreement with Mr. Raab. We also entered
into a change in control severance agreement with Dr. Charmot (which was superseded by his transition and
separation agreement as described in more detail below) and an amended and restated change in control
severance agreement with Mr. Kaufmann. In December 2014, we entered a change in control severance
agreement with Dr. Caldwell in connection with his commencement of employment with us.
Under Mr. Raab’s amended and restated employment agreement, in the event Mr. Raab’s employment with us is
involuntarily terminated for reason other than “cause” or he resigns for “good reason” (each, as defined below),
in each case more than three months prior to or more than 12 months after a change in control, then Mr. Raab
will receive: (i) continued payment of his annual base salary as in effect immediately prior to such termination
for a period of 12 months; (ii) payment of healthcare continuation costs for him and his eligible dependents for
up to 12 months following the date of such termination; and (iii) 12 months of accelerated vesting of any
outstanding equity awards, with any options remaining exercisable until 12 months following the date of
termination or the original expiration date. In the event Mr. Raab’s employment with us is involuntarily
terminated for reason other than cause or he resigns for good reason, in each case within three months prior to
and 12 months after a change in control, then Mr. Raab will receive: (i) a lump sum amount equal to 1.5
multiplied by the sum of his base salary as in effect immediately prior to such termination and his target annual
bonus for the year of termination; (ii) payment of healthcare continuation costs for him and his eligible
dependents for up to 18 months following the date of such termination; and (iii) full accelerated vesting of any
outstanding equity awards, with any options remaining exercisable until 12 months following the date of
termination or the original expiration date.
Under Dr. Caldwell’s change in control severance agreement, in the event Dr. Caldwell’s employment with us is
involuntarily terminated for reason other than cause or he resigns for good reason, in each case more than three
months prior to or more than 12 months after a change in control, then Dr. Charmot will receive: (i) continued
payment of his annual base salary as in effect immediately prior to such termination for a period of nine months;
and (ii) payment of healthcare continuation costs for him and his eligible dependents for up to 12 months
following the date of such termination. In the event Dr. Caldwell’s employment with us is involuntarily
terminated for reason other than cause or he resigns for good reason, in each case within three months prior to
and 12 months after a change in control, then Dr. Caldwell will receive: (i) a lump sum amount equal to the sum
of his base salary as in effect immediately prior to such termination and his target annual bonus for the year of
termination; (ii) payment of healthcare continuation costs for him and his eligible dependents for up to 12 months
following the date of such termination; and (iii) full accelerated vesting of any outstanding equity awards, with
any options remaining exercisable until 12 months following the date of termination or the original expiration
date.
In addition, under Dr. Caldwell’s change in control severance agreement, Dr. Caldwell received a signing bonus
equal to $100,000 in connection with his commencement of employment with us in December 2014. The signing
bonus is subject to reimbursement in the event that Dr. Caldwell terminates his employment without good reason,
or we terminate his employment for cause, in either case before the first anniversary of the commencement of his
employment with us (100% to be reimbursed) or during the period between the first and second anniversaries of
the commencement of employment with us (50% to be reimbursed).
Under Mr. Kaufmann’s amended and restated change in control severance agreement, in the event
Mr. Kaufmann’s employment with us is involuntarily terminated for reason other than cause or he resigns for
good reason, in each case more than three months prior to or more than 12 months after a change in control, then
Mr. Kaufmann will receive: (i) continued payment of his annual base salary as in effect immediately prior to
such termination for a period of nine months; and (ii) payment of healthcare continuation costs for him and his
eligible dependents for up to 12 months following the date of such termination. In the event Mr. Kaufmann’s
employment with us is involuntarily terminated for reason other than cause or he resigns for good reason, in each
case within three months prior to and 12 months after a change in control, then Mr. Kaufmann will receive: (i) a
lump sum amount equal to the sum of his base salary as in effect immediately prior to such termination and his
24
P
r
o
x
y
S
t
a
t
e
m
e
n
t
target annual bonus for the year of termination; (ii) payment of healthcare continuation costs for him and his
eligible dependents for up to 12 months following the date of such termination; and (iii) full accelerated vesting
of any outstanding equity awards, with any options remaining exercisable until 12 months following the date of
termination or the original expiration date.
For the purposes of Mr. Raab’s amended and restated employment agreement, Dr. Caldwell’s change in control
severance agreement, and Mr. Kaufmann’s amended and restated change in control severance agreement, “cause”
means (i) the NEO’s theft, dishonesty or falsification of any employment or company records that is non-trivial in
nature; (ii) malicious or reckless disclosure of our confidential or proprietary information or any material breach
by the NEO of his obligations under his proprietary information and inventions assignment agreement with us;
(iii) the conviction of the NEO of a felony (excluding motor vehicle violations) or the commission of gross
negligence or willful misconduct, where a majority of the non-employee members of the board of directors
reasonably determines that such act or misconduct has (A) seriously undermined the ability of the board of
directors or management to entrust him with important matters or otherwise work effectively with him,
(B) substantially contributed to our loss of significant revenues or business opportunities, or (C) significantly and
detrimentally affected the business or reputation of our company or any of our subsidiaries; and/or (iv) the willful
failure or refusal by the NEO to follow the reasonable and lawful directives of the board of directors, provided
such willful failure or refusal continues after his receipt of reasonable notice in writing of such failure or refusal
and a reasonable opportunity of not less than 30 days to correct the problem.
For the purposes of Mr. Raab’s amended and restated employment agreement, Dr. Caldwell’s change in control
severance agreement, and Mr. Kaufmann’s amended and restated change in control severance agreement, “good
reason” means the occurrence of: (i) a material diminution in the NEO’s authority, duties, or responsibilities,
which substantially reduces the nature or character of his position; (ii) a reduction by us of his base salary as in
effect immediately prior to such reduction; (iii) a relocation of his principal office to a location more than
50 miles from the location of our principal office as of immediately prior to such relocation, except for required
travel by him on company business; or (iv) any material breach by us of any provision of the NEO’s employment
agreement or offer letter which we do not cure within 30 days following written notice from the NEO, provided
that in order for “good reason” to exist, each of the following conditions must be met: (i) the foregoing good
reason conditions must have occurred without the NEO’s express written consent; (ii) the NEO must provide
written notice to us of such condition within 30 days of the initial existence of the condition; (iii) the condition
specified in such notice must remain uncorrected for 30 days after receipt of such notice; and (iv) the date of the
NEO’s resignation of employment must occur within 60 days after the initial existence of the condition specified
in such notice.
Terms and Conditions of Annual Bonuses
For 2014, our NEOs were eligible for performance-based cash incentives pursuant to the achievement of certain
corporate and individual performance objectives. The performance goals for these annual performance cash
bonuses were reviewed and approved by the board of directors. The determination of the amount of bonuses paid
to our NEOs generally reflects a number of considerations, including individual performance and financing and
research goals.
Each NEO’s target bonus opportunity is expressed as a percentage of base salary which can be achieved by
meeting corporate and individual performance goals. Our board of directors or our compensation committee has
historically reviewed these target percentages to ensure they are adequate, but does not follow a formula. Instead,
our board of directors or our compensation committee has set these rates based on each participating executive’s
experience in her or his role with our company and the level of responsibility held by each executive, which the
board of directors or our compensation committee believe directly correlates to her or his ability to influence
corporate results. For fiscal year 2014, our board of directors used a guideline target bonus opportunity of 30% of
base salary for Mr. Raab, 25% of base salary for Dr. Charmot, and 30% of base salary for Mr. Kaufmann.
Dr. Caldwell was not eligible to receive a performance bonus in 2014 because he commenced employment in
25
t
n
e
m
e
t
a
t
S
y
x
o
r
P
December 2014. In addition, while Dr. Charmot was originally eligible for a performance bonus in 2014, he
resigned his employment with us effective December 2014. As a result, Messrs. Raab and Kaufmann were the
only NEOs eligible to receive performance bonuses at the end of 2014.
For determining performance bonus amounts for our NEOs for 2014, our board of directors set certain corporate
performance goals. In setting these goals, our board of directors considered the status of our discovery programs,
our financial status, and our role in certain critical activities being conducted under the collaboration partnership
with AstraZeneca. Of the ten corporate goals, four were tied to the achievement of specific development
milestones for tenapanor, one was aimed at advancing our internal discovery programs, and the remaining five
addressed financing, operational and business development objectives. While the board of directors did not
specify specific goals for individuals, each individual’s participation in the achievement of the corporate goals
was assessed, as well as the executive’s handling of unplanned events and opportunities. For 2014, the corporate
and individual components of the annual bonus were weighted at 80% and 20%, respectively, for Mr. Raab and
Mr. Kaufmann. The board of directors determined that 90% of the corporate goals had been achieved or
exceeded, and that Messrs. Raab and Kaufmann each achieved or exceed 100% of their individual goals. The
board of directors determined that due to the company’s outstanding performance in 2014, the company’s
performance against its corporate goals should be set at 130% and each of Mr. Raab’s and Mr. Kaufmann’s
performance against personal goals should be set at 150%. In addition, the board of directors allocated an
additional discretionary bonus of $10,000 to Mr. Kaufmann due to his promotion to Chief Financial Officer
during 2014 and his performance during our IPO.
Following its review and determinations of corporate and individual achievements for 2014, the board of
directors awarded cash bonuses to Messrs. Raab and Kaufmann in amounts equal to 39.81% and 43.74% of each
of their base salaries, respectively. The NEOs’ 2014 bonuses are set forth in the “2014 Summary Compensation
Table” above.
Terms and Conditions of Equity Award Grants
Dr. Caldwell was the only NEO who received an equity award grant in 2014. The table above entitled
“Outstanding Equity Awards at 2014 Fiscal Year End” describes the material terms of other option awards made
in past fiscal years to our NEOs. In connection with Dr. Caldwell’s commencement of employment with us in
December 2014, Dr. Caldwell was granted an option to purchase 90,000 shares of our common stock under our
2014 Plan at an exercise price equal to $32.74, which was our fair market value of our common stock on the
grant date. Dr. Caldwell’s option vests and becomes exercisable as to 25% of the shares subject to the option on
the first anniversary of the vesting commencement date with the remaining 75% of the shares vesting and
becoming exercisable monthly thereafter in substantially equal installments until the fourth anniversary of the
vesting commencement date, subject to Dr. Caldwell continuing to provide services to us through such dates.
Terms and Conditions of Transition and Separation Agreement with Dr. Charmot
On September 4, 2014, we entered into a transition and separation agreement with Dr. Charmot, pursuant to
which Dr. Charmot continued in his role as our Chief Scientific Officer through December 23, 2014, at which
time he resigned his employment with us and resigned from our board of directors. In exchange for a general
release of claims against us and our affiliates, Dr. Charmot received a lump sum cash severance payment equal to
12 months’ of his base salary (or $317,750), subject to Dr. Charmot’s continued compliance with the terms of the
transition and separation agreement (including a two year non-solicitation restrictive covenant) and his
confidential information agreement with us. In addition, we paid to Dr. Charmot a lump sum cash payment equal
to 25% of his base salary (or $79,437). Dr. Charmot is also entitled to continued health coverage at the
Company’s expense until the earlier of December 23, 2016 or the date he is otherwise no longer eligible for
COBRA continuation coverage. Finally, the vesting of 100% of the unvested restricted stock awards (or the
equivalent of 58,969 shares of common stock) held by Dr. Charmot was accelerated in full. The separation
benefits set forth in Dr. Charmot’s transition and separation agreement supersede his offer letter with us and his
amended and restated change in control severance agreement.
26
Equity Plan Compensation Information
The following table provides certain information as of December 31, 2014, with respect to all of our equity
compensation plans in effect on that date.
Number of
Securities to
be Issued
Upon
Exercise of
Outstanding
Options,
Warrants
and Rights
(a)
Weighted-
Average
Exercise
Price of
Outstanding
Options,
Warrants
and Rights
(b)
Number of
Securities
Remaining
Available for
Future
Issuance
Under Equity
Compensation
Plans
(Excluding
Securities
Reflected in
Column (a))
(c)(3)
1,007,724
$5.51
1,468,044
—
—
—
1,007,724
$5.51
1,468,044
P
r
o
x
y
S
t
a
t
e
m
e
n
t
Plan Category
Equity Compensation Plans Approved by
Stockholders(1)(2)
Equity Compensation Plans Not Approved by
Stockholders
Total
(1)
Includes the Ardelyx, Inc., 2014 Equity Incentive Plan, 2014 Employee Stock Purchase Plan and 2008 Stock
Incentive Plan, as amended.
(2) The Ardelyx, Inc., 2014 Equity Incentive Plan and the Ardelyx, Inc., 2014 Employee Stock Purchase Plan
contain “evergreen” provisions, pursuant to which (i) the number of shares of common stock reserved for
issuance pursuant to awards under the 2014 Equity Inventive Plan shall be increased on the first day of each
year beginning in 2015 and ending in 2024, equal to the lesser of (A) four percent (4.0%) of the shares of
stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year, and
(B) such smaller number of shares of stock as determined by our board of directors; provided, however, that
no more than 10,683,053 shares of stock may be issued upon the exercise of incentive stock options, and
(ii) the maximum number of shares of common stock which will be authorized for sale under our 2014
Employee Stock Purchase Plan shall be increased on the first day of each year beginning in 2015 and ending
in 2024, equal to the lesser of (A) one percent (1.0%) of the shares of stock outstanding (on an as converted
basis) on the last day of the immediately preceding fiscal year, and (B) such smaller number of shares of
stock as determined by our board of directors.
Includes 202,762 shares that were available for future issuances as of December 31, 2014 under the 2014
Employee Stock Purchase Plan, which allows eligible to purchase shares of common stock with
accumulated payroll deductions.
(3)
27
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth information relating to the beneficial ownership of our common stock as of
April 21, 2015, by:
•
•
•
•
each person, or group of affiliated persons, known by us to beneficially own more than 5% of our
outstanding shares of common stock;
each of our directors and nominees for director;
each of our named executive officers; and
all directors and executive officers as a group.
t
n
e
m
e
t
a
t
S
y
x
o
r
P
The number of shares beneficially owned by each entity, person, director, nominee or executive officer is
determined in accordance with the rules of the SEC, and the information is not necessarily indicative of
beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over
which the individual has sole or shared voting power or investment power as well as any shares that the
individual has the right to acquire within 60 days of April 21, 2015 through the exercise of stock options or other
rights. Except as otherwise indicated, and subject to applicable community property laws, the persons named in
the table have sole voting and investment power with respect to all shares of common stock held by that person.
The percentage of shares beneficially owned is computed on the basis of 18,642,752 shares of our common stock
outstanding as of April 21, 2015. Shares of our common stock that a person has the right to acquire within
60 days of April 21, 2015 are deemed outstanding for purposes of computing the percentage ownership of the
person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership
of any other person, except with respect to the percentage ownership of all directors and executive officers as a
group. Unless otherwise indicated below, the address for each beneficial owner listed is c/o Ardelyx, Inc., at
34175 Ardenwood Blvd., Suite 200, Fremont, CA 94555.
Name and Address of Beneficial Owner
5% and Greater Stockholders
Entities Associated with New Enterprise
Associates(1)
Entities Associated with CMEA(2)
FMR LLC(3)
Cormorant Global Healthcare Master Fund, LP(4)
Named Executive Officers and Directors
Michael Raab(5)
Jeremy Caldwell
Mark Kaufmann(6)
Dominique Charmot, Ph.D.(7)
David Mott
Annalisa Jenkins, MMBS, MRCP
Gordon Ringold, Ph.D.(8)
Richard Rodgers(9)
Peter Schultz, Ph.D.(10)
All directors and executive officers as a group
Beneficial Ownership
Number of
Outstanding
Shares
Beneficially
Owned
Number of
Shares
Exercisable
Within 60 Days
Number of
Shares
Beneficially
Owned
Percentage
of Beneficial
Ownership
5,621,199
3,239,706
1,826,222
1,053,500
83,685
—
596
44,972
—
—
—
—
860,700
—
—
—
—
5,621,199
3,239,706
1,826,222
1,053,500
30.15%
17.38%
9.80%
5.65%
311,827
—
132,445
—
—
—
10,000
11,666
—
395,512
—
133,041
44,972
—
—
10,000
11,666
860,700
2.09%
—
*
*
—
—
*
*
4.62%
(10 persons)(11)
1,061,018
560,666
1,621,684
8.44%
*
Indicates beneficial ownership of less than 1% of the total outstanding shares of common stock.
28
P
r
o
x
y
S
t
a
t
e
m
e
n
t
(1)
Includes 5,619,734 shares held by New Enterprise Associates 12, Limited Partnership (“NEA 12”), as
reported on Form 13D/A filed with the SEC on December 18, 2014, by, NEA 12, NEA Partners 12, Limited
Partnership (“NEA Partners 12”), NEA 12 GP LLC (“NEA 12 LLC”), M. James Barrett (“Barrett”), Peter J.
Barris (“Barris”) Forest Baskett (“Baskett”), Ryan D. Drant (“Drant”), Patrick J. Kerins (“Kerins”), Krishna
S. Kolluri (“Kolluri”), and Scott D. Sandell (“Sandell”) and on Forms 4 filed with the SEC on December 29,
2014 by, NEA 12 LLC, NEA Partners 12, Barrett, Baskett, Drant, Kerins Kolluri and Scott D. Sandell
(“Sandell”). NEA 12 LLC is the sole general partner of NEA Partners 12, and NEA Partners 12 is the sole
general partner of NEA 12. Barrett, Barris, Baskett, Drant, Kerins, Kolluri and Sandell (together,
“Managers”) are the managers of NEA 12 LLC. NEA 12, NEA 12 LLC, NEA Partners 12 and the Managers
share voting and dispositive power with regard to the shares held directly by NEA 12. NEA Partners 12,
NEA 12 LLC and each of the Managers disclaims beneficial ownership of the shares held by NEA 12,
except to the extent of any respective pecuniary interest therein. Also includes 1,465 shares held by NEA
Ventures 2008, L.P. (“Ven 2008”), which shares are held indirectly by Karen P. Welsh, the general partner
of Ven 2008. Ms. Welsh disclaims beneficial ownership of the shares held by Ven 2008, except to the extent
of her pecuniary interest in such shares. The address of NEA 12 and Ven 2008 is 1954 Greenspring Drive,
Suite 600, Timonium, MD 21093.
(2) As reported on Form 13G filed with the SEC on February 12, 2015 by CMEA Ventures VII, GP, LLC
(“CMEA GP LLC”), CMEA Ventures VII GP, L.P. (“CMEA GP LP”), CMEA Ventures VII, L.P. (“CMEA
VII”), CMEA Ventures VII (Parallel”), L.P. (“CMEA VII Parallel”), David J. Collier (“Collier”), Faysal A.
Sohail (“Sohail”) and James F. Watson (“Watson”). CMEA GP LLC serves as the general partner of CMEA
GP LP, which serves as the general partner of CMEA VII and CMEA VII Parallel and may be deemed to
own beneficially the shares held by CMEA VII and CMEA VII Parallel. Collier, Watson and Sohail share
voting and investment power over and may be deemed to own beneficially the shares held by CMEA VII
and CMEA VII Parallel. Includes 3,158,716 shares held by CMEA VII and 80,990 shares held by CMEA
VII Parallel. The address of CMEA VII and CMEA VII Parallel is One Letterman Drive, Building C, Suite
CM 500, San Francisco, CA 94129.
(3) As reported on Schedule 13G filed with the SEC on February 13, 2015 by FMR LLC (“FMR”), Edward C.
Johnson 3rd, Abigail P. Johnson and Select Biotechnology Portfolio pursuant to a joint filing agreement.
Edward C. Johnson 3d is a Director and the Chairman of FMR LLC and Abigail P. Johnson is a Director,
the Vice Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the family of
Edward C. Johnson 3d, including Abigail P. Johnson, are the predominant owners, directly or through trusts,
of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The
Johnson family group and all other Series B shareholders have entered into a shareholders’ voting
agreement under which all Series B voting common shares will be voted in accordance with the majority
vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and
the execution of the shareholders’ voting agreement, members of the Johnson family may be deemed, under
the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR
LLC nor Edward C. Johnson 3d nor Abigail P. Johnson has the sole power to vote or direct the voting of the
shares owned directly by the various investment companies registered under the Investment Company Act
(“Fidelity Funds”) advised by Fidelity Management & Research Company (“FMR Co”), a wholly owned
subsidiary of FMR LLC, which power resides with the Fidelity Funds’ Boards of Trustees. Fidelity
Management & Research Company carries out the voting of the shares under written guidelines established
by the Fidelity Funds’ Boards of Trustees. FMR has its principal business office at 245 Summer Street,
Boston MA 02210.
(4) As reported on Schedule 13G/A filed with the SEC on February 17, 2015 by Cormorant Global Healthcare
Master Fund, LP (“Fund”), Cormorant Global Healthcare GP, LLC (“GP”), Cormorant Asset Management,
LLC (“Manager”) and Bihua Chen (“Chen”). GP serves as the general partner of the Fund, and Manager
serves as the investment manager of the Fund. Chen serves as the managing member of GP and Manager.
Each of Fund, GP, Manager and Chen disclaims beneficial ownership of such shares, except to the extent of
their pecuniary interest therein. The address of Fund, GP, Manager and Chen is 100 High Street, Suite 1105,
Boston, MA 02110.
29
(5) Consists of (i) 83,658 shares directly owned by Mr. Raab, (ii) 27 shares owned directly by Michael G. Raab,
trustee of the Michael G. Raab Living Trust dated July 25, 2012, and (iii) 311,827 shares that may be
acquired pursuant to the exercise of stock options within 60 days of April 21, 2015, of which 11.163 shares
would be unvested and subject to a right of repurchase if all 311,827 shares were exercised within 60 days
of April 21, 2015.
(6) Consists of (i) 596 shares directly owned by Mr. Kaufmann, and (ii) 132,445 shares that may be acquired
pursuant to the exercise of stock options within 60 days of April 21, 2015, of which 5,989 shares would be
unvested and subject to a right of repurchase if all 132,445 shares were exercised within 60 days of April 21,
2015.
(7) Consists of (i) 41,098 shares directly owned by Dr. Charmot, and (ii) 3,874 shares owned by Dominique
Charmot and Sylvie Charmot, Trustees of the Charmot 2012 Irrevocable Trust.
(8) Consists of 10,000 shares that may be acquired pursuant to the exercise of stock options within 60 days of
April 21, 2015.
(9) Consists of 11,666 shares that may be acquired pursuant to the exercise of stock options within 60 days of
April 21, 2015.
(10) Includes 4,492 shares that will remain unvested 60 days after April 21, 2015, and are subject to a right of
repurchase.
(11) Consists of 1,061,018 shares, of which 6,807 will remain unvested 60 days after April 21, 2015 and are
subject to a right of repurchase and 560,666 shares that may be acquired pursuant to the exercise of stock
options within 60 days of April 21, 2015, of which 44,235 shares will be unvested and subject to a right of
repurchase if exercised within 60 days of April 21, 2015. Does not include shares beneficially owned by
Dr. Charmot who resigned as our Chief Scientific Officer and member of our Board effective December 23,
2014.
t
n
e
m
e
t
a
t
S
y
x
o
r
P
30
P
r
o
x
y
S
t
a
t
e
m
e
n
t
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, requires the Company’s
directors and executive officers, and persons who own more than 10% of a registered class of the Company’s
equity securities, to file with the U.S. Securities and Exchange Commission, or SEC, initial reports of ownership
and reports of changes in ownership of common stock and other equity securities of the Company. Officers,
directors and greater than 10% stockholders are required by SEC regulations to furnish the Company with copies
of all Section 16(a) forms they file.
To the Company’s knowledge, based solely on a review of the copies of such reports furnished to the Company
and written representations that no other reports were required, during the year ended December 31, 2014, all
Section 16(a) filing requirements applicable to our officers, directors and greater than 10% beneficial owners
were complied with, except for Form 3 filings that were one day late for David Rosenbaum, Peter Schultz,
George Jue and Elizabeth Grammer due to administrative delays and a Form 4 filing for Michael Raab.
ADDITIONAL INFORMATION
Householding of Proxy Materials
The SEC has adopted rules known as “householding” that permit companies and intermediaries (such as brokers)
to deliver one set of proxy materials to multiple stockholders residing at the same address. This process enables
us to reduce our printing and distribution costs, and reduce our environmental impact. Householding is available
to both registered stockholders and beneficial owners of shares held in street name.
Registered Stockholders
If you are a registered stockholder and have consented to householding, then we will deliver or mail one set of
our proxy materials, as applicable, for all registered stockholders residing at the same address. Your consent will
continue unless you revoke it, which you may do at any time by providing notice to the Company’s Corporate
Secretary by telephone at (510) 745-1700 or by mail at Ardelyx, Inc., 34175 Ardenwood Blvd., Suite 200,
Fremont, CA 94555.
If you are a registered stockholder who has not consented to householding, then we will continue to deliver or
mail copies of our proxy materials, as applicable, to each registered stockholder residing at the same address.
You may elect to participate in householding and receive only one set of proxy materials for all registered
stockholders residing at the same address by providing notice to the Company as described above.
Street Name Holders
Stockholders who hold their shares through a brokerage may elect to participate in householding, or revoke their
consent to participate in householding, by contacting their respective brokers.
Annual Reports
This proxy statement is accompanied by our 2014 Annual Report to Stockholders, which includes our
Annual Report on Form 10-K for the fiscal year ended December 31, 2014, or the 10-K. The 10-K includes
our audited financial statements. We have filed the 10-K with the SEC, and it is available free of charge at
the SEC’s website at www.sec.gov and on our website at ir.ardelyx.com. In addition, upon written request
to the Company’s Corporate Secretary at Ardelyx, Inc., Suite 200, 34175 Ardenwood Blvd., Fremont, CA
94555, we will mail a paper copy of our 10-K, including the financial statements and the financial
statement schedules, to you free of charge.
31
Other Matters
As of the date of this proxy statement, our board of directors knows of no other matters that will be presented for
consideration at the 2015 Annual Meeting other than the matters described in this proxy statement. If other
matters are properly brought before the 2015 Annual Meeting, then proxies will be voted in accordance with the
recommendation of the board of directors or, in the absence of such a recommendation, in accordance with the
best judgment of the proxy holder.
By Order of the Board of Directors:
/s/ Elizabeth Grammer
Elizabeth Grammer
Vice President and General Counsel
By Order of the Board of Directors:
Fremont, California
April 24, 2015
t
n
e
m
e
t
a
t
S
y
x
o
r
P
32
=
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
(cid:95) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2014
OR
(cid:133) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
Commission File Number 001-36485
Ardelyx, Inc.
(Exact name of Registrant as specified in its Charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
34175 Ardenwood Blvd., Suite 200
Fremont, California
(Address of principal executive offices)
26-1303944
(I.R.S. Employer
Identification No.)
94555
(Zip Code)
Registrant’s telephone number, including area code: (510) 745-1700
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class:
Common Stock, par value $0.0001 per share
Name of Each Exchange on Which Registered:
The NASDAQ Global Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES (cid:133) NO (cid:95)
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES (cid:133) NO (cid:95)
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. YES (cid:95) NO (cid:133)
Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File
required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the Registrant was required to submit and post such files). YES (cid:95) NO (cid:133)
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be
contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K
or any amendment to this Form 10-K. (cid:95)
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definition of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer
(cid:133)
Accelerated filer
(cid:133)
(cid:95) (Do not check if a small reporting company)
Non-accelerated filer
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES (cid:133) NO (cid:95)
The aggregate market value of the Registrant’s common stock held by non-affiliates of the Registrant as of the last business day of the Registrant’s
most recently completed second fiscal quarter, June 30, 2014, based on the last reported sales price of the Registrant’s common stock of $15.97 per
share was $96,062,968.
The number of shares of Registrant’s Common Stock outstanding as of February 26, 2015 was 18,598,133.
Small reporting company
(cid:133)
DOCUMENTS INCORPORATED BY REFERENCE:
Portions of the Registrant’s Definitive Proxy Statement for its 2015 Annual Meeting of Stockholders, which will be filed with the Commission within
120 days after the close of the Registrant’s 2014 fiscal year, are incorporated by reference into Part III of this Report.
Table of Contents
Page
PART I
Item 1.
Business .........................................................................................................................................................................
Item 1A. Risk Factors ...................................................................................................................................................................
Item 1B. Unresolved Staff Comments ..........................................................................................................................................
Properties .......................................................................................................................................................................
Item 2.
Legal Proceedings .........................................................................................................................................................
Item 3.
Mine Safety Disclosures ................................................................................................................................................
Item 4.
PART II
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities ....
Item 5.
Selected Financial Data .................................................................................................................................................
Item 6.
Management’s Discussion and Analysis of Financial Condition and Results of Operations ........................................
Item 7.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk .......................................................................................
Financial Statements and Supplementary Data .............................................................................................................
Item 8.
Item 9.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure .......................................
Item 9A. Controls and Procedures ................................................................................................................................................
Item 9B. Other Information ..........................................................................................................................................................
3
29
62
62
62
62
63
66
67
78
79
99
99
99
PART III
Item 10. Directors, Executive Officers and Corporate Governance ............................................................................................ 100
Item 11. Executive Compensation ............................................................................................................................................... 100
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters ...................... 100
Item 13. Certain Relationships and Related Transactions, and Director Independence .............................................................. 100
Item 14. Principal Accounting Fees and Services ....................................................................................................................... 100
PART IV
Item 15. Exhibits, Financial Statement Schedules ....................................................................................................................... 101
PART I
Special Note Regarding Forward-Looking Statements
This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. Any statements
contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can
identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “due,”
“estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,”
“will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of
these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:
(cid:121) AstraZeneca’s decisions with respect to its future development of tenapanor;
(cid:121)
the timing of data from the ongoing Phase 2a trial of tenapanor and the timing of commencement of the Phase 3
development program of tenapanor;
(cid:121) our receipt of future milestone payments from our collaboration partners, and the expected timing of such payments;
(cid:121) our expectations regarding the potential market size and the size of the patient populations for our product candidates, if
approved for commercial use;
(cid:121)
(cid:121)
the likelihood and our expectations that we elect to exercise our co-promotion rights with respect to tenapanor or an
NaP2b inhibitor product, or exercise our co-fund rights with respect to the first Phase 3 clinical development program for
tenapanor;
the likelihood and potential for Sanofi to exercise its option to exclusively license our NaP2b inhibitor program;
(cid:121) our ability to maintain existing and our intention to establish new collaboration partnerships;
(cid:121) our ability to identify and validate targets and novel drug candidates using our proprietary drug discovery and design
platform including APECCS;
(cid:121) our ability to develop, acquire and advance product candidates into, and successfully complete, clinical trials;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
the timing or likelihood of regulatory filings, approvals and commercialization for our product candidates, including
tenapanor and our NaP2b inhibitors;
the implementation of our business model and strategic plans for our business, product candidates and technology;
the scope of protection we are able to establish and maintain for intellectual property rights covering tenapanor and our
NaP2b inhibitors;
estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain
additional capital;
(cid:121) our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;
(cid:121) our financial performance; and
(cid:121) developments and projections relating to our competitors and our industry.
These forward-looking statements relate to our future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance and achievements to be materially different from any
future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual
results to differ materially from current expectations include, among other things those listed under “Risk Factors” and elsewhere in
this Annual Report on Form 10-K.
Any forward-looking statement in this Annual Report on Form 10-K reflects our current views with respect to future events and
is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future-
growth. Given these uncertainties, you should not place undue reliance upon these forward-looking statements. Except as required by
law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes
available in the future.
1
This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our
business, and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates
and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies
is inherently subject to certain uncertainties and actual events or circumstances may differ materially from events and circumstances
reflected in this information. Unless otherwise specifically stated, we obtained this industry, market and other data from reports,
research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and
similar sources. In some cases, we do not expressly refer to sources from which this data is derived. In that regard, when we refer to
one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same
paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.
Unless the context requires otherwise, in this Annual Report on Form 10-K the terms “Ardelyx”, “we,” “us,” “our” and “the
Company” refer to Ardelyx, Inc.
Ardelyx(cid:147) and our logo are some of our trademarks used in this Annual Report on Form 10-K. We also use trademarks,
tradenames and service marks that are the property of other organizations. Solely for convenience, these trademarks and tradenames
referred to appear without the ® and ™ symbol, but, in the case of our trademark and tradenames, those references are not intended to
indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, to our trademarks or tradenames.
2
Item 1. Business.
Overview
We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal, or GI, tract to treat cardio-
renal, GI and metabolic diseases. We have developed a proprietary drug discovery and design platform enabling us, in a rapid and
cost-efficient manner, to discover and design novel drug candidates. Utilizing our platform, we discovered and designed our lead
product candidate, tenapanor, which in clinical studies has demonstrated the ability to improve the symptoms of constipation-
predominant irritable bowel syndrome, or IBS-C, and to reduce the absorption of both dietary sodium and phosphorus, which are key
factors in the progression of kidney disease. In 2012, we entered into a collaboration partnership with AstraZeneca AB, or
AstraZeneca, for the worldwide development and commercialization of tenapanor. AstraZeneca is responsible for all development and
commercialization costs for tenapanor and we have retained an option to co-promote in the United States. Together with AstraZeneca,
we have completed a Phase 2b clinical trial evaluating tenapanor in patients with IBS-C. Results from the study demonstrated
statistically significant and clinically meaningful improvements for IBS-C patients compared to patients receiving placebo, and at the
twice daily 50 mg dose, the study met its primary endpoint. We and AstraZeneca, have also completed a Phase 2b clinical trial
evaluating tenapanor in treating hyperphosphatemic patients with chronic kidney disease on dialysis, or CKD-5D, and the study met
its primary endpoint of lowering serum phosphate. In this study, the rate of diarrhea and the discontinuation rate due to diarrhea at the
highest doses were higher than expected based on previous clinical trials. Higher discontinuations rates due to diarrhea were observed
primarily in the 30mg once daily and 30mg twice daily dose groups. We plan to announce results of a Phase 2a trial in patients with
late-stage chronic kidney disease, or CKD, during the second quarter of 2015.
In February 2014, we licensed to Sanofi S.A., or Sanofi, our program evaluating small molecule NaP2b inhibitors for the
treatment of hyperphosphatemia in CKD-5D. We are also independently advancing other discovery and lead development programs
focused in cardio-renal, GI and metabolic diseases.
We continue to evolve our proprietary drug discovery and design platform. As part of this platform, we have developed a cell-
culture system that simulates gut tissue, which we refer to as Ardelyx Primary Enterocyte and Colonocyte Culture System, or
APECCS. We have ongoing work to identify human gastrointestinal tract-specific RNA transcripts and proteins and thus far have
identified over 3,800 proteins on the inner surface of the gut, many of which we believe may be drug targets.
Tenapanor is a minimally-absorbed, small molecule that acts locally in the gastrointestinal tract to inhibit the sodium transporter
NHE3 and reduce sodium uptake from the gut. We and AstraZeneca have evaluated or are evaluating tenapanor in fourteen human
clinical studies in over 1,000 individuals to date, including the following Phase 2 studies:
(cid:120) Phase 2b in IBS-C patients: We announced positive results from this study in October 2014. At the twice daily 50 mg
dose of tenapanor, the study met its primary efficacy endpoint of an increase in the complete spontaneous bowel
movement (CSBM) responder rate. Most secondary endpoints, including abdominal pain, the overall responder rate
and other abdominal and IBS-C symptoms, demonstrated statistically significant and clinically meaningful
improvements.
(cid:120) Phase 2b in CKD-5D patients with hyperphosphatemia: We announced results from this clinical trial in February 2015.
In the study, there was a statistically significant dose-related decrease in serum phosphate levels for tenapanor-treated
patients compared to patients receiving placebo (p=0.012). It was noted, however, that the rate of diarrhea and the rate
of discontinuations due to diarrhea were higher than expected based on previous clinical trials. Higher discontinuations
rates due to diarrhea were observed primarily in the 30mg once daily and 30mg twice daily dose groups. The overall
safety profile remains consistent with that observed in previous tenapanor trials.
(cid:120) Phase 2a Stage 3 CKD patients with type 2 diabetes mellitus, albuminuria and high blood pressure: This Phase 2a
randomized, double-blind, placebo-controlled clinical trial in 154 patients to evaluate the effects of tenapanor on
kidney function and fluid overload has completed enrollment. The results of this clinical trial are expected in the
second quarter of 2015.
We believe the market opportunity for tenapanor for these three potential patient populations is significant. We believe there are
approximately 4.4 million individuals in the United States with IBS-C. Additionally, we estimate, based on the utilization of
phosphate binders, the only approved therapies for hyperphosphatemia, that there are approximately 270,000 hyperphosphatemic
patients with CKD-5D in the United States. The worldwide market for phosphate binders in 2011 was reported to be $1.5 billion and
is projected to reach $2.3 billion by 2015. We believe there are approximately 1.8 million patients in the United States that have late-
stage, or stage 3b or stage 4 CKD with type 2 diabetes, or diabetic nephropathy.
3
Under our agreement, AstraZeneca has the right to determine which indications it will continue to develop. AstraZeneca has the
right to elect to develop one, two or all three of the indications, and AstraZeneca has the right to terminate the agreement upon written
notice to us. If AstraZeneca determines that it will advance any one of the indications forward into a Phase 3 clinical trial, we would
receive a royalty payment of $50.0 million. In addition, we would receive a $20.0 million development milestone if AstraZeneca
determines to move forward with the development of tenapanor by commencing a Phase 2b or Phase 3 clinical study in any of the
indications; provided that this milestone payment would be a $10.0 million payment if AstraZeneca decides to move forward with
only the IBS-C indication.
Utilizing our proprietary drug discovery and design platform, we are pursuing other internal discovery and lead-development
programs that are currently in the research phase. While we have identified molecules that exhibit attributes of the activity we are
seeking in each of the following programs, we have not yet selected a lead molecule in these programs.
(cid:120) NaP2b Program: We have discovered novel NaP2b inhibitors for the treatment of hyperphosphatemia in CKD-5D
patients by inhibiting the active absorption of phosphorus. In February 2014, we entered into an option and license
agreement with Sanofi under which we granted Sanofi an exclusive worldwide license to conduct research utilizing our
small molecule NaP2b inhibitors. Sanofi has the option to obtain an exclusive license to develop, manufacture and
commercialize our NaP2b inhibitors. Under our arrangement, Sanofi is responsible for all of the costs and expenses for
research and preclinical activities and, should it exercise its option, for the development and commercialization efforts
under the program, while we retain an option to co-promote licensed products in the United States.
(cid:120) RDX009 Program: Our focus is the discovery and development of minimally-absorbed TGR5 agonists that stimulate
GLP-2 and GLP-1 and have the potential when used in combination with a DPP4 inhibitor to treat inflammatory bowel
disease, or IBD, short bowel syndrome or non-alcoholic steatohepatitis, or NASH.
(cid:120) RDX013 Program: Our focus is the discovery and development of drug candidates to treat hyperkalemia, or elevated
serum potassium, commonly seen in CKD-5D patients and in patients with less severe CKD prior to dialysis.
Our operations to date have been funded by $56.2 million in equity investments primarily from leading venture capital
investment firms, $76.3 million in upfront and development milestone payments from our collaboration partners AstraZeneca and
Sanofi and $61.2 million net proceeds from our IPO in June 2014.
Our Proprietary Drug Discovery and Design Platform
Our platform is comprised of proprietary know-how and drug discovery and design tools such as APECCS. This platform
enables us, in a rapid and cost-efficient manner, to discover and design novel drug candidates that work exclusively in the GI tract to
treat cardio-renal, GI and metabolic diseases. By targeting receptors and transporters localized in the GI tract, we can modulate
important functions of the gut, such as absorption of specific nutrients and minerals, or the gut’s various hormonal functions, to treat
and prevent diseases while avoiding systemic toxicities.
Benefits of our Platform versus Traditional Drug Discovery
Traditional small molecule drug discovery and design focuses on drugs that are rapidly absorbed in the GI tract. Once absorbed,
those molecules typically need to survive the first-pass metabolism that occurs in the liver in order to arrive at the targeted cells or
tissues and provide the desired benefit or effect. Compared to the traditional approach employed by the pharmaceutical industry to
develop systemic drugs, we believe our proprietary drug discovery and design platform has several key benefits:
(cid:120) Exploits the natural functions of the gut to affect disease. The gut is not a passive organ. It is lined with a variety of cell
types that actively control the absorption of nutrients and minerals from the diet and serves to assist in the balance of
those in the body. The gut also functions as an endocrine gland, causing the release of hormones in response to various
stimuli. Additionally, the gut has multiple ways to communicate with the immune system and central nervous system.
Our platform allows us to discover and validate targets, and to design drugs to modulate these targets and active
functions of the gut in order to prevent and treat disease. With our drug candidates, we can stimulate receptors in the
gut to increase the release of endogenous hormones to take advantage of their natural effect on diseases and conditions.
We have identified over 3,800 human gastrointestinal tract-specific RNA transcripts and proteins on the inner surface
of the gut, many of which we believe may be drug targets.
4
(cid:120) Results in drug candidates with a superior safety profile that remain minimally-systemic. Traditional approaches to
drug development require the design of molecules to elicit an effect in a particular area or tissue of the body. To do
this, those molecules must be absorbed into the bloodstream thereby exposing many or all tissues to the drug and
potentially to the drug’s metabolites. Drug and metabolite exposure in tissues not relevant to treating the intended
disease or condition increases the chance of unwanted side effects. We avoid this systemic exposure by limiting the
penetration of our drug candidates through the gut and into the bloodstream or by ensuring rapid metabolism in the
blood. We believe that our approach minimizes the possibility that our drugs may bind to or affect unintended targets in
the body, reducing the potential for untoward side effects.
(cid:120) Reduces discovery time. Because our drug candidates are designed to be minimally-systemic and work locally, we
avoid the time that is dedicated in traditional drug discovery to designing molecules to achieve adequate bioavailability
and avoid undesirable off-target side effects, while still providing the desired pharmacologic response. When animal
studies confirm that one of our drug candidates is minimally-systemic and we observe minimal metabolism of the
candidate in the gut with the use of our discovery platform tools, we have a high degree of certainty that the drug
candidate will reach our intended target on the surface of the gut when administered orally.
(cid:120) Promotes efficient phenotypic screens. Our platform, particularly as enhanced with APECCS, allows us to conduct
efficient phenotypic screening as the cell system used for screening is a better representation of the GI as compared
with other technologies. The in vitro activity of selected hits is believed to be more predictive of in vivo activity
compared to more traditional approaches.
How our Proprietary Drug Discovery and Design Platform Works
Our platform allows us to identify and design novel minimally-systemic drug candidates to treat cardio-renal, GI and metabolic
diseases.
(cid:120)
Identify: We identify and evaluate receptors and transporters on the epithelia of the GI tract that may impact diseases
and we use a suite of techniques to characterize cell functions such as protein imaging and pharmacological probes in
order to confirm that such targets are found on cells of the lumen, or inside surface, of the intestines. Using our
scientific expertise and specialized know-how, along with traditional screening methodologies, we identify starting
chemistries that have the potential to engage actively with the targeted receptor or transporter. These starting tool
compounds are often absorbed into the bloodstream and have undesirable properties but serve the purpose of
confirming the presence of the target we are pursuing. We use medicinal chemistry techniques to optimize potency and
target engagement to eliminate or limit off-target activity and improve various drug properties of the compound.
(cid:120) Minimally-systemic: We use our medicinal chemistry expertise, together with a suite of tools and capabilities we have
developed to test and monitor the minimally–systemic qualities of our drugs. We then transform the optimized tool
compounds into pre-lead drug candidates that have low systemic availability, low gastric and intestinal metabolism,
favorable drug properties such as solubility and stability, and that affect the desired biological response in animals.
These pre-lead molecules are then optimized in all respects to create lead molecules that can enter IND-enabling
studies.
(cid:120) APECCS: APECCS, our novel cell-based system, involves the biopsy of various segments of the gut and the growth of
those cells under proprietary conditions to maintain, to the extent possible, the integrity and functionality of the various
cell types and substructures. We have developed this into a miniaturized format that allows us to utilize it for cell based
drug screening. In addition to using APECCS in the design of our small molecule drug candidates, we use the APECCS
technology to measure epithelial transport of ions and nutrients and to screen compounds to identify potential disease
modulators such as inhibitors or activators using phenotypic screening. APECCS has the potential to allow us to
identify novel targets, mechanisms of action and physiology as well as provide us an early understanding of how
identified compounds may interact with specific gut tissues. In addition, we believe that APECCS may also provide us
with a clear path to translate cell-based observations into in vivo rodent models and ultimately into human clinical
studies.
5
Our Strategy
Our goal is to be a leader in the discovery, development and commercialization of innovative, minimally-systemic, small
molecule therapeutics that work exclusively in the GI tract to treat cardio-renal, GI and metabolic diseases. Our strategy involves the
following:
Advance tenapanor into late-stage and pivotal clinical trials. We are actively involved with AstraZeneca in the development
efforts for tenapanor, and we participate in the strategic and operational management of the global tenapanor program. We are
focused on rapidly and efficiently advancing this program.
Use non-dilutive financing from our existing collaboration partnerships and the proceeds from our initial public offering to
expand our product pipeline and advance our earlier-stage product candidates into clinical trials. As of December 31, 2014, we
have received $76.3 million in non-dilutive funding from our collaboration partners, AstraZeneca and Sanofi. If we achieve our
milestones in these agreements, we would receive additional significant non-dilutive funding. We plan to use these payments to
continue our discovery and development efforts for our clinical and preclinical product candidates and to expand our product pipeline,
including through the potential acquisition or in-license of other products. In addition, we will continue to evaluate new collaboration
partnerships to enhance the discovery, development or commercialization of other product candidates in our product pipeline.
Leverage our technological capabilities and drug discovery and design platform to expand our product pipeline. We have
developed a unique approach to discover and develop new agents to treat diseases involving the exploitation of receptors and targets
on the epithelia of the GI tract that affect related biology to treat disease. We have built a suite of tools, knowledge and capabilities
around this approach and have leveraged such tools for the discovery of NHE3 inhibitors such as tenapanor, NaP2b inhibitors, TGR5
agonists and other drug candidates in our pipeline. We have developed APECCS to augment and help streamline the approach. We
plan to leverage these tools, capabilities and know-how to discover, develop and commercialize new first-in-class drugs that treat
cardio-renal, GI and metabolic diseases.
Develop commercial capabilities. With the co-promotion rights under the AstraZeneca and Sanofi partnerships, along with the
commercial expertise of our management team, we are well-positioned to develop a commercial presence in renal and GI diseases and
expect to develop U.S. commercial capabilities. Assuming that one or both of our collaboration partners continue to advance the
programs into Phase 3 clinical development and assuming the receipt of positive Phase 3 results, we expect to exercise our right to co-
promote one of our drug candidates with AstraZeneca or Sanofi, either of which would provide financial support that would assist us
in building a specialty sales and marketing team for this purpose. We also may develop additional commercial capabilities in
connection with other opportunities we choose to pursue.
Leverage our management team’s drug development and commercialization expertise to identify and secure complementary
in-licensing opportunities. Our management team has significant experience in the development and commercialization of products in
the cardio-renal, GI and metabolic fields in which we operate. We intend to leverage this expertise to pursue additional in-licensing
opportunities that expand our product pipeline within relevant therapeutic fields.
6
Our Product Pipeline
The following table summarizes key information about our product candidates:
Program
Indication
Research
Phase 1
2a
2b
Current Status
Development and Commercial Rights
Phase 2
Tenapanor
(NHE3 inhibitor)
IBS-C
CKD-5D
HyperPi
CKD
RDX002
(NaP2b inhibitor)
CKD-5D
HyperPi
RDX009
(TGR5 agonist)
RDX013
(K+ modulator)
Undisclosed
Programs
IBD, Short
Bowel, NASH
Hyper-
kalemia
N/A
Tenapanor
Summary of tenapanor
Pha
Phase 2b data reported
Oct 1, 2014
Pha
Phase 2b data reported
Feb 2, 2015
P
Phase 2a data in
2Q:2015
• $870mm total potential deal size including
$35mm up front + $237.5mm development
milestones; tiered royalties
• AZ funds and is responsible for all R&D
• Ardelyx has right to co-promote in U.S.
• $198mm total potential deal size; tiered royalties
• Sanofi funds and is responsible for all R&D
• Ardelyx has right to co-promote in United States
Research
Research
Research
Research
Tenapanor has demonstrated the ability to improve the symptoms of IBS-C and to reduce the absorption of both dietary sodium
and phosphorus, which are widely recognized as key factors in the progression of kidney disease. In addition to the evaluation of
tenapanor for the treatment of IBS-C, we and AstraZeneca have completed a Phase 2b clinical trial evaluating the potential for
tenapanor in the treatment of hyperphosphatemic patients with end-stage renal disease, or ESRD on dialysis, also known as CKD-5D.
A Phase 2a clinical trial is currently being conducted in order to understand the potential impact tenapanor may have on markers of
kidney disease and fluid status in CKD stage 3, or CKD-3 patients.
Tenapanor is a minimally-absorbed, small molecule that acts locally in the gastrointestinal tract to inhibit the NHE3 transporter
and reduce sodium uptake from the gut. In vitro studies have shown that tenapanor is a potent inhibitor of human NHE3 and specific
for NHE3 versus other transporters such as NHE1, NHE2 and NaP2b. When radiolabeled tenapanor was administered orally to rats,
we demonstrated that approximately 98% of the administered dose was recovered, unchanged, in feces, indicating that no substantial
metabolism occurred and that the drug was minimally-absorbed. In human studies of orally-administered tenapanor, the drug was
detected in the blood in only 0.7% of more than 3,000 collected serum samples, and even in those, at very low levels (< 1.5 ng/mL).
Results from a human ADME study demonstrated that tenapanor is minimally-absorbed. In such study, inactive metabolites were
identified in plasma samples that were approximately 9% of the parent compound. Tenapanor is stable at room temperature and has
been formulated into small tablets ranging in strength from 1 mg to 50 mg.
We have administered tenapanor to over 1,000 subjects to date including 347 healthy volunteers, 417 IBS-C subjects and about
255 patients with CKD and ESRD. Tenapanor has been administered in a single dose of up to 900 mg and for a period of up to 3
months at 100 mg/day. The most common side effects, generally observed in all clinical trials, consistent with the minimally-absorbed
exaggerated GI pharmacology of the drug were loose stools and diarrhea.
In animal studies and Phase 1 studies in healthy adult volunteers where fecal sodium was measured, we observed that tenapanor
has a significant effect on the diversion of dietary sodium into the stool. In addition, in IBS-C patients, we saw that tenapanor elicited
the expected pharmacological effect of increased fecal fluid that results from the inhibition of sodium absorption. The sodium effect of
tenapanor is related to its interaction with NHE3. NHE3 is a sodium-proton exchanger located on the epithelia or surface of the
intestinal lumen. NHE3 is also located on absorptive cells of the nephrons (structural units of the kidney that filter the blood). Its role
is to absorb sodium into the body from the intestine or, alternately, re-absorb it from the filtered plasma in the kidney in order to
maintain sodium balance in the body. The net flow of sodium (and chloride through other means) from the intestines also results in the
complementary absorption of intestinal water to maintain a constant blood sodium concentration.
7
In preclinical studies with tenapanor, we observed that, in addition to diverting sodium into the stool, tenapanor also inhibited
the absorption of phosphorus, and in several Phase 1 studies in healthy adults, we observed that tenapanor has a significant effect on
the diversion of dietary phosphorus into the stool. In in vitro studies we determined that tenapanor does not directly inhibit NaP2b or
PiT1, both of which are phosphorus transporters in the gut.
Tenapanor for treating IBS-C
In October 2014, we announced the positive results of our Phase 2b clinical study evaluating tenapanor in 371 IBS-C patients.
Results from this study demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for
tenapanor-treated patients compared to patients receiving placebo. At the twice daily 50 mg dose, the study met its primary efficacy
endpoint of an increase in the CSBM responder rate. Most secondary endpoints, including the overall responder rate, the abdominal
pain responder rate, and other abdominal and IBS-C symptoms, demonstrated statistically significant and clinically meaningful
improvements. Tenapanor was well-tolerated, and the safety results were consistent with those observed in previous tenapanor trials.
IBS-C is a GI disorder in which abdominal pain or discomfort is associated with constipation, which significantly affects the
health and quality of life of affected patients. It is unknown what causes IBS-C. There is no specific test or biomarker for IBS-C and
therefore, its presence is diagnosed by symptoms and by eliminating other disorders. IBS-C is very similar to chronic constipation and
it is clinically distinguished by a significant pain component.
Clinical data supporting tenapanor in IBS-C
We conducted a Phase 2b clinical trial in IBS-C patients and announced results from that study in October 2014. The clinical
trial was a randomized, double blind, placebo-controlled, multi-center study to evaluate the safety and efficacy of three dose levels of
tenapanor in 371 subjects with IBS-C as defined by the Rome III criteria and who had active disease as determined during a two-week
screening period. Subjects who qualified and who were randomized into the study received 5, 20, or 50 mg of tenapanor or placebo
twice daily for 12 consecutive weeks. At the end of this treatment period, subjects were followed for an additional 4 weeks. The
results were reported on an intent-to-treat basis.
The primary endpoint, CSBM responder rate, was achieved in 60.7% of patients receiving tenapanor 50 mg twice daily versus
33.7% receiving placebo (p<0.001). A CSBM responder was defined as a patient who had an increase of greater than or equal to one
CSBM from baseline during 6 out of 12 weeks. We also measured a more stringent CSBM response where a responder was defined as
a patient who an increase of greater than or equal to one CSBM from baseline and had three or more CSBMs per week during 9 out of
12 weeks. The CSBM 9 of 12 week responder rate was achieved in 23.8% of patients receiving tenapanor 50 mg twice daily versus
7.9% receiving placebo (p<0.004).
An abdominal pain responder was achieved in 65.5% of patients receiving tenapanor 50 mg twice daily versus 48.3% receiving
placebo (p<0.026). An abdominal pain responder was defined as a patient who experienced at least a 30% decrease in abdominal pain
from baseline for 6 of 12 weeks. We also measured a more stringent abdominal pain responder rate where a responder was defined as
a patient who experienced at least a 30% decrease in abdominal pain from baseline for 9 of 12 weeks. The abdominal pain 9 of 12
responder rate was achieved in 48.8% of patients receiving tenapanor 50 mg twice daily versus 31.5% receiving placebo (p<0.022).
The overall responder rate, or dual composite endpoint percent, was achieved in 50% of patients receiving tenapanor 50 mg
twice daily versus 23.6% receiving placebo (p<0.001). An overall responder was defined as a patient who was a CSBM responder and
an abdominal pain responder during the same week for 6 of 12 weeks. We also measured a more stringent overall responder rate
where a responder was defined as a patient who was both a CSBM responder and an abdominal pain responder during the same week
for 9 of 12 weeks. The overall 9 of 12 week responder rate was achieved in 20.2% of patients receiving tenapanor 50 mg twice daily
versus 6.7% receiving placebo (p<0.01).
Most other secondary endpoints measured also demonstrated significant improvements for patients receiving 50 mg tenapanor
twice daily compared to placebo-treated patients.
A dose response relationship among all doses was observed in the primary endpoint, as well as in most secondary endpoints,
although statistical significance was not achieved at the 5 mg or 20 mg doses. Additionally, the activity of tenapanor was maintained
throughout the entire 12-week treatment period.
8
Tenapanor was well-tolerated in these patients, and the safety results were consistent with those observed in previous tenapanor
trials. The most common adverse events at 50 mg twice daily (greater than or equal to 5%) that occurred more frequently in
tenapanor-treated patients compared to placebo-treated patients were diarrhea at 11.2% vs. 0%, and urinary tract infections at 5.6% vs.
4.4%. Overall rates of discontinuation due to adverse events were 4.5% for the tenapanor-treated patients (50 mg twice daily) and
3.3% for the placebo-treated patients. Based on the analysis of plasma samples tested as part of the study, the minimally-absorbed
nature of tenapanor was confirmed.
Size of the IBS-C market
Based on reports in the literature regarding the prevalence of IBS in the U.S. population and the percentage of individuals who
have IBS-C as opposed to other forms of IBS, we estimate that approximately 1.4% of the U.S. population has IBS-C, or about 4.4
million individuals. Of those, approximately 1.0 million patients have been diagnosed with IBS-C. Additionally, there are about 6.6
million IBS-C patients in Europe and about 3.4 million in Japan. The per-patient economic burden of IBS-C is estimated to be $1,500
to $7,500 per year in direct costs and $800 to $7,700 per year in indirect costs, implying the total burden in the United States is $2
billion to $15 billion.
Limitations of current products for IBS-C
Numerous treatments exist for the constipation component of IBS-C, many of which are over-the-counter. We are aware of two
prescription products marketed for IBS-C, Linzess (linaclotide) marketed by Ironwood Pharmaceuticals and Actavis and Amitiza
(lubiprostone) marketed by Sucampo and Takeda. In Phase 3 clinical trials of Linzess in IBS-C patients, up to 19.8% more patients
receiving Linzess than placebo reached the primary endpoint, overall responder rate, indicating a significant response during 6 out of
12 weeks of treatment. In these studies, Linzess caused diarrhea in up to 20% more patients than placebo.
Tenapanor’s competitive advantage in IBS-C
We believe that tenapanor may offer a significant benefit over currently marketed drugs like Amitiza and Linzess, due in part, to
the potential to adjust the dose and/or dose frequency of tenapanor in order to optimize its efficacy and minimize diarrhea. The data
we have generated in both animal and human studies have suggested that the effect of tenapanor for the treatment of IBS-C can be
modulated by adjusting its dose and dose frequency.
In our Phase 1 clinical trials in healthy adults, we observed a consistent and gradual increase of fecal sodium when the once
daily dose was increased from 3 mg to 100 mg, and we observed an approximate doubling of fecal sodium when the frequency of
dosing was increased to twice daily. In all of our studies, we have seen that stool form change correlates with the amount of sodium
diverted. In our Phase 2a clinical trial in IBS-C patients, we dosed up to 100 mg once daily and observed activity consistent with an
IBS-C drug and an incidence of diarrhea, a significant limitation of other IBS-C drugs that was similar to placebo. Our phase 2b
clinical trial demonstrated a stronger efficacy signal than the Phase 2a with a low to moderate rate of diarrhea of 11.2% versus
placebo. Given that we have observed a gradual dose response of sodium with increased dose and dose frequency of tenapanor and
that diarrhea represents an exaggerated pharmacological response to the drug, we believe it may be possible to start dosing at once
daily and/or a low dose. Those who do not respond would receive a higher dose or increased dose frequency. This ability to titrate the
dose of tenapanor, if proven in subsequent clinical trials in IBS-C patients, would represent a significant differentiation of tenapanor
versus currently commercialized products, and may allow optimization of dose response while limiting diarrhea.
Tenapanor for treating hyperphosphatemia in CKD-5D patients
In February 2015, we announced that our Phase 2b clinical trial evaluating tenapanor for the treatment of hyperphosphatemia in
CKD-5D patients, or ESRD patients on dialysis, met its primary endpoint of lowering serum phosphate. In this study, the rate of
diarrhea and the discontinuation rate due to diarrhea at the highest doses were higher than expected based on previous clinical trials.
Higher discontinuations rates due to diarrhea were observed primarily in the 30mg once daily and 30mg twice daily dose groups.
CKD is the progressive deterioration of renal function that can occur over several months or years. The symptoms of worsening
kidney function are nonspecific, and can include having less energy, reduced appetite, dry itchy skin, swollen feet and ankles, or
generally just not feeling well. If the deterioration continues and is not halted by either changes in life-style or with the assistance of
pharmacological intervention, the disease will likely cause significant cardiovascular morbidity, and can progress to ESRD, the final
stage of CKD, where kidney function will be lost entirely.
9
Current management of CKD-5D includes hemodialysis and peritoneal dialysis as a means to filter toxins from the blood once
kidneys have failed. Unless this intervention occurs, kidney failure results in the accumulation of waste products that may ultimately
cause death. Hemodialysis, the most common form of dialysis, generally requires a patient to visit a dialysis center at least three times
per week for a three- to five-hour session, significantly reducing quality of life.
Hyperphosphatemia in CKD-5D
Phosphorus, a vital element required for most cellular processes, is present in almost every food in the Western diet, and, in
individuals with normal kidney function, any excess dietary phosphorus is efficiently removed by the kidney and excreted in urine. In
adults with functioning kidneys, normal serum phosphorus levels are 2.6 to 3.8 mg/dL. With kidney failure, elevated phosphorus
becomes a toxin and is diagnosed as hyperphosphatemia when serum phosphorus levels are greater than 5.0 mg/dL. Although patients
with CKD-5D rely on dialysis to eliminate toxins, phosphorus is not readily removed by the procedure and other means of managing
phosphorus levels must be employed.
In CKD-5D, excess levels of phosphorus have been shown to lead to an increase in cardiovascular disease risk, as well as
increases in serum FGF-23, an important serum endocrine hormone that regulates phosphorus metabolism, and elevated parathyroid
hormone, also known as secondary hyperparathyroidism. These endocrine changes in CKD-5D patients are a concern as elevated
parathyroid hormone leads to the development of renal osteodystrophy, a condition of abnormal bone growth characterized by brittle
bones.
Elevated levels of FGF-23 are strongly associated with an increased risk of cardiovascular mortality. With concurrent elevated
calcium levels common in these patients, particularly when calcium is used as a means of controlling phosphorus, deposits containing
calcium and phosphate develop in arteries, joints, skin, soft tissue and other organs. Increased coronary artery calcification is
associated with an increased risk of heart disease, stroke and death.
Clinical data supporting tenapanor in hyperphosphatemia
We and AstraZeneca conducted a Phase 2b clinical study evaluating tenapanor in CKD-5D patients with hyperphosphatemia.
We announced results of this study in February 2015. This Phase 2b trial (ClinicalTrials.gov identifier NCT02081534) was a
randomized, double blind, placebo-controlled, multi-center, international study evaluating the safety and efficacy of six dose levels of
tenapanor (3 and 30 mg once daily, and 1, 3, 10, and 30 mg twice daily) in 161 hyperphosphatemic CKD-5D patients. The primary
efficacy endpoint was the change from baseline of S-phosphate levels to the end of treatment and the endpoint was analyzed using an
analysis of covariance model (ANCOVA). The study met its primary endpoint by demonstrating a statistically significant dose-related
decrease in serum phosphate levels for tenapanor-treated patients compared to patients receiving placebo (p=0.012).
The Effect of Tenapanor on Serum Phosphate in Hyperphosphatemic CKD-5D Patients
Group
1(cid:3)mg(cid:3)BID
3(cid:3)mg(cid:3)BID
10(cid:3)mg(cid:3)BID
30(cid:3)mg(cid:3)BID
3(cid:3)mg(cid:3)QD
30(cid:3)mg(cid:3)QD
Placebo
*LSMean = least square mean
n
23
21
23
24
22
21
26
LSMean*(cid:3)(mg/dL)
(cid:882)0.47
(cid:882)1.18
(cid:882)1.70
(cid:882)1.98
(cid:882)0.56
(cid:882)1.11
(cid:882)0.54
95%(cid:3)CI
((cid:3)(cid:882)1.18,(cid:3)0.24)
((cid:882)1.93,(cid:3)(cid:882)0.44)
((cid:882)2.41,(cid:3)(cid:882)0.99)
((cid:882)2.67,(cid:3)(cid:882)1.28)
((cid:882)1.28,(cid:3)0.17)
((cid:882)1.85,(cid:3)(cid:882)0.37)
((cid:882)1.21,(cid:3)0.13)
As shown in the table, a dose-response relationship was observed in the primary endpoint and twice daily dosing had better
pharmacodynamic activity than once daily dosing.
As expected, due to its pharmacological actions, the most frequent adverse event was diarrhea. The rate of diarrhea and the
discontinuation rate due to diarrhea at the highest doses were higher than expected based on previous clinical trials. Higher
discontinuations rates due to diarrhea were observed primarily in the 30mg once daily and 30mg twice daily dose groups. There were
no other notable gastrointestinal adverse events that appeared to be tenapanor related. The overall safety profile remains consistent
with that observed in previous tenapanor trials in this patient population.
10
Phase 2b CKD-5D Hyperphosphatemia Adverse Events: Gastrointestinal Disorders*
Preferred(cid:3)Term
n/group
Abdominal(cid:3)Distension
Abdominal(cid:3)Pain
Abdominal(cid:3)Pain(cid:3)Upper
Diarrhea
Diverticulum
Dyspepsia
Fecal(cid:3)Incontinence
Feces(cid:3)Soft
GI(cid:3)Hypermotility
GI(cid:3)Sounds(cid:3)Abnormal
Hemorrhoids
Nausea
Rectal(cid:3)Prolapse
Steatorrhea
Vomiting
1(cid:3)mg BID
23
3(cid:3)mg BID
21
1
10(cid:3)mg BID
23
30(cid:3)mg(cid:3)BID
25
3(cid:3)mg QD
22
30(cid:3)mg QD
21
Placebo
26
6
1
6
1
1
1
1
1
2
17
1
1
1
11
2
1
1
1
1
4
1
2
1
11
1
1
2
1
3
2
1
*Number of patients who had at least 1 AE in system organ class of gastrointestinal disorders; in these tables QD refers to once daily
dosing and BID refers to twice daily dosing.
Phase 2b CKD-5D Hyperphosphatemia Discontinuations Due to Adverse Events
Adverse(cid:3)Event(cid:3)Term
n/group
Discontinuations(cid:3)due(cid:3)to(cid:3)
AE/group*
Abdominal(cid:3)Pain
Diarrhea**
Nausea
Vomiting
Serum(cid:3)Calcium(cid:3)Decrease
Hyperphosphatemia
Dizziness
Atherosclerosis
1(cid:3)mg(cid:3) BID
23
3
3(cid:3)mg BID
21
3
2
1
3
1
10(cid:3)mg BID 30(cid:3)mg(cid:3)BID
23
3
3
25
9
1
8
3(cid:3)mg QD
22
1
30(cid:3)mg QD
21
7
Placebo
26
2
6
1
1
1
1
1
2
*There may be multiple reasons for a single discontinuation
**The term “diarrhea” also includes similar changes in stool form or bowel habits
Size of the hyperphosphatemia market
According to the most recent data available from the U.S. Renal Data System, in 2012 there were 408,711 patients on
hemodialysis in the United States. Additionally, according to the European ERA-EDTA Registry 2012 Annual Report and a study in
2010 by the Japanese Society for Dialysis Therapy, there were approximately 280,000 patients on hemodialysis in Europe and about
250,000 in Japan. We estimate, based on phosphate binder utilization, the only approved therapies for hyperphosphatemia, that there
are approximately 280,000, 225,000 and 220,000 CKD-5D patients with hyperphosphatemia in the United States, Europe and Japan,
respectively.
11
Limitations of current products for hyperphosphatemia
Since dialysis is unable to efficiently eliminate excess phosphorus, CKD-5D patients are put on restrictive low phosphorus diets
and are prescribed medications called phosphate binders, the only pharmacologic interventions currently marketed for the treatment of
hyperphosphatemia. Phosphate binders are a collection of drugs whose function is to bind, or absorb, dietary phosphorus and are taken
in conjunction with meals and snacks. They include calcium, iron or lanthanum, a rare-earth metal, which bind to and precipitate with
dietary phosphate in the GI tract. The goal is for patients to eliminate the precipitated phosphorus in their stool. A limitation of this
approach is the systemic excess absorption of calcium, iron or lanthanum, resulting in side effects and other unintended consequence
for CKD-5D patients. In an effort to eliminate these unwanted side effects, non-absorbed exchange resins, such as sevelamer were
developed to bind to phosphate in the GI tract and to be eliminated in stool.
Safety and tolerability have been significant concerns with many approved phosphate binders. The more common side effects of
approved phosphate binders include long-term vascular calcification, nausea and vomiting, diarrhea or constipation and ileus or
disruption of the normal propulsive ability of the GI tract.
CKD-5D patients take on average 10-14 oral medications each day, and they are severely restricted in their fluid intake. In
addition, to control their serum phosphorus, their phosphate binder-related pill burden is significant, typically consisting of nine or
more pills a day. The amount of phosphate a binder can remove is limited by its binding capacity, and therefore, increasing the dose,
and the pill burden, of the binder is the only way to increase the amount of phosphate being bound and excreted. As a result,
prescribed binder doses are intolerable for many patients.
The effectiveness of current treatment with phosphate binders is limited. For example, in a 2012 study conducted by Amgen in
1,430 ESRD patients on hemodialysis in the United States in which 89% of the patients in the study had previously been prescribed
phosphate binders, the average baseline serum phosphorus level was 6.4 mg/dL, significantly above the target for dialysis patients of
5.5 mg/dL and far above normal serum phosphorus levels of 2.6 to 3.8 mg/dL. Other studies suggest that this lack of efficacy is due
primarily to poor patient compliance associated with significant pill burden and other tolerability issues.
Tenapanor’s competitive advantage in hyperphosphatemia
Given that the objective is to lower serum phosphorus levels to below 5.5 mg/dL in dialysis patients, and that many of these
patients are unable to accomplish this goal with currently marketed phosphate binders, there is a clear medical need for new treatments
for hyperphosphatemia. We believe that there is a significant opportunity for new agents with new mechanisms, demonstrated
efficacy, a strong safety profile, and significantly lower pill burden. We believe that tenapanor, if approved, has the potential to have
the lowest pill burden among any of the marketed hyperphosphatemia drugs, with milligram rather than gram quantities dosed once or
twice daily.
Tenapanor for treating CKD: potential long-term benefit of sodium control
In an ongoing Phase 2a trial, we and AstraZeneca are exploring the potential benefit of tenapanor in treating patients with CKD
who still have some renal function and are not yet on dialysis. In order to explore the benefits of tenapanor in this population, we are
initially evaluating tenapanor for its effect on markers of kidney disease and fluid status. We expect results from this trial in the
second quarter 2015.
The decline in renal function in patients with CKD is initially asymptomatic and the rate of disease progression varies based on
genetics, ethnicity, the underlying cause, such as cardiovascular disease, diabetes, and many other factors. As the disease progresses,
signs and symptoms of CKD become more apparent and include fluid overload, hyperkalemia, metabolic acidosis, hypertension,
anemia, and mineral and bone disorders. Therapy to delay progression of the disease focuses on blood pressure control and reduction
in urinary protein excretion.
Sodium and fluid overload in CKD
In CKD patients, failing kidneys are less efficient at blood filtration and sodium elimination resulting in fluid and sodium
overload. This fluid overload correlates with the rapid decline of kidney function and the eventual requirement for renal replacement
therapy including hemodialysis. The effects of fluid overload include high blood pressure, worsening kidney and heart disease, fluid in
the lungs, or edema, causing dyspnea, or shortness of breath, and ultimately poor survival. Fluid overload has been shown to be an
independent predictor of mortality in both hemodialysis patients and in CKD patients.
12
In a study of CKD patients where sodium intake was restricted, the investigators demonstrated that lower sodium intake
corresponded to reduced blood pressure and albuminuria in those patients. Those two measures are indicators that kidney function
may be improving. Although generally acknowledged that excess sodium intake should be curtailed in this population, it is also
recognized that the majority of people who are told to restrict sodium intake are non-compliant. We believe that the pharmacologic
approach we are taking with tenapanor may have the same impact as a low sodium diet, but may improve compliance.
We believe that, if we are successful in demonstrating an improvement in UACR with a reasonable tolerability profile
particularly related to rate of diarrhea at effective doses, our ongoing Phase 2a clinical trial of tenapanor in CKD patients will provide
data to allow for further investment in larger trials evaluating tenapanor’s ability to delay CKD disease progression. We expect to
receive results from the ongoing Phase 2a study in the second quarter of 2015.
Limitations of current approaches to delay CKD progression
In an effort to preserve renal function, physicians often suggest a number of interventions and life-style modifications; however,
most of them are quite cumbersome and lead to poor patient compliance. Although low sodium diets are generally required for all
CKD patients, most patients are generally poorly compliant for a variety of reasons, including cost, lack of availability of low sodium
foods and the unwillingness to change eating habits.
Most CKD patients are also treated with a combination of therapies designed to delay progression of kidney disease by
controlling diabetes, blood pressure and decreasing fluid retention. Diuretics are often prescribed to inhibit sodium re-uptake in the
kidney and increase urinary sodium and water excretion. However, diuretics lose efficacy as kidney function declines, and are known
to cause electrolyte disorders such as hypokalemia (low potassium) and metabolic alkalosis (high bicarbonate level in the blood).
Hypertension medications referred to as ACE inhibitors, ARBs and mineral corticoid receptor blockers also reduce blood pressure
associated with fluid overload, which in turn can delay the rate of progression of CKD. In addition, these agents, particularly mineral
corticoid receptor blockers, can result in hyperkalemia (high potassium), preventing their widespread use in CKD patients.
Size of late-stage CKD market
Worldwide, there are about 64.6 million patients with stage 3 or 4 CKD all of which are at significant risk of kidney disease
progression, heart disease caused by vascular calcification and premature death. There are approximately 3.6 million patients in the
United States with stage 3b and 4 CKD. There are about 8.5 million and 2.3 million patients with stage 3b or 4 CKD in Europe and
Japan, respectively. Of these, there are about 1.8 million, 1.7 million and 0.6 million patients in the United States, Europe and Japan,
respectively that have both CKD and type 2 diabetes, the patient population currently studied in the ongoing Phase 2a CKD clinical
trial.
Preclinical and clinical data supporting tenapanor for CKD
In preclinical models, rats with CKD that were fed a high salt diet and exhibited hypervolemia, cardiac hypertrophy and arterial
stiffening, had improved measures of cardio-renal function including a dose-dependent reduction of extracellular fluid volume, left
ventricular hypertrophy, albuminuria, and blood pressure in a dose-dependent manner with administration of tenapanor. We observed
these effects whether tenapanor was administered prophylactically or after disease was established. In these studies, tenapanor also
prevented increases in glomerular area and urinary KIM-1, both markers of renal injury. In addition, rats dosed with a combination of
tenapanor and the blood pressure medication enalapril showed improvement in cardiac diastolic dysfunction and arterial pulse wave
velocity relative to those animals dosed with enalapril alone.
In human studies, tenapanor reduced urinary sodium excretion by 20 to 50 mmol/day and led to an increase of similar
magnitude in stool sodium. The results of these preclinical and clinical studies suggest that therapeutic alteration of sodium transport
with tenapanor in the gastrointestinal tract could lead to improvements in CKD and has informed the design of our development plan.
13
We and AstraZeneca are conducting an exploratory Phase 2a, randomized, double-blind, placebo- controlled study to evaluate
pharmacodynamics of tenapanor in patients with stage 3 CKD, type 2 diabetes mellitus with albuminuria and elevated systolic blood
pressure. One-hundred and fifty-four subjects have been randomized and enrollment is closed. The study consists of a 4-week run-in
period, 12 weeks of blinded treatment with tenapanor 5, 15, 30, or 60 mg BID or placebo, and a 2-week follow-up period.
Consent
Randomization
Tenapanor 5 mg to 60 mg BID
Run-in:
confirmation of
eGFR, UACR &
blood pressure
Screening
Follow up visit
Placebo BID
n(cid:167)77/group; 154 total
End of Treatment
Up to 4-
week run-in
12- week treatment
period
2-week
follow-up
Pharmacodynamic assessments, or assessments of biological effects of tenapanor, include the following measures: Urine
albumin-to-creatinine ratio, or UACR and eGFR (s-creatinine, and s-cystatin-c) which are indications of kidney function, blood
pressure, bioimpedance a measure of excess body fluid, mean weekly stool consistency and stool frequency and urinary and blood
markers associated with kidney disease. Safety assessments are performed at regular intervals and include physical examinations, vital
signs, body weights, electrocardiograms, and laboratory results from blood and urine tests.
If the results of the ongoing Phase 2a study demonstrate that tenapanor offers a benefit by decreasing elevated UACR, a
measure that roughly correlates with kidney disease severity and which has a significant component that may be independent of any
blood pressure effect, and if the agent can demonstrate a reasonable tolerability profile particularly related to rate of diarrhea, we
believe this may give us insight into the potential long-term benefit of tenapanor on delaying the progression of kidney disease.
Other Development Programs
Utilizing our proprietary drug discovery and design platform, we are pursuing other internal discovery and lead-development
programs that are currently in the research phase, including our RDX002 program partnered with Sanofi, and the two internal
programs that we have announced, RDX009 and RDX013. While we have identified molecules that exhibit certain of the activity we
are seeking in each of these programs, we have not yet selected a lead molecule in these programs.
RDX002 NaP2b Inhibitor for Hyperphosphatemia
RDX002 refers to our program aimed at discovering and evaluating small molecule inhibitors of the intestinal phosphate
transporter NaP2b (also known as NaPi2b, Npt2b and SLC34A2). Our RDX002 program includes a portfolio of minimally-absorbed
NaP2b inhibitors in the discovery and preclinical stage of development. We have licensed this program to Sanofi, and under the terms
of the agreement, Sanofi is responsible for completing discovery and preclinical work and, if it exercises its option, developing and
commercializing at least one NaP2b inhibitor resulting from the program.
NaP2b is an intestinal phosphate transporter whose activity is believed to account for a significant portion of dietary phosphate
absorption in humans. We believe the inhibition of NaP2b would provide utility for the treatment of hyperphosphatemia in CKD-5D
patients.
We have identified several NaP2b inhibitors that showed activity in vitro and in animal models. In rats with normal renal
function certain NaP2b compounds were able to reduce urinary excretion of phosphorus better than commercial phosphate binders
such as sevelamer or colestilan, even when these compounds were dosed at approximately 1/10 of the dose of the commercial binders.
In addition, our NaP2b compounds had additive effects when administered with sevelamer or colestilan. In a rat model designed to
emulate CKD (5/6 nephrectomized rats where one full kidney and 2/3 of the second kidney are removed) one of our NaP2b inhibitors
significantly reduced serum phosphorus and was additive or synergistic with sevelamer. This agent also significantly improved animal
survival in the same model.
14
Our identified NaP2b inhibitors work through a mechanism distinct from those employed by binders. Our NaP2b inhibitors are
designed to inhibit NaP2b, one of the primary phosphate transporters in the gut. We have shown that our inhibitors are able to inhibit
phosphate regardless of the amount of phosphate in the diet. We believe this mechanism would have a significant advantage over
phosphate binders, and may allow us to significantly decrease pill burden while retaining a similar phosphorus effect. Additionally, we
believe that the use of a NaP2b inhibitor in combination with a phosphate binder may allow the dose of the phosphate binder to be
reduced. We cannot predict whether or not these effects will be seen until the appropriate clinical trials are conducted.
RDX009 TGR5 agonists for IBD, Short Bowel Syndrome and NASH
Our RDX009 program is aimed at discovering and evaluating small molecule, orally-administered drug candidates that stimulate
TGR5. We believe the stimulation of TGR5 may have utility in several conditions, including inflammatory bowel disease, or IBD,
short bowel syndrome, and possibly type 2 diabetes and NASH.
TGR5 is a receptor present on the membrane of certain cells within the GI tract that responds to bile acids secreted in response
to food. In the normal physiological response, binding of bile acids to TGR5 stimulates the production of hormones such as glucagon-
like peptides 1 and 2 (GLP-1 and GLP-2). GLP-1 is involved in maintaining insulin sensitivity and in aiding glucose and lipid
metabolism. GLP-2 is involved in maintenance of the structural integrity of the gut as well as its growth.
We believe that endogenous and local secretion of GLP-1 and GLP-2 triggered by the stimulation of TGR5 receptors by an oral
TGR5 agonist may have significant therapeutic potential for the treatment of several conditions. An injectable, stabilized form of
GLP-2, called teduglutide (Gattex), is marketed for short bowel syndrome and has been studied in Crohn’s disease. GLP-2 is
hypothesized to work in IBD such as Crohn’s disease and ulcerative colitis, or UC, by stimulating the repair of the gut and improving
the structural integrity of gut wall that is damaged in patients with IBD. Injectable stabilized GLP-1 analogs that are commercially
available, such as exenatide (Byetta) and liraglutide (Victoza), are commonly used to treat type 2 diabetes, among other metabolic
conditions. Additionally, injectable GLP-1 analogs are being evaluated in the treatment of NASH because they are known to improve
lipid metabolism in the liver. In all of these cases, GLP-1 and GLP-2 analogs are injectable thus we believe an oral agent that can
emulate these effects would be welcome.
Historically one of the limitations for the development of TGR5 agonists has been the observation with systemic compounds
that stimulation of TGR5 in the gallbladder results in excess gallbladder filling, potentially increasing the risk of gallstones. Utilizing
our approach to design small molecules, we have created novel TGR5 agonist candidates that have extremely low systemic exposure
and we have shown that these agents do not result in excess gallbladder filling in preclinical animal models. These TGR5 agonists, in
combination with certain DPP4 inhibitors, also demonstrated significant activity in several different animal models of disease.
RDX013 for hyperkalemia
Our RDX013 program is aimed at discovering and evaluating small molecule, orally-administered drug candidates that
modulate the transport of potassium in the GI tract.
Our agents will be designed to enhance potassium secretion or prevent potassium absorption in the colon and correct
hyperkalemia disorders in CKD patients. We believe that specific potassium transporters in the intestines may serve as useful targets
for our program. We are also using APECCS to identify novel pathways to activate potassium flux from the interior of the GI
epithelium cells to the GI lumen. We believe that such agents may be used as stand-alone agents or used in combination with
potassium binders to boost efficacy or to reduce the pill burden of the potassium binders. Several agents we have developed have
demonstrated significant activity in animals.
Collaboration Partnerships
Collaboration partnership with AstraZeneca
Overview
In October 2012, we entered into a collaboration partnership with AstraZeneca for the development and commercialization of
our small molecule NHE3 inhibitors, including tenapanor as well as back-up compounds. Additionally, as part of the collaboration
partnership, we agreed to provide development support related to the licensed compounds subject to reimbursement by AstraZeneca
for our internal and external expenses incurred in providing such efforts, subject to an agreed upon cap on AstraZeneca’s obligation to
reimburse our costs for the Phase 2b clinical trial of tenapanor for IBS-C.
15
Under the terms of the agreement, we received a $35.0 million upfront payment and we are eligible to receive up to $237.5
million in development milestones, of which we have received $40.0 million. In addition to the $237.5 million in total development
milestones, we are also eligible to receive up to $597.5 million in sales and launch milestones which, when combined with the $35.0
million upfront payment, provides for potential payments of up to $870.0 million. Through December 31, 2014, we also received
$34.2 million in reimbursement for our development efforts provided under the agreement. We are also eligible to receive incremental
tiered royalties based on aggregate annual net sales of each licensed product starting in the high single digits and increasing to high
teen percentages as annual net sales increase. If we exercise our right to co-fund the first Phase 3 development program for tenapanor,
we could acquire an increase in our royalties by 1%, 2% or 3%, as described below under the heading “—Right to co-fund/royalty
buy-up.”
AstraZeneca solely funds all development and commercialization costs for licensed compounds and licensed products, except
for costs that we elect to undertake if we exercise our right to co-fund certain development efforts in exchange for an increase in the
royalty percentage, as described below under the heading “—Right to co-fund/royalty buy-up.”
AstraZeneca may choose to develop tenapanor for any indication. Provided that it is pursuing development for at least one
indication, AstraZeneca may choose not to develop tenapanor for any other indications. AstraZeneca must use commercially
reasonable efforts to develop, manufacture, seek regulatory approval for and commercialize a licensed product in each of certain
specified major markets.
Right to co-fund/royalty buy-up
We may elect to participate in the funding of the first Phase 3 development program for the first indication for the first licensed
product by paying a co-funding amount of $20.0 million, $30.0 million or $40.0 million. We may exercise this right within a specified
time period after the decision to proceed to Phase 3 clinical development for the first indication for the first licensed product. If we
elect to co-fund the Phase 3 development program for the specific indication for the relevant licensed product, we will receive a 1%,
2% or 3% increase in the royalty payable on net sales of the licensed product for all indications, depending upon the level of co-
funding that we elect. We may exercise this right only for a period of 60 days following AstraZeneca’s determination to proceed to the
first Phase 3 clinical development program for tenapanor for a specific indication. An election to participate in the co-fund will be
based, in part, on our analysis as to the likelihood of success of the Phase 3 clinical development program and the potential for
regulatory approval to commercialize tenapanor. The selected co-funding amount would be paid ratably over the estimated period of
the Phase 3 clinical development program.
Right to co-promote in the United States
We may elect to co-promote in the United States the first licensed product for the first indication for which Phase 3 clinical
development is completed. If we make such an election, we may also elect to co-promote the same licensed product for additional
indications for which Phase 3 clinical development is completed in the specified period. After we make a co-promotion election, we
must enter into a separate co-promotion agreement on terms and conditions set out in our agreement with AstraZeneca, which
includes, among other rights and obligations, a requirement for Ardelyx to provide a trained sales force for promoting the licensed
product, which may not also promote products that compete with the licensed product or other products then promoted by
AstraZeneca or its affiliates and AstraZeneca must reimburse us for our agreed-upon co-promotion efforts other than for general
training of our sales force. We will continue to have a right to receive royalties on net sales of licensed products as set forth in the
agreement even if we elect to co-promote the licensed product in the United States.
Other terms
For periods specified in the agreement, neither we nor AstraZeneca can research, develop or commercialize NHE3 inhibitors,
other than pursuant to the agreement.
16
The agreement will expire in its entirety upon the expiration of all applicable royalty terms for all licensed products in all
countries, and the satisfaction or expiration of all other payment obligations under the agreement. The royalty term for each licensed
product in each country is the period commencing with the first commercial sale of the applicable licensed product in the applicable
country and ending on the later of expiration of specified patent coverage or 10 years after the first commercial sale in the applicable
country. AstraZeneca has the right to terminate the agreement at any time in its entirety, upon specified prior written notice to us, and
is deemed to have so terminated the agreement if it ceases all exploitation of licensed products for a specified continuous time period
and does not provide a plan to recommence such exploitation within a particular time period thereafter. AstraZeneca may also
terminate the agreement on a country by country basis upon a specified prior written notice if there are third party patents that may be
infringed in particular countries by the development, manufacture or commercialization of licensed products, subject to certain
conditions. The agreement may also be terminated by us in the event that AstraZeneca actively assists in a legal challenge of any of
the patents exclusively licensed to AstraZeneca under the agreement, and it may be terminated by us or by AstraZeneca for a material
breach by or insolvency of the other party.
Collaboration partnership with Sanofi
Overview
In February 2014, we entered into a license option and license agreement with Sanofi under which we granted Sanofi an
exclusive worldwide license to conduct research utilizing our small molecule NaP2b inhibitors solely for the purpose of completing
activities under a preclinical development plan. Under the terms of this agreement, Sanofi has the option to obtain an exclusive license
to develop, manufacture and commercialize our NaP2b inhibitors. Sanofi may exercise this option at any time following the effective
date of the agreement and ending 45 days after the filing of an IND, subject to certain exceptions, and if Sanofi does not file an IND
on or before the 40 month anniversary at the completion of the technology transfer phase, the agreement will terminate.
Sanofi is responsible for conducting and funding all research, development and commercialization of licensed products under
the agreement. If Sanofi exercises its option, it must use commercially reasonable efforts to develop, seek regulatory approval for,
manufacture and commercialize a licensed product for any indication in each of certain specified major markets.
We received a $1.25 million upfront payment, and we are eligible to receive up to $196.75 million in development and
regulatory milestone payments. We are also eligible to receive incremental tiered royalties based on aggregate annual net sales of any
licensed product starting in the mid-single digits and increasing to low teen percentages as annual net sales increase, subject to
reduction in specified circumstances.
Right to co-promote in the United States
We may elect to co-promote in the United States for each licensed product for which Phase 3 clinical development is completed.
We may elect to provide a level of co-promotion support within a range specified in our agreement with Sanofi. If we make such an
election to co-promote, we have additional rights to elect to co-promote other licensed products under this agreement. After we make a
co-promotion election, we must enter into a separate co-promotion agreement on terms and conditions set out in our agreement with
Sanofi. Such co-promotion agreement must provide reasonable terms and conditions under which we will co-promote the relevant
licensed products, and will require Sanofi to compensate us for performing our co-promotion obligations. We will continue to have a
right to receive royalties on net sales of licensed products as set forth in the agreement even if we elect to co-promote the licensed
product in the United States.
Other terms
During the term of the agreement, and in certain circumstances for a specified period following termination of the agreement,
neither we nor Sanofi can, subject to certain exceptions described in the agreement, research, develop or commercialize a NaP2b
inhibitor other than pursuant to the agreement.
17
The agreement will expire if Sanofi does not exercise its option by the earlier of (i) 45 days after the filing of an IND for a
NaP2b inhibitor (subject to certain extensions for regulatory actions) and (ii) the expiration or termination of the agreement. If Sanofi
does exercise its option, the agreement will expire in its entirety upon the expiration of all applicable royalty terms for all licensed
products in all countries, and the satisfaction or expiration of all other payment obligations under the agreement. The royalty term for
each licensed product in each country is the period commencing with the first commercial sale of the applicable licensed product in
the applicable country and ending on the later of expiration of specified patent coverage or 10 years after the first commercial sale in
the applicable country. Sanofi has the right to terminate the agreement at any time in its entirety or on a country-by-country basis upon
specified prior written notice to us, and is deemed to have so terminated the agreement if it has not filed an IND for a licensed
compound within a specified period of time, if it fails to exercise its option within a specified period of time, or if, after exercising its
option, it ceases all exploitation of licensed products for a specified continuous time period and does not provide a plan to
recommence such exploitation within a particular time period thereafter. The agreement may also be terminated by us in the event that
Sanofi actively assists in a legal challenge of one of the patents exclusively licensed to Sanofi under the agreement, and it may be
terminated by us or by Sanofi for a material breach by or insolvency of the other party.
Commercialization of our Products
We retain co-promotion rights with our collaboration partners, AstraZeneca and Sanofi, in the United States, and under the
terms of our agreements, our commercialization costs will be funded by the collaboration partner. We expect, subject to certain
conditions set forth in the AstraZeneca agreement, to take advantage of these opportunities to co-promote our licensed products. We
intend to build a focused, specialized sales force in the United States to effectively support the commercialization of these and future
products.
If we co-promote our licensed products, we would develop a sales capability to target key prescribing physicians in nephrology,
gastroenterology, endocrinology or cardiology, depending on the product. We currently do not have any sales or marketing activities
or personnel. Within the time required under our agreements with AstraZeneca and Sanofi, if we exercise our co-promotion right we
will establish the required capabilities in advance of any product approval and commencement of commercialization to prepare for
product launch. If we are not able to establish these sales and marketing capabilities, either on our own or through collaboration with
AstraZeneca and Sanofi, any revenue from our future products that we commercialize may be materially adversely affected.
Competition
Competition for management of IBS-C
Numerous treatments exist for constipation and the constipation component of IBS-C, many of which are over-the-counter.
These include psyllium husk (such as Metamucil), methylcellulose (such as Citrucel), calcium polycarbophil (such as FiberCon),
lactulose (such as Cephulac), polyethylene glycol (such as MiraLax), sennosides (such as Exlax), bisacodyl (such as Ducolax),
docusate sodium (such as Colace), magnesium hydroxide (such as Milk of Magnesia), saline enemas (such as Fleet) and sorbitol.
These agents are generally inexpensive and work well to relieve temporary constipation.
We are aware of two prescription drugs currently on the U.S. market that are approved to treat IBS-C:
(cid:120) Linzess (linaclotide): Linzess is a drug developed by Ironwood Pharmaceuticals, Inc., approved in 2012 and 2013 for
IBS-C and chronic constipation in both the United States and in Europe. Linzess is based on the heat stable enterotoxin
produced in E. coli that causes traveler’s diarrhea. Linzess targets guanylate cyclase C in the intestines and, by doing
so, induces intestinal chloride and fluid secretion, which results in the outpouring of water into the intestine. Linzess in
a meta-analysis was deemed “moderately effective compared with placebo for improving typical symptoms of IBS-C”.
In two IBS-C phase 3 studies, Linzess had a 12.6% and 19.8% overall responder rate compared to the placebo. In these
studies, the most common side effect was diarrhea which occurred in 20% of the patients, and led to discontinuation of
5% of the patients.
(cid:120) Amitiza (lubiprostone): Amitiza was first approved in the United States in 2006 and is currently marketed by Sucampo
Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited for treatment of chronic idiopathic constipation, or
CIC, IBS-C and opioid-induced constipation, or OIC. Amitiza binds selectively to and activates the type-2 chloride
channel in the intestine releasing chloride and water into the intestine. In two IBS-C phase 3 studies, Amitiza’s overall
response rate (global relief of IBS-C symptoms) was about 6% greater than placebo. The primary adverse events were
nausea and diarrhea, which occurred in 8% and 7% of patients, respectively.
18
We are aware of several products in development targeting IBS-C and/or CIC. These include Ferring Pharmaceuticals,
Inc./Albireo AB’s elobixibat, an IBAT inhibitor in Phase 3 for CIC and in Phase 2 for IBS-C and Synergy Pharmaceuticals, Inc.’s
plecanatide, a GC-C agonist similar to linaclotide in Phase 3 for CIC and in Phase 2 for CIC and OIC as well, Synergy
Pharmaceuticals, Inc. has SP-333 in Phase 2 for OIC.
Competition for hyperphosphatemia
Phosphate binders are the only pharmacologic interventions currently marketed for the treatment of hyperphosphatemia.
Calcium-based binders are the least expensive option to treat hyperphosphatemia. In hemodialysis patients, sevelamer has a 40%
patient share versus 44% for calcium-based binders, 16% for lanthanum and 5% for iron-based binders. The various types of
phosphate binders commercialized in the United States include the following:
(cid:120) Calcium carbonate (many over-the-counter brands including Tums and Caltrate)
(cid:120) Calcium acetate (several prescription brands including PhosLo and Phoslyra)
(cid:120) Lanthanum carbonate (Fosrenol marketed by Shire)
(cid:120) Sevelamer hydrochloride (Renagel, marketed by Sanofi)
(cid:120) Sevelamer carbonate (Renvela, marketed by Sanofi)
(cid:120) Sucroferric oxyhydroxide (Velphoro, marketed by Vifor Fresenius)
(cid:120) Ferric citrate (Auryxia, marketed by Keryx)
Generic sevelamer was expected to enter the U.S. market in early 2014 after expiration of Sanofi’s patent, but as of early 2015,
no generic sevelamer has yet been approved. Generic sevelamer was approved, however, in certain jurisdictions in Europe in 2015.
Each of these agents has certain limitations. Calcium carbonate and calcium acetate can cause long term vascular calcification.
Lanthanum carbonate (Fosrenol) entered the market in 2004 as an alternative to calcium and aluminum based agents, but
nephrologists’ concerns about the long term toxicity from the absorption of metals such as lanthanum and its GI side effect profile
have limited its market penetration. Sevelamer hydrochloride (Renagel) is an acidic formulation of sevelamer that has been linked
with worsening of metabolic acidosis in patients. Sevelamer carbonate (Renvela) was developed as an improved formulation of
sevelamer to reduce incidence of acidosis. The active ingredient of both products, sevelamer, is associated long-term with vomiting
(22%), nausea (20%), diarrhea (19%), dyspepsia (16%), abdominal pain (9%), and flatulence (8%).
Ferric citrate (Auryxia), an iron-based phosphate binder, was approved by FDA in September 2014. While iron is often
deficient in CKD-5D patients because of CKD-associated anemia and lack of sufficient dietary iron, the FDA has required Auryxia to
add a warning of iron-overload in the label.
The hydrochloride form of sevelamer, Renagel, was launched in the United States by Genzyme Corporation in 1998 prior to its
acquisition by Sanofi, and the carbonate form, Renvela, was launched in 2008. Renvela is currently priced in the United States at a
cost of more than $10,000 per patient per year, Fosrenol (lanthanum carbonate) is priced at about $7,500 and calcium-based binders
are approximately $900. Despite its higher price, sevelamer is the leading phosphate binder product in the hemodialysis market with
36% patient share (versus 51% split among several calcium-based binders). Sanofi booked €684 million ($770 million) in worldwide
sales of sevelamer during 2013. The U.S. patents for sevelamer expired in February 2014 and generic launch was allowed in March
2014. Synthon announced the successful completion of a Phase 3 multicenter, randomized, double-blind, multiple-dose, crossover trial
in Europe to compare safety and demonstrate equivalence of serum phosphate control of Synthon sevelamer carbonate tablets to
Renvela tablets in chronic kidney disease patients on hemodialysis in April 2014. Currently, several pharmaceutical companies are
distributing Synthon manufactured sevelamer carbonate tablets in multiple European countries including, but not limited to, the UK,
Spain, Sweden and Denmark.
In addition to the currently marketed phosphate binders, we are aware of at least one other binder in development, fermagate
(Alpharen), an iron-based binder in Phase 2 being developed by Opko Health, Inc.
19
Competition for long-term management of CKD
There are no treatments for CKD that have been proven to reverse the disease. Additionally, various interventions, such as
improved diet, blood pressure control, and blood glucose control have had only moderate success in delaying the progression of the
disease. CKD patients are currently treated with a combination of diuretics and inhibitors of the renin-angiotensin aldosterone system,
or RAAS, to decrease fluid retention and improve hypertension.
There are several dozen generic and branded products that interfere with the RAAS pathway, or act as diuretics. Some of these
agents, such as furosemide and thiazide diuretics, were first used in the late 1950s. We are aware of a few new products being
developed for treatment of hypertension such as Novartis AG’s LCZ696, a dual inhibitor of angiotensin ll receptor and neutral
endopeptidase that is in Phase 3, and Palatin Technology, Inc.’s PL-3994, a long-acting natriuretic peptide receptor A agonist in Phase
2.
We are aware of certain investigational drugs that were being developed for delaying kidney decline as measured by eGFR.
Among other products, Concert Pharmaceuticals, Inc. is developing CTP-499 which showed protective effects on kidney function at
48 weeks in a Phase 2 clinical trial in patients with CKD and type 2 diabetes. We are aware of several drugs in Phase 2 clinical trials
being evaluated for diabetic nephropathy (excluding drugs for blood pressure) including ChemoCentryx, Inc.’s CCR antagonist
CCX140, Eli Lilly and Company’s TGF-beta monoclonal antibody LY2382770, Genkyotex S.A.’s dual NOX1/NOX4 inhibitor
GKT137831, Fibrogen, Inc.’s CTGF inhibitor FG-3019, Pfizer, Inc.’s long-acting PDE5 inhibitor PF-489791, and Noxxon Pharma
AG’s aptamer inhibitor of MCP-1/CCR2 NOX-E36. To our knowledge, none of these drugs has clinical data showing a delay in the
progression of CKD.
Intellectual Property
Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our drug candidates,
manufacturing and process discoveries, and other know-how, to operate without infringing the proprietary rights of others and to
prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other
methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are
important to the development and implementation of our business. We also rely on trade secrets and careful monitoring of our
proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent
protection.
As a normal course of business, we pursue composition-of-matter and method-of-use patents for our product candidates in key
therapeutic areas. We also seek patent protection for broader structural and functional attributes of our product candidates that enable a
minimally-systemic or minimally-absorbed profile.
The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and
factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and
its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will be protectable
or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as
patents in any particular jurisdiction or whether the claims of our issued patents will provide sufficient proprietary protection from
competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. If third parties prepare and file
patent applications in the United States that also claim technology or therapeutics to which we have rights, we, or our collaboration
partners, may have to participate in interference proceedings in the U.S. Patent and Trademark Office, or USPTO, to determine
priority of invention, which would result in substantial costs to us or our collaboration partners, even if the eventual outcome is
favorable to us.
The term of individual patents depends upon the legal term of the patents in countries in which they are obtained. In most
countries, including the United States, the patent term is generally 20 years from the earliest date of filing a non-provisional patent
application in the applicable country. In the United States, a patent’s term may, in certain cases, be lengthened by patent term
adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be
shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an
earlier expiration date.
20
In addition, in the United States, the Hatch-Waxman Act permits a patent term extension of up to five years beyond the
expiration of a U.S. patent as partial compensation for the patent term lost during the FDA regulatory review process occurring while
the patent is in force. A patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of
product approval, and only one patent applicable to each regulatory review period may be extended and only those claims covering the
approved drug, a method for using it or a method for manufacturing it may be extended. Similar provisions are available in the
European Union and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug. With respect to
tenapanor, our collaboration partner, AstraZeneca, and with respect to our NaP2b portfolio, under certain circumstances, our
collaboration partner, Sanofi, will be responsible for and have the right to control, with input from us, the selection of the appropriate
issued patent for filing to obtain any patent term extension that may be available under applicable laws.
We may rely, in some circumstances, on trade secrets to protect our technology. Although we take steps to protect our
proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may
independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or
disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees,
consultants, outside scientific collaboration partners, sponsored researchers and other advisors to execute confidentiality agreements
upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential
information concerning the business or financial affairs developed or made known to the individual during the course of the
individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the
case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or
planned business or research and development or made during the normal working hours, on our premises or using our equipment or
proprietary information, are our exclusive property.
NHE3 patents
Our NHE3 patent portfolio is wholly owned by us and exclusively licensed to AstraZeneca. This portfolio includes one issued
U.S. patent, U.S. Patent No. 8,541,448, covering the composition of tenapanor, and one issued Japanese patent, Japanese Patent No.
5502106 covering the composition of tenapanor. Both of these issued patents are predicted to expire in 2029. Five additional patent
applications are pending in the United States covering the composition of or methods of using tenapanor. We have related national
patent applications pending in Europe, China, India, Israel and a number of other countries. Any patents issuing from these patent
applications are also predicted to expire in 2029. An additional application that is eligible for worldwide filing is also pending, and we
expect that AstraZeneca will file national patent applications in Europe, Japan, China, India, Israel and a number of other countries at
the time when the PCT is converted to national filings.
NaP2b Patents
Our NaP2b portfolio is wholly owned by us, exclusively licensed to Sanofi, and includes four issued U.S. patents and three
pending U.S. applications covering the composition of or methods of using our NaP2b inhibitor compounds. The issued patents, and if
issued, the pending applications are predicted to expire in 2031. Related national patent applications are pending in Europe and Japan.
Any patents resulting from these patent applications, if issued, are also predicted to expire in 2031.
Manufacturing
AstraZeneca is responsible for the manufacture of all future clinical trial and commercial supplies of tenapanor, and should
Sanofi exercise its option to develop and commercialize NaP2b inhibitor compounds under our agreement, Sanofi will be responsible
for the manufacture of all clinical trial and commercial supplies.
To date, we have relied upon third-party contract manufacturing organizations, or CMOs, to manufacture both the active
pharmaceutical ingredient and final drug product dosage forms of our potential drug candidates used as clinical trial material. We
expect that we will continue to rely upon CMOs for the manufacture of our clinical trial materials for our own internal programs.
Government Regulation/FDA
The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and
burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs.
These agencies and other federal, state and local entities regulate research and development activities and the testing, manufacture,
quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-
approval monitoring and reporting, sampling, and export and import of our product candidates.
21
In the United States, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FFDCA, and the
FDA’s implementing regulations. If we fail to comply with applicable FDA or other requirements at any time during the drug
development process, the approval process or after approval, we may become subject to administrative or judicial sanctions. These
sanctions could include the FDA’s refusal to approve pending applications, license suspension or revocation, withdrawal of an
approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines,
civil penalties or criminal prosecution. Any FDA enforcement action could have a material adverse effect on us. FDA approval is
required before any new unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed in the
United States.
The process required by the FDA before a drug may be marketed in the United States generally involves:
(cid:121)
(cid:121)
(cid:121)
completion of extensive preclinical laboratory tests, preclinical animal studies and formulation studies, some performed in
accordance with the FDA’s current Good Laboratory Practice, or GLP, regulations;
submission to the FDA of an Investigational New Drug, or IND, application which must become effective before human
clinical trials in the United States may begin;
approval by an independent institutional review board, or IRB, or ethics committee at each clinical trial site before each
trial may be initiated;
(cid:121) performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice, or GCP,
regulations to establish the safety and efficacy of the drug candidate for each proposed indication;
(cid:121)
(cid:121)
(cid:121)
submission to the FDA of a new drug application, or NDA;
satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to
assess compliance with current Good Manufacturing Practice, or cGMP, regulations;
satisfactory completion of a potential review by an FDA advisory committee, if applicable; and
(cid:121) FDA review and approval of the NDA prior to any commercial marketing, sale or commercial shipment of the drug.
The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot
be certain that any approvals for our product candidates will be granted on a timely basis, if at all. Nonclinical tests include laboratory
evaluation of product chemistry, formulation, stability and toxicity, as well as animal studies to assess the characteristics and potential
safety and efficacy of the product. The results of preclinical tests, together with manufacturing information, analytical data and a
proposed clinical trial protocol and other information, are submitted as part of an IND to the FDA. Some preclinical testing may
continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA,
within the 30-day time period, raises concerns or questions relating to the IND and places the clinical trial on a clinical hold, including
concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA
must resolve any outstanding concerns before the clinical trial can begin. A separate submission to an existing IND must also be made
for each successive clinical trial conducted during product development.
Clinical trials involve the administration of the investigational drug to human subjects under the supervision of qualified
investigators. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, the
parameters to be used in monitoring safety and the effectiveness criteria to be used. Each protocol must be submitted to the FDA as
part of the IND.
An independent IRB or ethics committee for each medical center proposing to conduct a clinical trial must also review and
approve a plan for any clinical trial before it can begin at that center and the IRB must monitor the clinical trial until it is completed.
The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that
the subjects are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP requirements, including
the requirements for informed consent.
22
All clinical research performed in the United States in support of an NDA must be authorized in advance by the FDA under the
IND regulations and procedures described above. However, a sponsor who wishes to conduct a clinical trial outside the United States
may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted
under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA so long as the clinical trial is
conducted in compliance with GCP and if the FDA is able to validate the data from the study through an onsite inspection, if
necessary. GCP includes review and approval by an independent ethics committee, such as an IRB, and obtaining and documenting
the freely given informed consent of the subject before study initiation. If the applicant seeks approval of an NDA solely on the basis
of foreign data, the FDA will only accept such data if they are applicable to the U.S. population and U.S. medical practice, the studies
have been performed by clinical investigators of recognized competence, and the data may be considered valid without the need for an
on-site inspection by the FDA, or if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through
an on-site inspection or through other appropriate means.
Clinical trials
The clinical investigation of a new drug is typically conducted in three or four phases, which may overlap or be combined.
(cid:121) Phase 1: Clinical trials are initially conducted in a limited population of subjects to test the drug candidate for safety, dose
tolerance, absorption, metabolism, distribution and excretion in healthy humans or, on occasion, in patients with severe
problems or life-threatening diseases to gain an early indication of its effectiveness.
(cid:121) Phase 2: Clinical trials are generally conducted in a limited patient population to evaluate dosage tolerance and
appropriate dosage, identify possible adverse effects and safety risks, and evaluate preliminarily the efficacy of the drug
for specific targeted indications in patients with the disease or condition under study.
(cid:121) Phase 3: Clinical trials are typically conducted when Phase 2 clinical trials demonstrate that a dose range of the product
candidate is effective and has an acceptable safety profile. Phase 3 clinical trials are commonly referred to as “pivotal”
studies, which typically denotes a study which presents the data that the FDA or other relevant regulatory agency will use
to determine whether or not to approve a drug. Phase 3 clinical trials are generally undertaken with large numbers of
patients, such as groups of several hundred to several thousand, to further evaluate dosage, to provide substantial evidence
of clinical efficacy and to further test for safety in an expanded and diverse patient population at multiple, geographically-
dispersed clinical trial sites.
(cid:121) Phase 4: In some cases, FDA may condition approval of an NDA for a product candidate on the sponsor’s agreement to
conduct additional clinical trials after NDA approval. In other cases, a sponsor may voluntarily conduct additional clinical
trials post approval to gain more information about the drug. Such post approval trials are typically referred to as Phase 4
clinical trials.
Concurrent with clinical trials, companies usually complete additional preclinical studies and must also develop additional
information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the drug in
commercial quantities in accordance with GMP requirements. The manufacturing process must be capable of consistently producing
quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity,
strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability
studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.
The FDA, the IRB or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds,
including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials are
overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board
or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on
access to certain data from the study. We may also suspend or terminate a clinical trial based on evolving business objectives and/or
competitive climate.
New drug applications
The results of preclinical studies and of the clinical trials, together with other detailed information, including extensive
manufacturing information and information on the composition of the drug, are submitted to the FDA in the form of an NDA
requesting approval to market the drug for one or more specified indications. The FDA reviews an NDA to determine, among other
things, whether a drug is safe and effective for its intended use.
23
Under the Prescription Drug User Fee Act, the FDA has a goal of responding to standard review NDAs of new molecular
entities within ten months after the 60 day filing review period, or six months after the 60 day filing review period for priority review
NDAs, but this timeframe is often extended by FDA requests for additional information or clarification. The FDA may refer the
application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved.
The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.
Before approving an application, the FDA will inspect the facility or the facilities at which the finished drug product, and
sometimes the active pharmaceutical ingredient, or API, is manufactured, and will not approve the drug unless cGMP compliance is
satisfactory. The FDA may also inspect the sites at which the clinical trials were conducted to assess their compliance, and will not
approve the drug unless compliance with cGCP requirements is satisfactory.
After the FDA evaluates the NDA and conducts inspections of manufacturing facilities where the drug product and/or its API
will be produced, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing
of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle
of the application is complete and the application is not ready for approval. A Complete Response Letter may require additional
clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant, expensive and time-consuming requirements
related to clinical trials, preclinical studies or manufacturing. Even if such additional information is submitted, the FDA may
ultimately decide that the NDA does not satisfy the criteria for approval. The FDA could also approve the NDA with a Risk
Evaluation and Mitigation Strategy, or REMS, plan to mitigate risks, which could include medication guides, physician
communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk
minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of
adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market
testing may include Phase 4 clinical trials and surveillance to further assess and monitor the product’s safety and effectiveness after
commercialization. The FDA has the authority to prevent or limit further marketing of a drug based on the results of these post-
marketing programs. Once the FDA approves an NDA, or supplement thereto, the FDA may withdraw the approval if ongoing
regulatory requirements are not met or if safety problems are identified after the drug reaches the market.
Drugs may be marketed only for the FDA approved indications and in accordance with the provisions of the approved labeling.
Further, if there are any modifications to the drug, including changes in indications, labeling, or manufacturing processes or facilities,
the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the
applicant to develop additional data or conduct additional preclinical studies and clinical trials.
The testing and approval processes require substantial time, effort and financial resources, and each may take several years to
complete. The FDA may not grant approval on a timely basis, or at all. Even if we believe a clinical trial has demonstrated safety and
efficacy of one of our drug candidates for the proposed indication, the results may not be satisfactory to the FDA. Nonclinical and
clinical data may be interpreted by the FDA in different ways, which could delay, limit or prevent regulatory approval. We may
encounter difficulties or unanticipated costs in our efforts to secure necessary governmental approvals which could delay or preclude
us from marketing drugs. The FDA may limit the indications for use or place other conditions on any approvals that could restrict the
commercial application of the drugs. After approval, certain changes to the approved drug, such as adding new indications,
manufacturing changes, or additional labeling claims are subject to further FDA review and approval. Depending on the nature of the
change proposed, an NDA supplement must be filed and approved before the change may be implemented. For many proposed post-
approval changes to an NDA, but excluding efficacy supplements to an NDA, the FDA has up to 180 days to review the application.
As with new NDAs, the review process is often significantly extended by the FDA requests for additional information or clarification.
Other regulatory requirements
Any drugs manufactured or distributed by us or our collaboration partners pursuant to FDA approvals would be subject to
continuing regulation by the FDA, including recordkeeping requirements and reporting of adverse experiences associated with the
drug. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state
agencies, and are subject to periodic announced and unannounced inspections by the FDA and certain state agencies for compliance
with ongoing regulatory requirements, including cGMP, which impose certain procedural and documentation requirements upon us
and our third party manufacturers. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to
possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or
possible civil penalties. We cannot be certain that we or our present or future third party manufacturers or suppliers will be able to
comply with the cGMP regulations and other ongoing FDA regulatory requirements. If we or our present or future third party
manufacturers or suppliers are not able to comply with these requirements, the FDA may, among other things, halt our clinical trials,
require us to recall a drug from distribution or withdraw approval of the NDA for that drug.
24
The FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-
to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities
involving the Internet. A company can make only those claims relating to safety and efficacy that are approved by the FDA. Failure to
comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and
potential civil and criminal penalties. Physicians may prescribe legally available drugs for uses that are not described in the product’s
labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties.
Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not
regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on
manufacturers’ communications regarding off-label use.
Fraud and abuse laws
In the United States, the research, manufacturing, distribution, sale and promotion of drug products and medical devices are
potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for
Medicare & Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of
Inspector General), the U.S. Department of Justice, state Attorneys General, and other state and local government agencies. These
laws include but are not limited to, the Anti-Kickback Statute, the federal False Claims Act, the federal Physician Sunshine Payment
Act, and other state and federal laws and regulations.
The Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its
behalf) to knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business,
including the purchase, order, or prescription of a particular drug, for which payment may be made under a federal healthcare
program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines,
administrative civil money penalties, and exclusion from participation in federal healthcare programs. In addition, the Affordable Care
Act, among other things, amends the intent requirement of the federal Anti-Kickback Statute and federal criminal healthcare fraud
statutes. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. Moreover, the
Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the
federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False Claims Act.
The federal False Claims Act prohibits anyone from knowingly presenting, or causing to be presented, for payment to federal
programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for
items or services not provided as claimed, or claims for medically unnecessary items or services. Although we would not submit
claims directly to payors, manufacturers can be held liable under these laws if they are deemed to “cause” the submission of false or
fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label.
In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of
prices used to calculate Medicaid rebate information and other information affecting federal, state, and third-party reimbursement for
our products, and the sale and marketing of our products, are subject to scrutiny under this law. For example, pharmaceutical
companies have been prosecuted under the federal False Claims Act in connection with their off-label promotion of drugs. Penalties
for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties of
between $5,500 and $11,000 for each separate false claim, the potential for exclusion from participation in federal healthcare
programs, and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also
implicate various federal criminal statutes. If the government were to allege that we were, or convict us of, violating these false claims
laws, we could be subject to a substantial fine and may suffer a decline in our stock price. In addition, private individuals have the
ability to bring actions under the federal False Claims Act and certain states have enacted laws modeled after the federal False Claims
Act.
In addition to the laws described above, the Patient Protection and Affordable Care Act, as amended by the Health Care and
Education Reconciliation Act, collectively known as the Affordable Care Act, also imposed new reporting requirements on drug
manufacturers for payments made to physicians and teaching hospitals, as well as ownership and investment interests held by
physicians and their immediate family members. Failure to submit required information may result in civil monetary penalties of up to
an aggregate of $150,000 per year (or up to an aggregate of $1 million per year for “knowing failures”), for all payments, transfers of
value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. The period
between August 1, 2013 and December 31, 2013 was the first reporting period and manufacturers were required to report aggregate
payment data by March 31, 2014, and will be required to report detailed payment data and submit legal attestation to the accuracy of
such data during Phase 2 of the program (which begins in May 2014 and extends for at least 30 days). Thereafter, manufacturers must
submit reports by the 90th day of each subsequent calendar year.
25
Many states have also adopted laws similar to the federal laws discussed above. Some of these state prohibitions apply to the
referral of patients for healthcare services reimbursed by any insurer, not just federal healthcare programs such as Medicare and
Medicaid. There has also been a recent trend of increased regulation of payments made to physicians and other healthcare providers.
Certain states mandate implementation of compliance programs, impose restrictions on drug manufacturers’ marketing practices
and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians. Many of these laws contain
ambiguities as to what is required to comply with such laws, which may affect our sales, marketing, and other promotional activities
by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their
implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and perhaps federal, authorities.
Because we intend to commercialize products that could be reimbursed under a federal healthcare program and other
governmental healthcare programs, we plan to develop a comprehensive compliance program that establishes internal controls to
facilitate adherence to the rules and program requirements to which we will or may become subject. Although compliance programs
can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Due to the
breadth of these laws, the absence of guidance in the form of regulations or court decisions, and the potential for additional legal or
regulatory change in this area, it is possible that our future sales and marketing practices and/or our future relationships with
physicians and other healthcare providers might be challenged under such laws. Any action against us for violation of these laws, even
if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the
operation of our business.
Third-party coverage and reimbursement
Sales of pharmaceutical products depend in significant part on the availability of coverage and adequate reimbursement by
third-party payors, such as state and federal governments, including Medicare and Medicaid, and commercial managed care providers.
In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors.
Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for our product candidates, if
approved, will be made on a payor by payor basis. As a result, the coverage determination process is often a time-consuming and
costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor
separately, with no assurance that coverage and adequate reimbursement will be obtained. Third-party payors may limit coverage to
specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular
indication. A decision by a third-party payor not to cover our product candidates could reduce physician utilization of our products
once approved and have a material adverse effect on our future sales, results of operations and financial condition. Moreover, a
payor’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved.
Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate
return on our investment in product development.
In addition, in July 2010, CMS released its final rule to implement a bundled prospective payment system for the treatment of
ESRD patients as required by the Medicare Improvements for Patients and Providers Act, or MIPPA. The bundled payment includes
all renal dialysis services furnished for outpatient maintenance dialysis, including ESRD-related drugs and biologicals. The final rule
delayed the inclusion of oral medications without intravenous equivalents in the bundled payment until January 1, 2014 and in April
2014, President Obama signed the Protecting Access to Medicare Act of 2014, which further extends this implementation date to
January 1, 2024. As a result of the recent legislation, beginning in 2024, ESRD-related drugs will be included in the bundle and
separate Medicare reimbursement will no longer be available for such drugs, as it is today under Medicare Part D. While it is too early
to project the full impact bundling may have on the phosphate binder industry, the impact could potentially cause dramatic price
reductions for tenapanor, if approved.
Healthcare reform
In March 2010, President Obama signed one of the most significant healthcare reform measures in decades. The Affordable
Care Act substantially changes the way healthcare will be financed by both governmental and private insurers, and significantly
impacts the pharmaceutical industry.
The Affordable Care Act contains a number of provisions, including those governing enrollment in federal healthcare programs,
reimbursement changes and fraud and abuse, which will impact existing government healthcare programs and will result in the
development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality
reporting system and feedback program. Additionally, the Affordable Care Act:
(cid:121)
(cid:121)
increases the minimum level of Medicaid rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1%;
requires collection of rebates for drugs paid by Medicaid managed care organizations;
26
(cid:121)
(cid:121)
(cid:121)
expands eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to
additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below
133% of the federal poverty level, thereby potentially increasing a manufacturer’s Medicaid rebate liability;
expands access to commercial health insurance coverage through new state-based health insurance marketplaces, or
exchanges;
requires manufacturers to participate in a coverage gap discount program, under which they must agree to offer 50 percent
point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap
period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D, beginning January
2011; and
(cid:121)
imposes a non-deductible annual fee on pharmaceutical manufacturers or importers who sell “branded prescription drugs”
to specified federal government programs.
In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was
enacted. In August 2011, the Budget Control Act of 2011 among other things, created the Joint Select Committee on Deficit
Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit
reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation’s automatic reduction to several
government programs. This includes aggregate reductions to Medicare payments to providers of 2 percent per fiscal year, which went
into effect on April 1, 2013. In January 2013, the ATRA was enacted, which, among other things, further reduced Medicare payments
to several providers, including hospitals, imaging centers and cancer treatment centers. These new laws and the regulations and
policies implementing them, as well as other healthcare reform measures that may be adopted in the future, may have a material
adverse effect on our industry generally and on our ability to successfully develop and commercialize our products.
Other regulations
We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing
practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur
significant costs to comply with such laws and regulations now or in the future.
Employees
As of December 31, 2014, we had 34 full-time employees, including a total of 13 employees with Ph.D. degrees. Within our
workforce, 27 employees are engaged in research and development and the remaining 7 in general management and administration,
including finance, legal, and business development. None of our employees are represented by labor unions or covered by collective
bargaining agreements. We believe that we maintain good relations with our employees.
Research and Development
The costs were $25.9 million, $28.1 million and $10.2 million in research and development in the years 2014, 2013 and 2012,
respectively. See “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” for additional
detail regarding our research and development activities.
About Ardelyx
We commenced operations in 2007. Our principal offices are located at 34175 Ardenwood Blvd., Suite 200, Fremont, CA
94555, and our telephone number is (510) 745-1700. Our website address is www.ardelyx.com. The information contained in, or that
can be accessed through, our website is not part of this Annual Report on Form 10-K.
Financial Information about Segments
We operate only in one business segment. See Note 1 to our financial statements included in this Annual Report on Form 10-K.
27
Available Information
We file electronically with the Securities and Exchange Commission, or SEC, our annual reports on Form 10-K, quarterly
reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as
amended. We make available on our website at www.ardelyx.com, free of charge, copies of these reports, as soon as reasonably
practicable after we electronically file such material with, or furnish it to, the SEC. The public may read or copy any materials we file
with the SEC at the SEC’s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. The public may obtain information
on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains
reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address
of that website is www.sec.gov. The information in or accessible through the SEC and our website are not incorporated into, and are
not considered part of, this filing. Further, our references to the URLs for these websites are intended to be inactive textual references
only.
28
Item 1A. Risk Factors.
Our business involves significant risks, some of which are described below. You should carefully consider these risks, as well as other
information in this Annual Report on Form 10-K, including our financial statements and the related notes and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations.” The occurrence of any of the events or developments
described below could harm our business, financial condition, results of operations, cash flows, the trading price of our common stock
and our growth prospects. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also
impair our business operations.
Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements
We have a limited operating history, have incurred significant losses since our inception and we will incur losses in the future. We
have only one product candidate in clinical trials and no product sales, which, together with our limited operating history, makes it
difficult to assess our future viability.
We are a clinical-stage biopharmaceutical company with a limited operating history. Biopharmaceutical product development is
a highly speculative undertaking and involves a substantial degree of risk. To date, we have focused substantially all of our efforts on
our research and development activities, including developing our lead product candidate, tenapanor, and developing our proprietary
drug discovery and design platform. To date, we have not commercialized any products or generated any revenue from the sale of
products. We are not profitable and have incurred losses in each year since our inception in October 2007, and we do not know
whether or when we will become profitable. We have only a limited operating history upon which to evaluate our business and
prospects. We continue to incur significant research, development and other expenses related to our ongoing operations. Our net loss
for the years ended December 31, 2014, 2013 and 2012 was $3.2 million, $6.6 million and $9.8 million, respectively. As of
December 31, 2014, we had an accumulated deficit of $71.9 million.
If we do not receive anticipated milestone payments from our collaboration partners, AstraZeneca AB, or AstraZeneca and
Sanofi S.A., or Sanofi, our operating losses will substantially increase for the foreseeable future as we continue our discovery,
research, development, manufacturing and commercialization activities. There can be no assurance that we will receive any potential
milestones under our agreements with AstraZeneca and/or Sanofi. For a discussion of the risks associated with our preclinical and
clinical development programs with, and potential for milestone payments from, AstraZeneca and Sanofi, see below under “—Risks
Related to Our Business.”
Even if we receive the anticipated milestone payments or receive royalty payments from our collaboration partners, we may not
be able to achieve or sustain profitability. For example, we may choose to exercise our right to co-fund a portion of the first Phase 3
clinical development program for tenapanor, incurring expenses of up to $40.0 million, and we would likely incur continued operating
losses during the period we are co-funding the program. In addition, our receipt of milestone payments from our collaboration partners
may not result in the recognition of revenue in the period received, as we may be required to amortize the milestone payment over a
period of time. Depending upon such requirement and the period of amortization, we may continue to incur losses even after the
receipt of such milestone payments. Therefore, there can be no assurance that our losses will not increase into the future. Our prior
losses, combined with possible future losses, have had and will continue to have an adverse effect on our stockholders’ equity and
working capital. Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a
period-to-period comparison of our results of operations may not be a good indication of our future performance.
We have never generated any revenue from product sales and may never be profitable.
We have no products approved for sale and have never generated any revenue from product sales. Our ability to generate
revenue from product sales and achieve profitability depends on our ability, and the ability of our collaboration partners, to
successfully complete the development of and obtain the regulatory and marketing approvals necessary to commercialize one or more
of our product candidates. We do not anticipate generating revenue from product sales for the foreseeable future. Our ability to
generate future revenue from product sales or pursuant to milestone payments depends heavily on many factors, including but not
limited to:
(cid:121)
(cid:121)
(cid:121)
the completion of research and preclinical and clinical development of our product candidates;
together with our collaboration partners, obtaining regulatory approvals for our product candidates;
the ability of our collaboration partners to successfully commercialize and/or our ability to commercialize or co-promote,
if we so choose, our product candidates;
29
(cid:121) developing a sustainable and scalable manufacturing process for any approved product candidates and establishing and
maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality)
products to support clinical development and the market demand for our product candidates, if approved;
(cid:121) obtaining market acceptance of our product candidates, if approved, as viable treatment options;
(cid:121)
(cid:121)
addressing any competing technological and market developments;
identifying, assessing, acquiring, in-licensing and/or developing new product candidates;
(cid:121) negotiating favorable terms in any collaboration partnership, licensing or other arrangements into which we may enter;
(cid:121) maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and
know-how, and our ability to develop, manufacture and commercialize our product candidates and products without
infringing intellectual property rights of others; and
(cid:121)
attracting, hiring, and retaining qualified personnel.
In cases where we, or our collaboration partners, are successful in obtaining regulatory approvals to market one or more of our
product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which regulatory approval
is granted, the accepted price for the product, the ability to get reimbursement at any price and whether we have royalty and/or co-
promotion rights for that territory. If the number of patients suitable for our product candidates is not as significant as we estimate, the
indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is
narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from the sale of such
products, even if approved. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent
periods. Our failure to generate revenue from product sales would likely depress our market value and could impair our ability to raise
capital, expand our business, discover or develop other product candidates or continue our operations. A decline in the value of our
common stock could cause our stockholders to lose all or part of their investment.
We may require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed
on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development or other operations.
Since our inception, most of our resources have been dedicated to our research and development activities, including developing
our lead product candidate, tenapanor, and developing our proprietary drug discovery and design platform. As of December 31, 2014,
we had working capital of $89.5 million, including capital resources consisting of cash and cash equivalents of $107.3 million. We
believe that we will continue to expend substantial resources for the foreseeable future, including costs associated with research and
development, conducting preclinical studies and clinical trials, obtaining regulatory approvals, and sales and marketing. Because the
outcome of any clinical trial and/or regulatory approval process is highly uncertain, we cannot reasonably estimate the actual amounts
necessary to successfully complete the development, regulatory approval process and commercialization or co-promotion of any of
our product candidates.
Based on our current operating plan, we believe that our existing capital resources will allow us to fund our operating plan
through at least the next 12 months. However, our operating plan may change as a result of many factors currently unknown to us, and
we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many factors, including,
but not limited to:
(cid:121)
(cid:121)
the decision of AstraZeneca whether or not to continue the development of tenapanor or exercise its right of termination
under the agreement to return the program to us;
the achievement of development and regulatory milestones resulting in the payment to us from our collaboration partners
of contractual milestone payments and the timing of receipt of such payments, if any;
(cid:121) our decision whether or not to exercise our right to co-fund the first Phase 3 clinical development program for tenapanor,
in which case we may invest $20.0 million, $30.0 million or $40.0 million to acquire an increase of 1%, 2% or 3%,
respectively, in the royalties payable to us by AstraZeneca on net sales of tenapanor;
(cid:121)
(cid:121)
the progress, timing, scope, results and costs of our preclinical studies and clinical trials for our product candidates that
have not been licensed, including the ability to enroll patients in a timely manner for clinical trials;
the time and cost necessary to obtain regulatory approvals for our product candidates that have not been licensed and the
costs of post-marketing studies that could be required by regulatory authorities;
(cid:121) our ability and the ability of our collaboration partners to successfully commercialize and/or co-promote our product
candidates;
30
(cid:121)
the manufacturing, selling and marketing costs associated with product candidates, including the cost and timing of
building our sales and marketing capabilities;
(cid:121) our ability to establish and maintain collaboration partnerships, in-license/out-license or other similar arrangements and
the financial terms of such agreements;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
the timing, receipt, and amount of sales of, or royalties on, our future products, if any;
the sales price and the availability of adequate third-party reimbursement for our product candidates;
the cash requirements of any future acquisitions or discovery of product candidates;
the number and scope of preclinical and discovery programs that we decide to pursue or initiate;
the time and cost necessary to respond to technological and market developments; and
the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property
rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of
infringement brought by others in connection with the development, manufacture or commercialization of our product
candidates.
Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not
available to us on a timely basis, we may be required to delay, limit, reduce or terminate our research and development activities,
preclinical and clinical trials for our product candidates for which we retain such responsibility and our establishment and maintenance
of sales and marketing capabilities or other activities that may be necessary to commercialize or co-promote our product candidates.
Risks Related to Our Business
If AstraZeneca exercises its right to terminate its collaboration partnership with us, we would not receive any additional milestone
payments or revenue from this collaboration partnership, and our results of operations and financial condition will be materially
and adversely affected.
In October 2012, we entered into a license agreement with AstraZeneca granting it an exclusive worldwide license to our small
molecule NHE3 inhibitor program, which includes our lead product candidate, tenapanor, for all indications. Under this agreement,
AstraZeneca has responsibility for completing all nonclinical and clinical development and obtaining and maintaining regulatory
approval for tenapanor from the FDA and regulatory agencies outside of the United States. Ultimately, if tenapanor is advanced
through clinical trials and receives marketing approval from the FDA or comparable foreign regulatory agencies, AstraZeneca will be
responsible for the commercialization of tenapanor, subject to our right to elect to participate in certain co-promotion activities in the
United States. AstraZeneca has the right to terminate this collaborative partnership at any time for any reason upon written notice to
us. If AstraZeneca elects to terminate the collaborative partnership with us, our business would be materially and adversely harmed
and depending on the timing of such event:
(cid:121) we would not be eligible to receive any of the remaining development or regulatory milestone payments or royalties on
product sales of tenapanor;
(cid:121)
the development of tenanapor may be significantly delayed as a result of the need to transition the program back to us;
(cid:121) we would bear all of the risks and costs related to the further development and commercialization of tenapanor;
(cid:121) we may not be able to obtain a sufficient supply of clinical trial material from AstraZeneca to support the continued
development of tenapanor, and as a result the development of tenapanor may be significantly delayed;
(cid:121) we may encounter difficulty and delay associated with the transfer of the manufacturing process from AstraZeneca to a
third party contract manufacturer, and such third party contract manufacturer may not be able to manufacture clinical or
commercial supplies of tenapanor in the time frame, at the scale or to the specifications required;
(cid:121)
in order to fund further development and commercialization of tenanapor, we would need to raise substantial additional
capital in order to internally pursue the development of the program, and even if we raise additional capital, we may need
to seek out and establish alternative collaboration partnerships with third-party collaboration partners for the program,
which may not be possible, or we may not be able to do so on terms which are acceptable to us, in which case it may be
necessary for us to limit the size or scope of the program or delay the program, in either case, in a manner that would
adversely impact our ability to realize value from the program; and
(cid:121) our cash expenditures would increase significantly if it is necessary for us to hire a significant number of additional
employees and allocate limited resources to the development and commercialization of tenapanor.
31
Any of these events would have a material adverse effect on our results of operations and financial condition.
We are substantially dependent on the success of our lead product candidate, tenapanor, which may not be successful in
nonclinical studies or clinical trials, receive regulatory approval or be successfully commercialized.
To date, we have invested a significant amount of our efforts and financial resources in the research and development of
tenapanor, which is currently our lead product candidate and only product candidate in clinical trials. Our near-term prospects,
including our ability to finance our operations through the receipt of milestone payments and generate revenue from product sales, will
depend heavily on AstraZeneca’s decision whether or not to continue the development of tenapanor, and should it determine to
continue development, on the successful development and AstraZeneca’s commercialization of tenapanor, if approved. The clinical
and commercial success of tenapanor will depend on a number of factors, including the following:
(cid:121) whether tenapanor’s safety and efficacy profile is satisfactory to the U.S. Food and Drug Administration, or FDA, and
foreign regulatory authorities to warrant marketing approval;
(cid:121) whether FDA or foreign regulatory authorities require additional clinical trials prior to approval to market tenapanor;
(cid:121)
(cid:121)
the prevalence and severity of adverse side effects of tenapanor;
the results of a long-term rat carcinogenicity study required for approval of tenapanor, which will not be known for at
least one and half years, and which may be delayed for a significant period of time for reasons outside of the control of
AstraZeneca, particularly if AstraZeneca is required to restart or modify the study for any reason;
(cid:121) whether, as a result of the observation of the absorption of inactive metabolites of tenapanor seen in our radiolabeled
human ADME study, the FDA or foreign regulatory authorities require additional nonclinical studies prior to the
commencement of Phase 3 activities, which, if required, could delay the development of tenapanor;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
the timely receipt of necessary marketing approvals from the FDA and foreign regulatory authorities;
the ability of AstraZeneca and us through our co-promotion rights, if we choose to exercise such rights and are not
precluded from doing so under the terms of our agreement with AstraZeneca or any subsequent co-promotion agreements,
to successfully commercialize tenapanor, if approved for marketing and sale by the FDA or foreign regulatory authorities,
including educating physicians and patients about the benefits, administration and use of tenapanor;
achieving and maintaining compliance with all regulatory requirements applicable to tenapanor;
acceptance of tenapanor as safe, effective and well-tolerated by patients and the medical community;
the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing
treatments;
(cid:121) obtaining and sustaining an adequate level of coverage and reimbursement for tenapanor by third-party payors;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
the effectiveness of AstraZeneca’s marketing, sales and distribution strategy and operations;
the ability of AstraZeneca, or any third-party manufacturer it contracts with, to successfully scale up the manufacturing
process for tenapanor, which has not yet been demonstrated, and to manufacture supplies of tenapanor and to develop,
validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing
practice, or cGMP, requirements;
enforcing intellectual property rights in and to tenapanor;
avoiding third-party interference, opposition, derivation or similar proceedings with respect to our patent rights, and
avoiding other challenges to our patent rights and patent infringement claims; and
a continued acceptable safety and tolerability profile of tenapanor following approval.
Most of these factors are beyond our control, including clinical development, the regulatory submission process, manufacturing,
marketing and sales efforts of AstraZeneca.
32
As a first-in-class drug, tenapanor, has not been extensively studied in humans and the nonclinical and clinical data on its effect
in the human body is limited to the trials and studies that we and AstraZeneca have completed. As a first-in-class drug, there is a
higher likelihood that approval may not be attained as compared to a class of drugs with approved products. We cannot be certain that
tenapanor will be successful in preclinical studies, clinical trials or receive regulatory approval. Further, it may not be possible or
practicable to demonstrate, or if approved, to market on the basis of, certain of the benefits we believe tenapanor possesses, including
the reduction of sodium absorption in patients with CKD, which is unlikely to be an endpoint to be considered for approval in CKD
patients. Additionally, the reduction of serum phosphorus is currently an approvable endpoint in CKD-5D patients, but not in the
broader CKD patient population in the United States. If the number of patients in the market for tenapanor or the price that the market
can bear is not as significant as we estimate, we may not generate significant revenue from sales of tenapanor, if approved.
Accordingly, there can be no assurance that tenapanor will ever be successfully commercialized or that we will ever generate revenue
from sales of tenapanor. If we and AstraZeneca are not successful in completing the development of, obtaining approval for, and
commercializing tenapanor, or are significantly delayed in doing so, our business will be materially harmed.
We are dependent on AstraZeneca for the development, regulatory approval, manufacture and commercialization of our small
molecule NHE3 inhibitor program, which includes tenapanor, and if AstraZeneca exercises its right to terminate the agreement,
does not elect to continue development of one or more indications for tenapanor, fails to perform as expected, or is unable to
obtain the required regulatory approvals for tenapanor, the potential for us to generate future revenue from milestone and royalty
payments from tenapanor would be significantly reduced and our business would be materially and adversely harmed.
The potential for us to obtain future development milestone payments and, ultimately, generate revenue from royalties from
tenapanor depends entirely on the successful development, regulatory approval, marketing and commercialization of tenapanor by
AstraZeneca. In addition to the risks inherent in the development of a drug product candidate, our collaboration partnership with
AstraZeneca may not be successful due to a number of important factors, including the following:
(cid:121) prior to the 175th day after the database lock for the Phase 2b clinical trial in hyperphosphatemic ESRD patients,
AstraZeneca may terminate the license for any reason with 30-days’ prior written notice and thereafter AstraZeneca may
terminate the license with 120-days’ prior written notice;
(cid:121)
if our agreement with AstraZeneca terminates, we will no longer have rights to receive potential revenue under the
agreement with AstraZeneca for future milestones or royalties, in which case we would need to identify alternative means
to continue the development, manufacture and commercialization of tenapanor, alone or with others.
(cid:121) AstraZeneca has the unilateral ability to choose not to develop tenapanor for one or more indications for which it has been
or is currently being evaluated, including the IBS-C indication and the hyperphosphatemia indication, provided it pursues
at least one indication,
(cid:121) AstraZeneca may choose to pursue an indication that is not in our strategic best interest or to delay the pursuit of, or
forego an indication, even if clinical data is supportive of further development for such indication;
(cid:121) AstraZeneca’s strategic withdrawal from selling gastrointestinal, or GI, products and the differing treatment of the IBS-C
indication in our agreement implies that AstraZeneca may choose not to develop the IBS-C indication even though our
recently announced Phase 2b clinical data in IBS-C patients indicated that at the 50 mg twice daily dose, the study met its
primary efficacy endpoint; AstraZeneca may choose not to develop and commercialize tenapanor in all relevant markets;
(cid:121) AstraZeneca may take considerably more time advancing tenapanor through the clinical and regulatory process than we
currently anticipate, which could materially delay the achievement of milestones and, consequently the receipt of
milestone payments from AstraZeneca;
(cid:121) AstraZeneca’s obligation to use “commercially reasonable efforts” with regard to the development, regulatory approval,
manufacture and commercialization of tenapanor under our agreement leaves AstraZeneca with discretion in determining
the efforts and resources that it will apply to the development, regulatory approval, manufacture and commercialization of
tenapanor;
(cid:121)
subject to our right to elect to participate in co-promotion activities in the United States, AstraZeneca controls all aspects
of the commercialization of tenapanor;
(cid:121) AstraZeneca may change the focus of its development and commercialization efforts or pursue higher-priority programs
and, accordingly, reduce the efforts and resources allocated to tenapanor, which will have the direct effect of reducing our
co-promotion activities as our level of co-promotion is limited to a percentage of the overall commercialization activities;
(cid:121) AstraZeneca may fail to develop a commercially viable formulation or manufacturing process for tenapanor, and may fail
to manufacture or supply sufficient drug substance of tenapanor for commercial use, if approved, which could result in
lost revenue;
33
(cid:121) AstraZeneca may not comply with all applicable regulatory requirements or may fail to report safety data in accordance
with all applicable regulatory requirements;
(cid:121) AstraZeneca may sublicense its rights with respect to tenapanor to one or more third parties without our consent;
(cid:121) AstraZeneca may not dedicate the resources that would be necessary to carry tenapanor through clinical development or
may not obtain the necessary regulatory approvals; and
(cid:121)
if AstraZeneca is acquired during the term of our collaboration partnership, the acquiror may have different strategic
priorities that could cause it to terminate our agreement or reduce its commitment to our collaboration partnership.
The timing and amount of any milestone and royalty payments we may receive under our agreement will depend on, among
other things, the efforts, allocation of resources, and successful development and commercialization of tenapanor by AstraZeneca
under our agreement. There can be no assurance that any of the development and regulatory milestones will be achieved or that we
will receive any future milestone payments under the agreement. In addition, in certain circumstances we may believe that we have
achieved a particular milestone and AstraZeneca may disagree with our belief. In that case, receipt of that milestone payment may be
delayed or may never be received, which may require us to adjust our operating plans.
If AstraZeneca does not perform in the manner we expect or fulfill its responsibilities in a timely manner, or at all, the clinical
development, regulatory approval and commercialization efforts related to tenapanor could be delayed or terminated and it could
become necessary for us to assume the responsibility at our own expense for the clinical development of tenapanor. In that event, we
would likely be required to substantially limit the size and scope of the development and commercialization of tenapanor or seek
additional financing to fund further development, or to identify alternative collaboration partners for tenapanor, and our potential to
generate future revenue from royalties and milestone payments from tenapanor would be significantly reduced or delayed and our
business would be materially and adversely harmed.
Our election to co-fund the first Phase 3 clinical development program for tenapanor must be made in a limited time period
following AstraZeneca’s determination to proceed to the first Phase 3 clinical development program for tenapanor and, as a result,
we may make a substantial capital investment for a product candidate based on limited clinical data.
Under our agreement with AstraZeneca, we may elect to participate in the funding of the first Phase 3 clinical development
program for the first indication of tenapanor by investing a co-funding amount of $20.0 million, $30.0 million or $40.0 million to
acquire an increase of 1%, 2% or 3%, respectively, in the royalties payable to us by AstraZeneca on net sales of tenapanor. We may
exercise this right only for a limited period of 60 days following AstraZeneca’s determination to proceed to the first Phase 3 clinical
development program for tenapanor for a specific indication. An election to participate in the co-fund will be based, in part, on our
analysis as to the likelihood of success of the Phase 3 clinical development program and the potential for regulatory approval to
commercialize tenapanor, as well as on an analysis of the capital requirements to advance our other programs. As a result, we will be
required to make a substantial capital investment in tenapanor prior to the initiation of the first pivotal clinical trial and if tenapanor is
unsuccessful in its pivotal trial or if it never receives regulatory approval, we will not receive any financial return on this capital
investment.
We have not yet negotiated our agreement with AstraZeneca specifying all of the terms of our co-promotion right.
Pursuant to our license agreement with AstraZeneca, we have retained a co-promotion right with respect to tenapanor in the
United States. While the license agreement includes the material terms of our co-promotion right, we and AstraZeneca mutually
agreed to negotiate a separate agreement specifying the detailed activities and responsibilities in respect of the marketing and co-
promotion of tenapanor following our election to exercise our co-promotion rights. If we elect to exercise our co-promotion rights, the
separate agreement we negotiated with AstraZeneca may place restrictions or additional obligations on us, including financial
obligations. Any restrictions or additional obligations may restrict our co-promotion activities or involve more significant financial
obligations than we currently anticipate.
34
Exercising our co-promotion right under our license agreement with AstraZeneca may restrict our future commercialization
and/or co-promotion activities.
Our agreement with AstraZeneca prohibits us from using the same sales force to co-promote tenapanor as we do to promote
other products that compete with tenapanor or with any other products that are then being actively promoted by AstraZeneca or its
affiliates. If we elect to co-promote tenapanor, we may therefore be required to have a separate sales forces to promote other products
we may elect to co-promote under our agreement with Sanofi, or other products we develop and commercialize on our own, should
any of such products be competitive with tenapanor or with any other products promoted by AstraZeneca or its affiliates. The exercise
of the co-promotion right under our agreement with AstraZeneca, could adversely affect the efficiency and cost of our promotion
efforts for our products and, effectively, may prohibit us from exercising our co-promotion rights under our agreement with Sanofi or
with respect to other co-promotion rights with future collaboration partners.
If Sanofi does not exercise its option to obtain an exclusive license to develop, manufacture and commercialize our NaP2b
inhibitors or if it exercises the option and subsequently terminates any development program under its collaboration partnership
with us, any potential milestone payments or revenue from product sales under this collaboration partnership will be significantly
reduced or non-existent, and our results of operations and financial condition will be materially and adversely affected.
In February 2014, we entered into a License Option and License Agreement with Sanofi under which we granted Sanofi an
exclusive worldwide license to conduct research utilizing our small molecule NaP2b inhibitors, which we refer to as our RDX002
program, solely for the purpose of completing activities under a preclinical development plan. We believe the inhibition of NaP2b, an
intestinal phosphate transporter, would provide utility for the treatment of hyperphosphatemia in CKD-5D patients, which is also the
lead indication for which we and AstraZeneca are developing tenapanor.
Under the terms of this agreement, Sanofi has the option to obtain an exclusive license to develop, manufacture and
commercialize our NaP2b inhibitors. Sanofi may exercise this option at any time following the effective date of the agreement and
ending 45 days after the filing of an investigational new drug application, or IND, subject to certain exceptions, and if Sanofi does not
file an IND on or before the 40th month anniversary of the completion of the technology transfer phase, the agreement will terminate.
If Sanofi does not exercise its option under its agreement with us, or terminates its rights and obligations with respect to the
development program or the entire agreement, then depending on the timing of such event:
(cid:121)
the development of our NaP2b inhibitor program may be terminated or significantly delayed;
(cid:121) we would bear all of the risks and costs related to the further development and commercialization of product candidates
that were previously the subject of the agreement if we decided to continue work under the NaP2b inhibitor program
independently;
(cid:121) we would not be eligible to receive any of the remaining development or regulatory milestone payments or royalties on
product sales;
(cid:121)
in order to fund further development and commercialization of the NaP2b program, we may need to raise additional
capital if we choose to internally pursue the development of the program, or we may need to seek out and establish
alternative collaboration partnerships with third-party collaboration partners for the program, which may not be possible,
or we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the
size or scope of the programs or increase our expenditures and seek additional funding by other means; and
(cid:121) our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate scarce
resources to the development and commercialization of the NaP2b program.
Any of these events would have a material adverse effect on our results of operations and financial condition.
In addition, we may be effectively prohibited from co-promoting any product candidates arising from the NaP2b program if we
have previously exercised our co-promotion right under our agreement with AstraZeneca. For additional information regarding the
effect of exercising our co-promotion right with AstraZeneca, see the risk factor above titled “Exercising our co-promotion right under
our license agreement with AstraZeneca may restrict our future commercialization and/or co-promotion activities.”
35
Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and we may encounter substantial
delays in our clinical studies. Furthermore, results of earlier studies and trials may not be predictive of future trial results.
Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we, or our collaboration
partners, must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during
the clinical trial process. For example, in a Phase 2a study evaluating tenapanor in ESRD patients with fluid overload, while
pharmacological activity of tenapanor was confirmed, the study failed to meet the primary endpoint of a statistically significant
difference between tenapanor and placebo in change in interdialytic weight gain from baseline to week 4. The results of preclinical
and clinical studies of our product candidates may not be predictive of the results of later-stage clinical trials. For example, the
positive results generated to date in preclinical and clinical studies for tenapanor do not ensure that the ongoing clinical trial, or future
clinical trials, will demonstrate similar results. An unacceptable adverse event profile may present challenges for the future
development and commercialization of a product candidate for a particular condition despite receipt of positive efficacy data in a
clinical study. For example, in a Phase 2b study evaluating tenapanor for the treatment of hyperphosphatemia in CKD-5D patients, or
ESRD patients on dialysis, we observed that the study met its primary endpoint by demonstrating a statistically significant dose-
related decrease in serum phosphate levels for tenapanor-treated patients compared to patients receiving placebo, while also observing
that the rate of diarrhea and the discontinuation rate due to diarrhea at the highest doses were higher than expected based upon
previous clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite
having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical,
biopharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials for similar indications
that we are pursuing due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies, and we
cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to
obtain regulatory approval for our product candidates.
We may experience delays in our ongoing or future trials, and we do not know whether future clinical trials will begin on time,
need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be
delayed or terminated for a variety of reasons, including delay or failure to:
(cid:121) obtain regulatory approval to commence a trial, if applicable;
(cid:121)
reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites,
the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial
sites;
(cid:121) obtain institutional review board, or IRB, approval at each site;
(cid:121)
recruit suitable patients in a timely manner to participate in our trials;
(cid:121) have patients complete a trial or return for post-treatment follow-up;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
ensure that clinical sites observe trial protocol, comply with good clinical practices, or GCPs, or continue to participate in
a trial;
address any patient safety concerns that arise during the course of a trial;
address any conflicts with new or existing laws or regulations;
initiate or add a sufficient number of clinical trial sites; or
(cid:121) manufacture sufficient quantities of product candidate for use in clinical trials.
Patient enrollment is a significant factor in the timing of clinical trials and is affected by many factors, including the size and
nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical
trial, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in
relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are
investigating.
We could also encounter delays if a clinical trial is suspended or terminated by us, our collaboration partner for the product
candidate, by the IRBs of the institutions in which such trials are being conducted, by an independent data safety monitoring board, or
DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a
number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols,
inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical
hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental
regulations or administrative actions or lack of adequate funding to continue the clinical trial.
36
Further, conducting clinical trials in foreign countries presents additional risks that may delay completion of clinical trials.
These risks include the failure of physicians or enrolled patients in foreign countries to adhere to clinical protocol as a result of
differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory
schemes and political and economic risks relevant to such foreign countries. In addition, the FDA may determine that the clinical trial
results obtained in foreign subjects do not represent the safety and efficacy of a product candidate when administered in U.S. patients
and are thus not supportive of an NDA approval in the United States.
If there are delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects
of our product candidates may be harmed, and our ability to generate revenue from product sales from any of these product candidates
will be delayed. In addition, any delays in completing the clinical trials will increase costs, slow down our product candidate
development and approval process and jeopardize the ability to commence product sales and generate revenue from product sales.
Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that
cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory
approval of our product candidates.
Our unlicensed product candidates are at an early stage of development and we may not be successful in our efforts to develop
these products or expand our pipeline of product candidates.
A key element of our strategy is to expand our pipeline of products candidates utilizing our proprietary drug discovery and
design platform and to advance such product candidates through clinical development. Our current unlicensed product candidates are
in the discovery and lead identification stages of preclinical development and will require substantial preclinical and clinical
development, testing and regulatory approval prior to commercialization. In particular, tenapanor is our only product candidate in
clinical trials and our other product candidates are in the preclinical stage with significant research and development required before
we could file an IND with regulatory authorities to begin clinical studies. Of the large number of drugs in development, only a small
percentage of such drugs successfully complete the FDA regulatory approval process and are commercialized. Accordingly, even if
we are able to continue to fund our development programs, there can be no assurance that any product candidates will reach the clinic
or be successfully developed or commercialized.
Research programs to identify product candidates require substantial technical, financial and human resources, whether or not
any product candidates are ultimately identified. Although our research and development efforts to date have resulted in several
development programs, we may not be able to develop product candidates that are safe, effective and well-tolerated. Our research
programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical
development or commercialization for many reasons, including the following:
(cid:121)
(cid:121)
the research methodology used and our drug discovery and design platform may not be successful in identifying potential
product candidates;
competitors may develop alternatives that render our product candidates obsolete or less attractive;
(cid:121) product candidates we develop may nevertheless be covered by third parties’ patents or other exclusive rights;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
the market for a product candidate may change during our program so that the continued development of that product
candidate is no longer reasonable;
a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is
unlikely to be effective, well-tolerated or otherwise does not meet applicable regulatory criteria;
a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
a product candidate may not be accepted as safe, effective and well-tolerated by patients, the medical community or third-
party payors, if applicable.
Even if we are successful in continuing to expand our pipeline, through our own research and development efforts or by
pursuing in-licensing or acquisition of product candidates, the potential product candidates for which we identify or acquire rights may
not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that
indicate that they are unlikely to receive marketing approval and achieve market acceptance. If we do not successfully develop and
commercialize a product pipeline, we may not be able to generate revenue from product sales in future periods or ever achieve
profitability.
37
Our proprietary drug discovery and design platform, and, in particular, APECCS, is a new approach to the discovery, design and
development of new product candidates and may not result in any products of commercial value.
We have developed a proprietary drug discovery and design platform to enable the identification, screening, testing, design and
development of new product candidates, and we recently enhanced this platform with the addition of APECCS. We plan to utilize
APECCS to identify new and potentially novel targets in the GI tract. We have also identified over 3,800 human gastrointestinal tract-
specific RNA transcripts and proteins on the inner surface of the gut, many of which we believe may be drug targets. However, there
can be no assurance that APECCS will be able to identify new targets in the GI tract or that any of these potential targets or other
aspects of our proprietary drug discovery and design platform will yield product candidates that could enter clinical development and,
ultimately, be commercially valuable.
Although we expect to continue to enhance the capabilities of our APECCS system by advancing the cell culture and screening
process and/or acquiring new technologies to broaden the scope of APECCS, we may not be successful in any of our enhancement and
development efforts. For example, we may not be able to enter into agreements on suitable terms to obtain technologies required to
develop certain capabilities of APECCS. In addition, we may not be successful in developing the conditions necessary to grow
multiple segments of intestine or from multiple species, or otherwise develop assays or cell cultures necessary to expand these
capabilities. If our enhancement or development efforts are unsuccessful, we may not be able to advance our drug discovery
capabilities as quickly as we expect or identify as many potential drugable targets as we desire.
We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product
candidates or indications that may be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and managerial resources, we have focused on research programs and product candidates that
relate to discovery and development of non-systemic drugs that work in the GI tract. As a result, we may forego or delay pursuit of
opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource
allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending
on current and future research and development programs and product candidates for specific indications may not yield any
commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product
candidate, we may relinquish valuable rights to that product candidate through collaboration partnerships, licensing or other royalty
arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights
to such product candidate.
We rely on third parties to conduct some of our preclinical and nonclinical studies and all of our clinical trials. If these third
parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory
approval for or commercialize our product candidates.
We do not have the ability to independently conduct clinical trials and, in some cases, preclinical or nonclinical studies. We rely
on medical institutions, clinical investigators, contract laboratories, collaboration partners and other third parties, such as CROs, to
conduct clinical trials on our product candidates. The third parties with whom we contract for execution of the clinical trials we are
conducting with AstraZeneca, as well as those third parties with whom we will contract for execution of clinical trials for our internal
programs, play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third
parties are not our employees, and except for contractual duties and obligations, we control only certain aspects of their activities and
have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely, and will continue
to rely, on these third parties to conduct some of our preclinical and nonclinical studies and all of our clinical trials, we remain
responsible for ensuring that each of our studies and clinical trials is conducted in accordance with the applicable protocol, legal,
regulatory and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these
third parties are required to comply with current good laboratory practices, or GLPs, for preclinical and nonclinical studies, and good
clinical practices, or GCPs, for clinical studies. GLPs and GCPs are regulations and guidelines enforced by the FDA, the Competent
Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for all of
our products in preclinical and clinical development, respectively. Regulatory authorities enforce GCPs through periodic inspections
of trial sponsors, principal investigators and trial sites. If we or any of our third party contractors fail to comply with applicable
regulatory requirements, including GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the
European Medicines Agency, or EMA, or comparable foreign regulatory authorities may require us to perform additional clinical
trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority,
such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials
must be conducted with product produced under current good manufacturing practices or cGMP regulations. Our failure to comply
with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.
38
Even if our product candidates obtain regulatory approval, they may never achieve market acceptance or commercial success,
which will depend, in part, upon the degree of acceptance among physicians, patients, patient advocacy groups, health care payors
and the medical community.
Even if our product candidates obtain FDA or other regulatory approvals, and are ultimately commercialized, our product
candidates may not achieve market acceptance among physicians, patients, third-party payors, patient advocacy groups, health care
payors and the medical community. Market acceptance of our product candidates for which marketing approval is obtained depends
on a number of factors, including:
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
the efficacy of the products as demonstrated in clinical trials;
the prevalence and severity of any side effects and overall safety and tolerability profile of the product;
the clinical indications for which the product is approved;
advantages over existing therapies;
acceptance by physicians, major operators of clinics and patients of the product as a safe, effective and well-tolerated
treatment;
relative convenience and ease of administration of our products;
the potential and perceived advantages of our product candidates over current treatment options or alternative treatments,
including future alternative treatments;
the cost of treatment in relation to alternative treatments and willingness to pay for our products, if approved, on the part
of physicians and patients;
the availability of alternative products and their ability to meet market demand;
the strength of our or our collaboration partners’ marketing and distribution organizations;
the quality of our relationships with patient advocacy groups; and
sufficient third-party coverage or reimbursement.
Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success
would adversely affect our results of operations.
Our product candidates may cause undesirable side effects or have other properties that could delay our clinical trials, or delay or
prevent regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences
following regulatory approval, if any. If any of our product candidates receives marketing approval and we or others later identify
undesirable side effects caused by the product candidate, the ability to market the product candidates could be compromised.
Undesirable side effects caused by our product candidates could cause us, our collaboration partners, or regulatory authorities to
interrupt, delay or halt clinical trials, result in the delay or denial of regulatory approval by the FDA or other comparable foreign
regulatory authorities or limit the commercial profile of an approved label. To date, patients treated with tenapanor have experienced
drug-related side effects including diarrhea, nausea, flatulence, abdominal discomfort, abdominal pain, abdominal distention and
changes in electrolytes, and in the Phase 2b evaluating tenapanor for the treatment of hyperphosphatemia in CKD-5D patients, we
observed that the rate of diarrhea and the discontinuation rate due to diarrhea at the highest doses was higher than expected based upon
the results of previous clinical trials. In the event that trials conducted by us or AstraZeneca with tenapanor, or trials we conduct with
our other product candidates, reveal an unacceptable severity and prevalence of these or other side effects, such trials could be
suspended or terminated and the FDA or comparable foreign regulatory authorities could order AstraZeneca or us to cease further
development of or deny approval of tenapanor, or any such other product candidate, for any or all targeted indications. Additionally,
despite a positive efficacy profile, the prevalence and/or severity of these or other side effects could cause us or AstraZeneca to cease
further development of a product candidate for a particular indication, or entirely. The drug-related side effects could affect patient
recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these
occurrences may harm our business, financial condition and prospects significantly.
39
In addition, in the event that any of our product candidates receives regulatory approval and we or others later identify
undesirable side effects caused by one of our products, a number of potentially significant negative consequences could occur,
including:
(cid:121)
regulatory authorities may withdraw their approval of the product or seize the product;
(cid:121) we, or our collaboration partners, may be required to recall the product;
(cid:121)
additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the
product or any component thereof, including the imposition of a Risk Evaluation and Mitigation Strategies, or REMS,
plan that may require creation of a Medication Guide outlining the risks of such side effects for distribution to patients, as
well as elements to assure safe use of the product, such as a patient registry and training and certification of prescribers;
(cid:121) we, or our collaboration partners, may be subject to fines, injunctions or the imposition of civil or criminal penalties;
(cid:121)
regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a
contraindication;
(cid:121) we could be sued and held liable for harm caused to patients;
(cid:121)
the product may become less competitive; and
(cid:121) our reputation may suffer
Any of the foregoing events could prevent us, or our collaboration partners, from achieving or maintaining market acceptance of
a particular product candidate, if approved, and could result in the loss of significant revenue to us, which would materially and
adversely affect our results of operations and business.
We face substantial competition and our competitors may discover, develop or commercialize products faster or more successfully
than us.
The biotechnology and pharmaceutical industries are highly competitive, and we face significant competition from companies in
the biotechnology, pharmaceutical and other related markets that are researching and marketing products designed to address diseases
that we are currently developing products to treat. If approved for marketing by the FDA or other regulatory agencies, tenapanor, or
our other product candidates, would compete against existing treatments. For example, tenapanor will, if approved, compete directly
with phosphate binders for the treatment of hyperphosphatemia in patients with CKD-5D, including sevelamer hydrochloride
(Renagel) and sevelamer carbonate (Renvela), which were launched by Genzyme. Synthon announced the successful completion of a
Phase 3 multicenter, randomized, double-blind, multiple-dose, crossover trial in Europe to compare safety and demonstrate
equivalence of serum phosphate control of Synthon sevelamer carbonate tablets to Renvela tablets in chronic kidney disease patients
on hemodialysis in April 2014. Currently, several pharmaceutical companies are distributing Synthon manufactured sevelamer
carbonate tablets in multiple European countries including, but not limited to, the UK, Spain, Sweden and Denmark. In addition to the
currently marketed phosphate binders, Keryx has received FDA approval for ferric citrate (Auryxia), an iron-based binder, that is also
approved in Japan and we are aware of fermagate (Alpharen), an iron-based binder in Phase 2 being developed by Opko Health.
While there are no treatments for CKD that have been proven to reverse the disease we are aware of certain investigational
drugs that were being developed for delaying kidney decline as measured by estimated glomerular filtration rate, or eGFR. Among
other products, Concert Pharmaceuticals is developing CTP-499 which showed protective effects on kidney function at 48 weeks in a
Phase 2 clinical trial in patients with CKD and type 2 diabetes.
Numerous treatments exist for constipation and the constipation component of IBS-C, many of which are over-the-counter.
These include psyllium husk (such as Metamucil), methylcellulose (such as Citrucel), calcium polycarbophil (such as FiberCon),
lactulose (such as Cephulac), polyethylene glycol (such as MiraLax), sennosides (such as Exlax), bisacodyl (such as Ducolax),
docusate sodium (such as Colace), magnesium hydroxide (such as Milk of Magnesia), saline enemas (such as Fleet) and sorbitol.
These agents are generally inexpensive and work well to relieve temporary constipation. We are also aware of two prescription drugs
currently on the U.S. market that are approved to treat IBS-C, Linzess (linaclotide), which was developed by Ironwood
Pharmaceuticals and was approved in 2012 and 2013 for IBS-C and chronic constipation in both the United States and in Europe, and
Amitiza (lubiprostone), which was first approved in the United States in 2006 and is currently marketed by Sucampo and Takeda for
treatment of chronic idiopathic constipation, or CIC, IBS-C and opioid induced constipation, or OIC.
40
It is possible that our competitors will develop and market drugs or other treatments that are less expensive and more effective
than our product candidates, or that will render our product candidates obsolete. It is also possible that our competitors will
commercialize competing drugs or treatments before we, or our collaboration partners, can launch any products developed from our
product candidates. We also anticipate that we will face increased competition in the future as new companies enter into our target
markets.
Many of our competitors have materially greater name recognition and financial, manufacturing, marketing, research and drug
development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result
in even more resources being concentrated in our competitors. Large pharmaceutical companies in particular have extensive expertise
in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government
agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially
competitive products or technologies. These organizations may also establish exclusive collaboration partnerships or licensing
relationships with our competitors.
We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we
may not be able to co-promote tenapanor, if approved, or commercialize or co-promote any of our other product candidates.
We currently do not have a sales organization. In order to co-promote tenapanor or commercialize or co-promote any of our
other product candidates, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make
arrangements with third parties to perform these services, and we may not be successful in doing so. If one or more of our product
candidates receives regulatory approval, we expect to establish a specialty sales organization with technical expertise and supporting
distribution capabilities to co-promote and/or commercialize our product candidates, which will be expensive and time consuming. As
a company, we have no prior experience in the marketing, sale and distribution of pharmaceutical products and there are significant
risks involved in building and managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals,
generate sufficient sales leads, provide adequate training to sales and marketing personnel, comply with regulatory requirements
applicable to the marketing and sale of drug products and effectively manage a geographically dispersed sales and marketing team.
Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the
commercialization of these products.
We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to
augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to
enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates.
We rely completely on third parties to manufacture our preclinical and clinical drug supplies, and we intend to rely on third parties
to produce commercial supplies of any approved product candidate. Our business would be harmed if those third parties fail to
obtain approval of the FDA, Competent Authorities of the Member States of the EEA or comparable regulatory authorities, fail to
provide us with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.
We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture our preclinical
and clinical drug supplies for use in the conduct of our preclinical and clinical studies, and we lack the resources and the capability to
manufacture any of our product candidates on a clinical or commercial scale. The facilities used by our contract manufacturers to
manufacture any drug products must be approved by the FDA pursuant to inspections that will be conducted after an NDA is
submitted to the FDA. We do not control the manufacturing process of our product candidates, and, other than with respect to
tenapanor, we are completely dependent on our contract manufacturing partners for compliance with the regulatory requirements,
known as cGMPs, for manufacture of both active drug substances and finished drug products. Under our agreement with AstraZeneca,
the manufacturing of tenapanor is the responsibility of AstraZeneca. We are entirely dependent on AstraZeneca for all aspects of the
manufacturing and validation process, as well as providing all commercial supply of tenapanor. For additional information regarding
the risks of our dependence on AstraZeneca, see the risk factors above titled “We are substantially dependent on the success of our
lead product candidate, tenapanor, which may not be successful in nonclinical studies or clinical trials, receive regulatory approval or
be successfully commercialized” and “We are dependent on AstraZeneca for the development, regulatory approval, manufacture and
commercialization of our small molecule NHE3 inhibitor program, which includes tenapanor, and if AstraZeneca fails to perform as
expected, or is unable to obtain the required regulatory approvals for tenapanor, the potential for us to generate future revenue from
milestone and royalty payments from tenapanor would be significantly reduced and our business would be materially and adversely
harmed.”
41
If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict
regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their
manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality
control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these
facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find
alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market
our product candidates, if approved.
We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates
for our clinical studies. There are a limited number of suppliers for raw materials that we use to manufacture our drugs, and there may
be a need to identify alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our
product candidates for our clinical studies, and, if approved, ultimately for commercial sale. We do not have any control over the
process or timing of the acquisition of these raw materials by our manufacturers. Although we generally do not begin a clinical study
unless we believe we have on hand, or will be able to manufacture a sufficient supply of a product candidate to complete such study,
any significant delay or discontinuity in the supply of a product candidate, or the raw material components thereof, for an ongoing
clinical study due to the need to replace a third-party manufacturer could considerably delay completion of our clinical studies,
product testing, and potential regulatory approval of our product candidates, which could harm our business and results of operations.
Third-party payor coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain
adequate coverage and reimbursement for our products, if approved, could limit our ability to market those products and decrease
our ability to generate revenue.
The pricing, coverage and reimbursement of our product candidates, if approved, must be adequate to support a commercial
infrastructure. The availability and adequacy of coverage and reimbursement by governmental and private payors are essential for
most patients to be able to afford treatments such as ours, assuming approval. Sales of our product candidates will depend
substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid for by health
maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government
authorities, private health insurers, and other third-party payors. If coverage and reimbursement are not available, or are available only
to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the
approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on
our investment.
There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United
States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &
Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services responsible for administering the
Medicare program, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private
payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what
CMS will decide with respect to reimbursement for products such as ours.
In July 2010, CMS released its final rule to implement a bundled prospective payment system for the treatment of ESRD
patients as required by the Medicare Improvements for Patients and Providers Act, or MIPPA. The bundled payment covers a bundle
of items and services routinely required for dialysis treatments furnished to Medicare beneficiaries in Medicare-certified ESRD
facilities or at their home, including the cost of certain routine drugs. The final rule delayed the inclusion of oral medications without
intravenous equivalents in the bundled payment until January 1, 2014 and in April 2014, President Obama signed the Protecting
Access to Medicare Act of 2014, which further extends this implementation date to January 1, 2024. As a result of the recent
legislation, beginning in 2024, ESRD-related drugs will be included in the bundle and separate Medicare reimbursement will no
longer be available for such drugs, as it is today under Medicare Part D. While it is too early to project the full impact bundling may
have on the industry, the impact could potentially cause dramatic price reductions for tenapanor, if approved. We and AstraZeneca
may be unable to sell tenapanor, if approved, to dialysis providers on a profitable basis if third-party payors reduce their current levels
of payment, or if our costs of production increase faster than increases in reimbursement levels.
42
Outside the United States, international operations are generally subject to extensive governmental price controls and other
market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, Japan, China and other
countries has and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of
medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies
to fix their own prices for medicinal products, but monitor and control company profits. Additional foreign price controls or other
changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets
outside the United States, the reimbursement for our products may be reduced compared with the United States and may be
insufficient to generate commercially reasonable revenue and profits.
Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare
costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result,
these caps may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in
connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of
health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general,
particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high
barriers are being erected to the entry of new products.
If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit
commercialization of our product candidates.
We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even
greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is
found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may
include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence,
strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot
successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit
commercialization of our product candidates. Even successful defense would require significant financial and management resources.
Regardless of the merits or eventual outcome, liability claims may result in:
(cid:121) decreased demand for our product candidates;
(cid:121)
injury to our reputation;
(cid:121) withdrawal of clinical trial participants;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
costs to defend the related litigation;
a diversion of management’s time and our resources;
substantial monetary awards to trial participants or patients;
regulatory investigations, product recalls or withdrawals, or labeling, marketing or promotional restrictions;
loss of revenue; and
the inability to commercialize or co-promote our product candidates.
Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect
against potential product liability claims could prevent or inhibit the commercialization of any products we develop. We currently
carry product liability insurance covering use in our clinical trials in the amount of $10.0 million in the aggregate. Although we
maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is
not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies
also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We
will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not
covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future,
we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.
43
We are highly dependent on the services of our President and Chief Executive Officer, Michael Raab, our Executive Vice
President and Chief Scientific Officer, Jeremy Caldwell, Ph.D., and our Senior Vice President of Drug Development, David
Rosenbaum, Ph.D. If we are not able to retain these members of our management team, or recruit additional management, clinical
and scientific personnel, our business will suffer.
Our success depends in part on our continued ability to attract, retain and motivate highly qualified personnel. In particular, we
are highly dependent upon Michael Raab, our President and Chief Executive Officer, Jeremy Caldwell, Ph.D., our Chief Scientific
Officer and David Rosenbaum, Ph.D., our Senior Vice President of Drug Development. The loss of services of any of these
individuals could delay or impair the successful development of our product pipeline, completion of our planned clinical trials or the
commercialization of our product candidates. Although we have entered into employment agreements with our senior management
team, including Mr. Raab and Drs. Caldwell and Rosenbaum, these agreements are terminable at will with or without notice and,
therefore, we may not be able to retain their services as expected. Although we have not historically experienced unique difficulties
attracting and retaining qualified employees, we could experience such problems in the future. For example, competition for qualified
personnel in the biotechnology and pharmaceuticals field is intense due to the limited number of individuals who possess the skills and
experience required by our industry. In addition to the competition for personnel, the San Francisco Bay area in particular is
characterized by a high cost of living. As such, we could have difficulty attracting experienced personnel to our company and may be
required to expend significant financial resources in our employee recruitment and retention efforts.
We will need to continue to increase the size of our organization, and we may experience difficulties in managing growth.
As of December 31, 2014, we had 34 full-time employees. We will need to continue to expand our managerial, operational,
finance and other resources in order to manage our operations, preclinical and clinical trials, research and development activities,
regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities, including co-promotion
activities. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. Our
need to effectively execute our growth strategy requires that we:
(cid:121)
(cid:121)
(cid:121)
expand our general and administrative functions;
establish and build a marketing and commercial organization;
identify, recruit, retain, incentivize and integrate additional employees;
(cid:121) manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and
(cid:121)
continue to improve our operational, legal, financial and management controls, reporting systems and procedures.
If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience
constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our
ability to implement our business strategy.
We incur significant costs as a result of operating as a public company, and our management will devote substantial time to new
compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-
Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business.
We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company
reporting obligations under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and regulations regarding
corporate governance practices. The listing requirements of The NASDAQ Global Market require that we satisfy certain corporate
governance requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals
and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a
substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and
regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. Any
changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on
a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure
associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our
board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors’
and officers’ insurance, on acceptable terms.
44
In addition, we are in the process of implementing enterprise resource planning, or ERP, system for our company. An ERP
system is intended to combine and streamline the management of our financial, accounting, human resources, sales and marketing and
other functions, enabling us to manage operations and track performance more effectively. However, an ERP system will require us to
complete many processes and procedures for the effective use of the system or to run our business using the system, which may result
in substantial costs. Additionally, during the conversion process, we may be limited in our ability to convert any business that we
acquire to the ERP. Any disruptions or difficulties in implementing or using an ERP system could adversely affect our controls and
harm our business, including our ability to forecast or make sales and collect our receivables. Moreover, such disruption or difficulties
could result in unanticipated costs and diversion of management attention.
We are subject to Section 404 of The Sarbanes-Oxley Act of 2002, or Section 404, and the related rules of the Securities and
Exchange Commission, or SEC, which generally require our management and independent registered public accounting firm to report
on the effectiveness of our internal control over financial reporting. Beginning with the second annual report that we will be required
to file with the SEC, Section 404 requires an annual management assessment of the effectiveness of our internal control over financial
reporting. However, for so long as we remain an emerging growth company as defined in the Jumpstart Our Business Startups Act of
2012, or JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to
public companies that are emerging growth companies, including, but not limited to, not being required to comply with the auditor
attestation requirements of Section 404. Once we are no longer an emerging growth company or, if prior to such date, we opt to no
longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public
accounting firm on the effectiveness of our internal controls over financial reporting. We will remain an emerging growth company
until the earlier of (1) the last day of the fiscal year following the fifth anniversary of the completion of our IPO (December 31, 2019),
(2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.0 billion, or (3) the last day of the fiscal
year in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-
affiliates exceeds $700 million as of the prior June 30th, and (4) the date on which we have issued more than $1.0 billion in non-
convertible debt during the prior three-year period.
To date, we have not conducted any other review of our internal control for the purpose of providing the reports required by
Section 404 and the related SEC rules. During the course of our review and testing, we may identify deficiencies and be unable to
remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over
financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our
independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control
over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial
information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and
timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate
and timely basis could result in sanctions, lawsuits, delisting of our shares from The NASDAQ Global Market or other adverse
consequences that would materially harm our business.
We may form additional collaboration partnerships in the future with respect to our independent programs, and we may not realize
the benefits of such collaborations.
We may form collaboration partnerships, create joint ventures or enter into licensing arrangements with third parties with
respect to our independent programs that we believe will complement or augment our existing business. We have historically engaged,
and intend to continue to engage, in partnering discussions with a range of pharmaceutical and biotechnology companies and could
enter into new collaboration partnerships at any time. We face significant competition in seeking appropriate collaboration partners,
and the negotiation process to secure appropriate terms is time-consuming and complex. Any delays in identifying suitable
collaboration partners and entering into agreements to develop our product candidates could also delay the commercialization of our
product candidates, which may reduce their competitiveness even if they reach the market. Moreover, we may not be successful in our
efforts to establish such a collaboration partnership for any future product candidates and programs on terms that are acceptable to us,
or at all. This may be because our product candidates and programs may be deemed to be at too early of a stage of development for
collaborative effort, our research and development pipeline may be viewed as insufficient, and/or third parties may not view our
product candidates and programs as having sufficient potential for commercialization, including the likelihood of an adequate safety
and efficacy profile. Even if we are successful in entering into a collaboration partnership or license arrangement, there is no guarantee
that the collaboration partnership will be successful, or that any future collaboration partner will commit sufficient resources to the
development, regulatory approval, and commercialization effort for such products, or that such alliances will result in us achieving
revenues that justify such transactions.
45
We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions
to our management.
We intend to consider strategic transactions, such as acquisitions of companies, asset purchases, and or in-licensing of products,
product candidates or technologies. Additional potential transactions that we may consider include a variety of different business
arrangements, including spin-offs, collaboration partnerships, joint ventures, restructurings, divestitures, business combinations and
investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term
expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our
operations and financial results. For example, these transactions may entail numerous operational and financial risks, including:
(cid:121) up-front, milestone and royalty payments, equity investments and financial support of new research and development
candidates including increase of personnel, all of which may be substantial;
(cid:121)
exposure to unknown liabilities;
(cid:121) disruption of our business and diversion of our management’s time and attention in order to develop acquired products,
product candidates or technologies;
(cid:121)
incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions;
(cid:121) higher-than-expected acquisition and integration costs;
(cid:121) write-downs of assets or goodwill or impairment charges;
(cid:121)
increased amortization expenses;
(cid:121) difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and
personnel;
(cid:121)
(cid:121)
impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management
and ownership; and
inability to retain key employees of any acquired businesses.
Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature
described above, any transactions that we do complete may be subject to the foregoing or other risks and could have a material
adverse effect on our business, results of operations, financial condition and prospects.
If we seek and obtain approval to commercialize our product candidates outside of the United States, or otherwise engage in
business outside of the United States, a variety of risks associated with international operations could materially adversely affect
our business.
We may decide to seek marketing approval for certain of our product candidates outside the United States or otherwise engage
in business outside the United States, including entering into contractual agreements with third-parties. We expect that we will be
subject to additional risks related to entering into these international business markets and relationships, including:
(cid:121) different regulatory requirements for drug approvals in foreign countries;
(cid:121) differing United States and foreign drug import and export rules;
(cid:121)
reduced protection for intellectual property rights in foreign countries;
(cid:121) unexpected changes in tariffs, trade barriers and regulatory requirements;
(cid:121) different reimbursement systems, and different competitive drugs;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
economic weakness, including inflation, or political instability in particular foreign economies and markets;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
foreign taxes, including withholding of payroll taxes;
foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other
obligations incident to doing business in another country;
(cid:121) workforce uncertainty in countries where labor unrest is more common than in the United States;
(cid:121) production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;
46
(cid:121) potential liability resulting from development work conducted by these distributors; and
(cid:121) business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.
Our business involves the use of hazardous materials and we and third-parties with whom we contract must comply with
environmental laws and regulations, which can be expensive and restrict how we do business.
Our research and development activities involve the controlled storage, use and disposal of hazardous materials, including the
components of our product candidates and other hazardous compounds. We and manufacturers and suppliers with whom we may
contract are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous
materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our
manufacturers’ facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an
interruption of our commercialization efforts, research and development efforts and business operations, environmental damage
resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of
these materials and specified waste products. We cannot guarantee that that the safety procedures utilized by third-party manufacturers
and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk
of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such
liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or
interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to
become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not
currently carry biological or hazardous waste insurance coverage.
Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches,
which could result in a material disruption of our product development programs.
Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors
and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and
telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date,
if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For
example, the loss of clinical trial data from completed or ongoing clinical trials for any of our product candidates could result in delays
in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any
disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or
proprietary information, we could incur liability and the further development of our product candidates could be delayed.
We may be adversely affected by the current global economic environment.
Our ability to attract and retain collaboration partners or customers, invest in and grow our business and meet our financial
obligations depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the
prevailing economic conditions and financial, business and other factors beyond our control, such as the rate of unemployment, the
number of uninsured persons in the United States and inflationary pressures. Our results of operations could be adversely affected by
general conditions in the global economy and in the global financial markets. The recent global financial crisis caused extreme
volatility and disruptions in the capital and credit markets. We cannot anticipate all the ways in which the current global economic
climate and global financial market conditions could adversely impact our business.
We are exposed to risks associated with reduced profitability and the potential financial instability of our collaboration partners
or customers, many of which may be adversely affected by volatile conditions in the financial markets. For example, unemployment
and underemployment, and the resultant loss of insurance, may decrease the demand for healthcare services and pharmaceuticals. If
fewer patients are seeking medical care because they do not have insurance coverage, our collaboration partners or customers may
experience reductions in revenues, profitability and/or cash flow that could lead them to reduce their support of our programs or
financing activities. If collaboration partners or customers are not successful in generating sufficient revenue or are precluded from
securing financing, they may not be able to pay, or may delay payment of, accounts receivable that are owed to us. In addition, the
volatility in the financial markets could cause significant fluctuations in the interest rate and currency markets. We currently do not
hedge for these risks. The foregoing events, in turn, could adversely affect our financial condition and liquidity. In addition, if
economic challenges in the United States result in widespread and prolonged unemployment, either regionally or on a national basis,
prior to the effectiveness of certain provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and
Education Reconciliation Act, collectively known as the Affordable Care Act, a substantial number of people may become uninsured
or underinsured. To the extent economic challenges result in fewer individuals pursuing or being able to afford our product candidates
once commercialized, our business, results of operations, financial condition and cash flows could be adversely affected.
47
We may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans
may not adequately protect us from a serious disaster.
Our corporate headquarters and other facilities are located in the San Francisco Bay Area, which in the past has experienced
severe earthquakes. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our
operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.
If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our
headquarters, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and
enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue
our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited
and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of
the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of
earthquake insurance, could have a material adverse effect on our business.
Risks Related to Government Regulation
The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently
unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be
substantially harmed.
The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products are
subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations
differ from country to country. Neither we nor any of our collaboration partners is permitted to market any drug product in the United
States until we receive marketing approval from the FDA. We have not submitted an application or obtained marketing approval for
any of our product candidates anywhere in the world. Obtaining regulatory approval of a new drug application, or NDA, can be a
lengthy, expensive and uncertain process. In addition, failure to comply with FDA and other applicable United States and foreign
regulatory requirements may subject us to administrative or judicially imposed sanctions or other actions, including:
(cid:121) warning letters;
(cid:121)
(cid:121)
civil and criminal penalties;
injunctions;
(cid:121) withdrawal of regulatory approval of products;
(cid:121) product seizure or detention;
(cid:121) product recalls;
(cid:121)
(cid:121)
total or partial suspension of production; and
refusal to approve pending NDAs or supplements to approved NDAs.
Prior to obtaining approval to commercialize a drug candidate in the United States or abroad, we or our collaboration partners
must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or other foreign
regulatory agencies, that such drug candidates are safe and effective for their intended uses. The number of nonclinical studies and
clinical trials that will be required for FDA approval varies depending on the drug candidate, the disease or condition that the drug
candidate is designed to address, and the regulations applicable to any particular drug candidate. Results from nonclinical studies and
clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our drug candidates are
promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering drug
candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA or
other regulatory authorities denying approval of a drug candidate for any or all targeted indications.
48
The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many
years following the commencement of clinical studies, and depends upon numerous factors. The FDA and comparable foreign
authorities have substantial discretion in the approval process and we may encounter matters with the FDA or such comparable
authorities that requires us to expend additional time and resources and delay or prevent the approval of our product candidates. For
example, the FDA may require us to conduct additional studies or trials for drug product either prior to or post-approval, such as
additional drug-drug interaction studies or safety or efficacy studies or trials, or it may object to elements of our clinical development
program such as the number of subjects in our current clinical trials from the United States. In addition, approval policies, regulations
or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical
development and may vary among jurisdictions, which may cause delays in the approval or result in a decision not to approve an
application for regulatory approval. Despite the time and expense exerted, failure can occur at any stage. Applications for our product
candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:
(cid:121)
(cid:121)
(cid:121)
(cid:121)
the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our, or our
collaboration partners’, clinical studies;
the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full
population for which approval is sought;
the FDA or comparable foreign regulatory authorities may disagree with the interpretation of data from preclinical studies
or clinical studies;
the data collected from clinical studies of our product candidates may not be sufficient to support the submission of a
NDA or other submission or to obtain regulatory approval in the United States or elsewhere;
(cid:121) we or our collaboration partners may be unable to demonstrate to the FDA or comparable foreign regulatory authorities
that a product candidate’s risk-benefit ratio for its proposed indication is acceptable;
(cid:121)
(cid:121)
the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures
and specifications, or facilities of third-party manufacturers responsible for clinical and commercial supplies; and
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a
manner rendering our clinical data insufficient for approval.
This lengthy approval process, as well as the unpredictability of the results of clinical studies, may result in our failure and/or
that of our collaboration partners to obtain regulatory approval to market any of our product candidates, which would significantly
harm our business, results of operations, and prospects. Additionally, if the FDA requires that we conduct additional clinical studies,
places limitations in our label, delays approval to market our product candidates or limits the use of our products, our business and
results of operations may be harmed.
In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or
more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval
contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not
include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing
scenarios could materially harm the commercial prospects for our product candidates.
Even if we receive regulatory approval for a product candidate, we will be subject to ongoing regulatory obligations and continued
regulatory review, which may result in significant additional expense. Additionally, any product candidates, if approved, could be
subject to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with
regulatory requirements or experience unanticipated problems with our products.
Even if a drug is approved by the FDA or foreign regulatory authorities, the manufacturing processes, labeling, packaging,
distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive
and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and
reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. As
such, we and our third party contract manufacturers will be subject to continual review and periodic inspections to assess compliance
with regulatory requirements. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all
areas of regulatory compliance, including manufacturing, production, and quality control. Regulatory authorities may also impose
significant restrictions on a product’s indicated uses or marketing or impose ongoing requirements for potentially costly post-
marketing studies. Furthermore, any new legislation addressing drug safety issues could result in delays or increased costs to assure
compliance.
49
We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with
requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs
are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved label.
As such, we may not promote our products for indications or uses for which they do not have FDA approval.
Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or
frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may
result in, among other things:
(cid:121) warning letters, fines or holds on clinical trials;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or
mandatory product recalls;
injunctions or the imposition of civil or criminal penalties;
suspension or revocation of existing regulatory approvals;
suspension of any of our ongoing clinical trials;
refusal to approve pending applications or supplements to approved applications submitted by us;
restrictions on our or our contract manufacturers’ operations; or
(cid:121) product seizure or detention, or refusal to permit the import or export of products.
Any government investigation of alleged violations of law could require us to expend significant time and resources in response,
and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely
affect our ability to commercialize our product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn,
the value of our company and our operating results will be adversely affected.
In addition, the FDA’s policies may change and additional government regulations may be enacted that could prevent, limit or
delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption
of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we
may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.
We and our collaboration partners and contract manufacturers are subject to significant regulation with respect to manufacturing
our product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements or may
not be able to meet supply demands.
All entities involved in the preparation of product candidates for clinical studies or commercial sale, including our existing
contract manufacturers for our product candidates and AstraZeneca, and those contract manufacturers it may rely upon with respect to
the manufacture of tenapanor, are subject to extensive regulation. Components of a finished therapeutic product approved for
commercial sale or used in late-stage clinical studies must be manufactured in accordance with cGMP. These regulations govern
manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to
control and assure the quality of investigational products and products approved for sale. Poor control of production processes can
lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not
be detectable in final product testing. We, our collaboration partners, or our contract manufacturers must supply all necessary
documentation in support of an NDA or comparable regulatory filing on a timely basis and must adhere to cGMP regulations enforced
by the FDA and other regulatory agencies through their facilities inspection programs. Some of our contract manufacturers have never
produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority
approvals to do so. The facilities and quality systems of some or all of our collaboration partners and third-party contractors must pass
a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product
candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the
preparation of our product candidates or our other potential products or the associated quality systems for compliance with the
regulations applicable to the activities being conducted. Although we oversee the contract manufacturers, we cannot control the
manufacturing process of, and are completely dependent on, other than with respect to tenapanor, our contract manufacturing partners
for compliance with the regulatory requirements. AstraZeneca is fully responsible for the manufacture of tenapanor, and we are
entirely dependent upon AstraZeneca for compliance with the regulatory requirements. If these facilities do not pass a pre-approval
plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are
corrected to the satisfaction of the regulatory authority, if ever. In addition, we have no control over the ability of our contract
manufacturers to maintain adequate quality control, quality assurance and qualified personnel.
50
The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of
our collaboration partners and third-party contractors. If any such inspection or audit identifies a failure to comply with applicable
regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit,
we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party
to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or
permanent suspension of production or closure of a facility. Any such remedial measures imposed upon us or third parties with whom
we contract could materially harm our business.
If we, our collaboration partners, or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or
other applicable regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending
application for a new drug product, withdrawal of an approval, or suspension of production. As a result, our business, financial
condition, and results of operations may be materially harmed.
Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified
through an NDA, a supplemental NDA or equivalent foreign regulatory filing, which could result in further delay. The regulatory
agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers
may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.
These factors could cause us to incur higher costs and could cause the delay or termination of clinical studies, regulatory
submissions, required approvals, or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual
requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost,
our clinical studies may be delayed or we could lose potential revenue.
If we fail to comply or are found to have failed to comply with FDA and other regulations related to the promotion of our products
for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.
The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation
by the FDA and other government agencies. If tenapanor, or our other product candidates, receives marketing approval, we and our
collaborating partners will be restricted from marketing the product outside of its approved labeling, also referred to as off-label
promotion. However, physicians may nevertheless prescribe an approved product to their patients in a manner that is inconsistent with
the approved label, which is an off-label use. We intend to implement compliance and training programs designed to ensure that our
sales and marketing practices comply with applicable regulations regarding off-label promotion. Notwithstanding these programs, the
FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our product candidates for
unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable regulations regarding
the promotion of products for unapproved uses.
Over the past several years, a significant number of pharmaceutical and biotechnology companies have been the target of
inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in
connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and
various U.S. Attorneys’ Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the
Federal Trade Commission and various state Attorneys General offices. These investigations have alleged violations of various federal
and state laws and regulations, including claims asserting antitrust violations, violations of the Food, Drug and Cosmetic Act, the
False Claims Act, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the
promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations
originate as “qui tam” actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of
the government alleging that a person or entity has presented a false claim, or caused a false claim to be submitted, to the government
for payment. The person bringing a qui tam suit is entitled to a share of any recovery or settlement. Qui tam suits, also commonly
referred to as “whistleblower suits,” are often brought by current or former employees. In a qui tam suit, the government must decide
whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone.
If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a qui tam suit
and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to
substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements
pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and
regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and
reputation.
51
If approved, tenapanor and our other product candidates may cause or contribute to adverse medical events that we are required to
report to regulatory agencies and if we fail to do so we could be subject to sanctions that would materially harm our business.
Some participants in clinical studies of tenapanor have reported adverse effects after being treated with tenapanor, including
diarrhea, nausea, flatulence, abdominal discomfort, abdominal pain, abdominal distention and changes in electrolytes and in the Phase
2b evaluating tenapanor for the treatment of hyperphosphatemia in CKD-5D patients, we observed that the rate of diarrhea and the
discontinuation rate due to diarrhea at the highest doses was higher than expected based upon the results of previous clinical trials. If
we are successful in commercializing any products, FDA and foreign regulatory agency regulations require that we report certain
information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our
obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may
fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have
become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is
unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign
regulatory agency could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products
or delay in approval or clearance of future products.
Our employees, independent contractors, principal investigators, CROs, collaboration partners, consultants and vendors may
engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, collaboration partners,
consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include
intentional, reckless and/or negligent conduct or unauthorized activities that violate: (1) FDA regulations, including those laws that
require the reporting of true, complete and accurate information to the FDA; (2) manufacturing standards; (3) federal and state
healthcare fraud and abuse laws and regulations; or (4) laws that require the reporting of true and accurate financial information and
data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations
intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a
wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. These activities also include the improper use of information obtained in the course of clinical trials, which could result
in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and
other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or
unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to
be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending
ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant
civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and
other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of
our operations, any of which could adversely affect our ability to operate our business and our results of operations.
Failure to obtain regulatory approvals in foreign jurisdictions would prevent us from marketing our products internationally.
In order to market any product in the EEA (which is composed of the 28 Member States of the European Union plus Norway,
Iceland and Liechtenstein), and many other foreign jurisdictions, separate regulatory approvals are required. In the EEA, medicinal
products can only be commercialized after obtaining a Marketing Authorization, or MA. Before granting the MA, the EMA or the
competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of
scientific criteria concerning its quality, safety and efficacy.
The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain
approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by
regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries,
and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign
countries or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on
the regulatory process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA
approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file we may not receive
necessary approvals to commercialize our products in any market.
52
We and our collaboration partners may be subject to healthcare laws, regulation and enforcement; our failure or the failure of our
collaboration partners to comply with these laws could have a material adverse effect on our results of operations and financial
conditions.
Although we do not currently have any products on the market, once we begin commercializing our products, we and our
collaboration partners may be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal
government and the states and foreign governments in which we conduct our business. The laws that may affect our ability to operate
as a commercial organization include:
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting,
receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an
individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under
federal healthcare programs such as the Medicare and Medicaid programs;
federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing
to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;
federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false
statements relating to healthcare matters;
the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information
Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions
and protects the security and privacy of protected health information;
the federal physician sunshine requirements under the Affordable Care Act, which requires manufacturers of drugs,
devices, biologics, and medical supplies to report annually to the CMS information related to payments and other transfers
of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by
physicians and other healthcare providers and their immediate family members;
state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to
items or services reimbursed by any third-party payor, including commercial insurers;
state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance
guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments
that may be made to healthcare providers and other potential referral sources;
state laws that require drug manufacturers to report information related to payments and other transfers of value to
physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of
health information in certain circumstances, many of which differ from each other in significant ways, thus complicating
compliance efforts; and
(cid:121) European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions
with and payments to healthcare providers.
Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that
some of our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation
of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and
their provisions are open to a variety of interpretations. Further, the Affordable Care Act, among other things, amends the intent
requirement of the federal anti-kickback and criminal health care fraud statutes. A person or entity no longer needs to have actual
knowledge of this statute or specific intent to violate it. In addition, the Affordable Care Act provides that the government may assert
that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent
claim for purposes of the false claims statutes. Any action against us for violation of these laws, even if we successfully defend against
it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our
operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to
us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our
operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely
affect our ability to market our products and adversely impact our financial results.
53
Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory
clearance or approval of our product candidates and to produce, market and distribute our products after clearance or approval is
obtained.
From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions
governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In
addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our
business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or
lengthen review times of our product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation
or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other
things, require:
(cid:121)
(cid:121)
(cid:121)
(cid:121)
additional clinical trials to be conducted prior to obtaining approval;
changes to manufacturing methods;
recall, replacement, or discontinuance of one or more of our products; and
additional record keeping.
Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In
addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business,
financial condition and results of operations.
In addition, the full impact of recent healthcare reform and other changes in the healthcare industry and in healthcare spending is
currently unknown, and may adversely affect our business model. In the United States, the Affordable Care Act was enacted in 2010
with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and
private insurers. The Affordable Care Act, among other things, increased the minimum Medicaid rebates owed by manufacturers
under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care
organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare
Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices
of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer’s outpatient
drugs to be covered under Medicare Part D.
In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was
enacted. On August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select
Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013
through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government
programs. This included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on
April 1, 2013. On January 2, 2013, the ATRA was signed into law, which, among other things, further reduced Medicare payments to
several providers, including hospitals.
It is likely that federal and state legislatures within the United States and foreign governments will continue to consider changes
to existing healthcare legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that
have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care
organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect the demand for any
drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our
ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain
profitability, and the level of taxes that we are required to pay.
54
Risks Related to Intellectual Property
We may become subject to claims alleging infringement of third parties’ patents or proprietary rights and/or claims seeking to
invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, delay or prevent the
development and commercialization of tenapanor or any other product candidates.
There have been many lawsuits and other proceedings asserting infringement or misappropriation of patents and other
intellectual property rights in the pharmaceutical and biotechnology industries. There can be no assurances that we will not be subject
to claims alleging that the manufacture, use or sale of tenapanor or any other product candidates nor that any activities conducted by
us, infringes existing or future third-party patents, or that such claims, if any, will not be successful. Because patent applications can
take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised
before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the
manufacture, use or sale of tenapanor or other product candidates or by the operation of our business. Moreover, we may face patent
infringement claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio
may thus have no deterrent effect. We may be unaware of one or more issued patents that would be infringed by the manufacture, sale
or use of tenapanor or our other product candidates.
We may be subject to third-party patent infringement claims in the future against us or our collaboration partners that would
cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages, including treble
damages and attorney’s fees if we are found to be willfully infringing a third party’s patents. We may be required to indemnify future
collaboration partners against such claims. We are not aware of any threatened or pending claims related to these matters, but in the
future litigation may be necessary to defend against such claims. If a patent infringement suit were brought against us or our
collaboration partners, we or they could be forced to stop or delay research, development, manufacturing or sales of the product or
product candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we or
our collaboration partners may choose to seek, or be required to seek, a license from the third party and would most likely be required
to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we or our
collaboration partners were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the
same intellectual property. Ultimately, we could be prevented from commercializing a product, or forced to redesign it, or to cease
some aspect of our business operations if, as a result of actual or threatened patent infringement claims, we or our collaboration
partners are unable to enter into licenses on acceptable terms. Even if we are successful in defending against such claims, such
litigation can be expensive and time consuming to litigate and would divert management’s attention from our core business. Any of
these events could harm our business significantly.
In addition to infringement claims against us, if third parties prepare and file patent applications in the United States that also
claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the United States
Patent and Trademark Office, or the USPTO, to determine which party is entitled to a patent on the disputed invention. We may also
become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our
intellectual property rights with respect to our products and technology. Since patent applications are confidential for a period of time
after filing, we cannot be certain that we were the first to file any patent application related to our product candidates.
If our intellectual property related to our product candidates is not adequate or if we are not able to protect our trade secrets or our
confidential information, we may not be able to compete effectively in our market.
We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property
related to our product candidates, our drug discovery and development platform and our development programs. Any disclosure to or
misappropriation by third parties of our confidential or proprietary information could enable competitors to quickly duplicate or
surpass our technological achievements, thus eroding our competitive position in our market.
55
The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be
uncertain. The patent applications that we own or license may fail to result in issued patents in the United States or in foreign
countries. Additionally, our research and development efforts may result in product candidates for which patent protection is limited
or not available. Even if patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which
may result in such patents being narrowed, invalidated or held unenforceable. For example, U.S. patents can be challenged by any
person before the new USPTO Patent Trial and Appeals Board at any time before one year after that person is served an infringement
complaint based on the patents. Patents granted by the European Patent Office may be similarly opposed by any person within nine
months from the publication of the grant. Similar proceedings are available in other jurisdictions, and in the United States, Europe and
other jurisdictions third parties can raise questions of validity with a patent office even before a patent has granted. Furthermore, even
if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others
from designing around our claims. For example, a third party may develop a competitive product that provides therapeutic benefits
similar to one or more of our product candidates but has a sufficiently different composition to fall outside the scope of our patent
protection. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to
our product candidates is successfully challenged, then our ability to commercialize such product candidates could be negatively
affected, and we may face unexpected competition that could have a material adverse impact on our business. Further, if we encounter
delays in our clinical trials, the period of time during which we or our collaboration partners could market tenapanor or other product
candidates under patent protection would be reduced.
Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the
scope of our proprietary rights, and the outcome of such litigation would be uncertain. If we or one of our collaboration partners were
to initiate legal proceedings against a third party to enforce a patent covering the product candidate, the defendant could counterclaim
that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an
allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a
misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner
were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability against our
intellectual property related to a product candidate, we would lose at least part, and perhaps all, of the patent protection on such
product candidate. Such a loss of patent protection would have a material adverse impact on our business. Moreover, our competitors
could counterclaim that we infringe their intellectual property, and some of our competitors have substantially greater intellectual
property portfolios than we do.
We also rely on trade secret protection and confidentiality agreements to protect proprietary know-how that may not be
patentable, processes for which patents may be difficult to obtain and/or enforce and any other elements of our drug discovery and
development processes that involve proprietary know-how, information or technology that is not covered by patents. Although we
require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or
technology, to assign their inventions to us, and endeavor to execute confidentiality agreements with all such parties, we cannot be
certain that we have executed such agreements with all parties who may have helped to develop our intellectual property or who had
access to our proprietary information, nor can we be certain that our agreements will not be breached by such consultants, advisors or
third parties, or by our former employees. The breach of such agreements by individuals or entities who are actively involved in the
discovery and design of our potential drug candidates, or in the development of our discovery and design platform, including
APECCS, could require us to pursue legal action to protect our trade secrets and confidential information, which would be expensive,
and the outcome of which would be unpredictable. If we are not successful in prohibiting the continued breach of such agreements,
our business could be negatively impacted. We cannot guarantee that our trade secrets and other confidential proprietary information
will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially
equivalent information and techniques.
Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws
of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in
the United States and abroad. If we are unable to prevent material disclosure of the intellectual property related to our technologies to
third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely
affect our business, results of operations and financial condition.
56
If we or our collaboration partners do not obtain patent term extension in the United States under the Hatch-Waxman Act and in
foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product
candidates, our business may be materially harmed.
Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, if any, one of the U.S.
patents covering each of such approved product(s) or the use thereof may be eligible for up to five years of patent term restoration
under the Hatch-Waxman Act. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product.
Patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates.
Nevertheless, we or our collaboration partners may not be granted patent term extension either in the United States or in any foreign
country because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or
otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during
any such extension, afforded by the governmental authority could be less than we request.
If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we or our
collaboration partners request, the period during which we or our collaboration partners will have the right to exclusively market our
product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our
revenue could be reduced, possibly materially.
Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly
patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity.
Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, the
United States has recently enacted and is currently implementing wide-ranging patent reform legislation, including the Leahy-Smith
America Invents Act signed into law on September 16, 2011. That Act includes a number of significant changes to U.S. patent law.
These include provisions that affect the way patent applications are prosecuted and new venues and opportunities for competitors to
challenge patent portfolios. Because of that Act, the U.S. patent system is now a “first to file” system, which may make it more
difficult to obtain patent protection for inventions and increase the uncertainties and costs surrounding the prosecution of our or our
collaboration partners’ patent applications and the enforcement or defense of our or our collaboration partners’ issued patents, all of
which could materially adversely affect our business, results of operations and financial condition.
The United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent
protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing
uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to
the value of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and
regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce
our existing patents and patents that we might obtain in the future.
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee
payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or
eliminated for non-compliance with these requirements.
The USPTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment
and other provisions to maintain patent applications and issued patents. Noncompliance with these requirements can result in
abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.
We may not be able to enforce our intellectual property rights throughout the world.
The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States.
Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign
jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other
intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of
our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory
licensing laws under which a patent owner must grant licenses to third parties.
57
Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and
divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property
rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all
jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such
countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries
may affect our ability to obtain and enforce adequate intellectual property protection for our technology.
We may be subject to claims that we or our employees have misappropriated the intellectual property, including know-how or trade
secrets, of a third party, or claiming ownership of what we regard as our own intellectual property.
Many of our employees, consultants and contractors were previously employed at or engaged by other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors,
executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although
we try to ensure that our employees, consultants and contractors do not use the intellectual property and other proprietary information
or know-how or trade secrets of others in their work for us, and do not perform work for us that is in conflict with their obligations to
another employer or any other entity, we may be subject to claims that we or these employees, consultants and contractors have used
or disclosed such intellectual property, including know-how, trade secrets or other proprietary information. In addition, an employee,
advisor or consultant who performs work for us may have obligations to a third party that are in conflict with their obligations to us,
and as a result such third party may claim an ownership interest in the intellectual property arising out of work performed for us. We
are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend
against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights or personnel, or access to consultants and contractors. Even if we are successful in defending against such
claims, litigation could result in substantial costs and be a distraction to management.
In addition, while we typically require our employees, consultants and contractors who may be involved in the development of
intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an
agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or
against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to
paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending
against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel.
58
Risks Related to Our Common Stock
Our stock price may be volatile and our stockholders may not be able to resell shares of our common stock at or above the price
they paid.
The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors,
some of which are beyond our control. These factors include those discussed in this “Risk Factors” section of this Annual Report on
Form 10-K and others such as:
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
announcements regarding decisions by AstraZeneca to terminate or delay development of tenapanor for one or more
indications, or to terminate the collaboration partnership;
results from, or any delays in, clinical trial programs relating to our product candidates, including the ongoing and planned
clinical trials for tenapanor;
announcements relating to our collaboration partnership with Sanofi regarding its option to develop and commercialize
NaP2b inhibitors;
ability to commercialize or obtain regulatory approval for our product candidates, or delays in commercializing or
obtaining regulatory approval;
announcements of regulatory approval or a complete response letter to tenapanor, or specific label indications or patient
populations for its use, or changes or delays in the regulatory review process;
announcements relating to future collaboration partnerships;
(cid:121) our election, and the related announcement, to exercise our co-fund right with respect to the first Phase 3 clinical
development program for tenapanor;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
announcements of therapeutic innovations or new products by us or our competitors;
adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and
marketing activities;
changes or developments in laws or regulations applicable to our product candidates;
the success of our testing and clinical trials;
the success of our efforts to acquire or license or discover additional product candidates;
any intellectual property infringement actions in which we may become involved;
announcements concerning our competitors or the pharmaceutical industry in general;
achievement of expected product sales and profitability;
(cid:121) manufacture, supply or distribution shortages;
(cid:121)
actual or anticipated fluctuations in our operating results;
(cid:121) FDA or other U.S. or foreign regulatory actions affecting us or our industry or other healthcare reform measures in the
United States;
changes in financial estimates or recommendations by securities analysts;
trading volume of our common stock;
sales of our common stock by us, our executive officers and directors or our stockholders in the future;
(cid:121)
(cid:121)
(cid:121)
(cid:121) general economic and market conditions and overall fluctuations in the United States equity markets; and
(cid:121)
the loss of any of our key scientific or management personnel.
In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in
particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad
market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a
stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our
stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our
management would be diverted from the operation of our business, which could seriously harm our financial position. Any adverse
determination in litigation could also subject us to significant liabilities.
59
We are an “emerging growth company” and as a result of the reduced disclosure and governance requirements applicable to
emerging growth companies, our common stock may be less attractive to investors.
We are an “emerging growth company,” as defined in the JOBS Act, and we intend to take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not emerging growth companies including,
but not limited to, not being required to comply with the auditor attestation requirements of Section 404, reduced disclosure
obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of
holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not
previously approved. If some investors find our common stock less attractive as a result of our reliance on the JOBS Act exemption,
there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of
these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until
the earlier of (1) the last day of the fiscal year following the fifth anniversary of the completion of our IPO (December 31, 2019),
(2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.0 billion, or (3) the last day of the fiscal
year in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-
affiliates exceeds $700 million as of the prior June 30th, and (4) the date on which we have issued more than $1.0 billion in non-
convertible debt during the prior three-year period.
If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our
stock price may decline.
We may from time to time issue additional shares of common stock at a discount from the current trading price of our common
stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at
such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future,
including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into
common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.
Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market,
the trading price of our common stock could decline. As of December 31, 2014, we had 18,589,245 shares of common stock
outstanding. Of those shares, on such date, 10,538,920 were held by current directors, executive officers and other affiliates, or may
otherwise be subject to Rule 144 under the Securities Act of 1933, or the Securities Act.
In addition, as of December 31, 2014, 1,007,724 shares of common stock that are subject to outstanding options, will be eligible
for sale in the public market to the extent permitted by the provisions of various vesting schedules, and Rule 144 and Rule 701 under
the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market,
the trading price of our common stock could decline.
The holders of approximately 11.0 million shares of our outstanding common stock as of December 31, 2014, are entitled to
rights with respect to the registration of their shares under the Securities Act, subject to vesting schedules. Registration of these shares
under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for
shares purchased by affiliates. Any sales of securities by these stockholders could have a material adverse effect on the trading price of
our common stock.
Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control
over matters subject to stockholder approval.
As of December 31, 2014, our executive officers, directors, holders of 5% or more of our capital stock and their respective
affiliates beneficially owned approximately two-thirds of our outstanding voting stock. Therefore, these stockholders will have the
ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder
approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents,
or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition
proposals or offers for our common stock that certain stockholders may feel are in their best interest as one of our stockholders.
60
Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider
favorable and may lead to entrenchment of management.
Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could
significantly reduce the value of our shares to a potential acquirer or delay or prevent changes in control or changes in our
management without the consent of our board of directors. The provisions in our charter documents include the following:
(cid:121)
a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the
membership of a majority of our board of directors;
(cid:121) no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director
candidates;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of
directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies
on our board of directors;
the required approval of at least 66 2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on
removal of directors without cause;
the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and
other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to
significantly dilute the ownership of a hostile acquiror;
the ability of our board of directors to alter our bylaws without obtaining stockholder approval;
the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt, amend or repeal
our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and
removal of directors;
a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special
meeting of our stockholders;
the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the
chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force
consideration of a proposal or to take action, including the removal of directors; and
advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or
to propose matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquiror from
conducting a solicitation of proxies to elect the acquiror’s own slate of directors or otherwise attempting to obtain control
of us.
In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial.
We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under
Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock
unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.
Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims
against us and may reduce the amount of money available to us.
Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our
directors and officers, in each case to the fullest extent permitted by Delaware law.
In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our
indemnification agreements that we have entered into with our directors and officers provide that:
(cid:121) We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at
our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify
such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to
the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such
person’s conduct was unlawful.
(cid:121) We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by
applicable law.
61
(cid:121) We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding,
except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person
is not entitled to indemnification.
(cid:121) We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings
initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of
directors or brought to enforce a right to indemnification.
(cid:121) The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into
indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such
persons.
(cid:121) We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to
directors, officers, employees and agents.
We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders’ ability to achieve a return
on their investment will depend on appreciation in the price of our common stock.
We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to
invest our future earnings, if any, to fund our growth. Additionally, the terms of our loan and security agreements could restrict our
ability to pay dividends. Therefore, our stockholders are not likely to receive any dividends on our common stock for the foreseeable
future. Since we do not intend to pay dividends, our stockholders’ ability to receive a return on their investment will depend on any
future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even
maintain the price at which our holders have purchased it.
Item 1B. Unresolved Staff Comments.
None.
Item 2. Properties.
Our headquarters is currently located in Fremont, California. In September 2014, we increased our leased space of
approximately 27,620 square feet by an additional 12,161 square feet and extended the lease term from September 2016 through
September 2019. We believe that our existing facilities are adequate for our current needs, as the facilities have sufficient laboratory
space to house additional scientists to be hired as we expand. When our lease expires, we may exercise our renewal options or look for
additional or alternate space for our operations and we believe that suitable additional or alternative space will be available in the
future on commercially reasonable terms.
Item 3. Legal Proceedings.
We are not currently a party to any material litigation or other material legal proceedings.
Item 4. Mine Safety Disclosures.
Not applicable.
62
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Price Range of Common Stock
Our common stock commenced trading on The NASDAQ Global Select Market under the symbol “ARDX” on June 19, 2014.
Prior to that date, there was no public trading market for our common stock. The following table sets forth, for the periods indicated,
the high and low reported sales prices of our common stock as reported on The NASDAQ Global Select Market:
2014:
Second Quarter (from June 19, 2014) .......................... $
Third Quarter ............................................................... $
Fourth Quarter ............................................................. $
High
Low
16.00
21.60
35.48
$
$
$
14.05
11.37
15.10
As of February 26, 2015, there were 58 holders of record of our common stock. The last reported sale price of the common
stock on February 26, 2015 was $16.01 per share.
63
Stock Price Performance Graph
The following stock performance graph compares our total stock return with the total return for (i) the NASDAQ Composite
Index and the (ii) the NASDAQ Biotechnology Index for the period from June 19, 2014 (the date our common stock commenced
trading on The NASDAQ Global Market) through December 31, 2014. The figures represented below assume an investment of $100
in our common stock at the closing price of $14.11 on June 19, 2014 and in the NASDAQ Composite Index and the NASDAQ
Biotechnology Index on June 19, 2014 and the reinvestment of dividends into shares of common stock. The comparisons in the table
are required by the Securities and Exchange Commission, or SEC, and are not intended to forecast or be indicative of possible future
performance of our common stock. This graph shall not be deemed “soliciting material” or be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities under that
Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended,
or the Securities Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such
filing.
$140.00
$135.00
$130.00
$125.00
$120.00
$115.00
$110.00
$105.00
$100.00
ARDX
IXIC
NBI
6/19/2014
6/30/2014
9/30/2014
12/31/2014
September 30, 2014 December 31, 2014
133.88
108.64
121.38
100.71
103.08
109.22
$
$
$
$
$
$
$100 investment in stock or index
Ardelyx, Inc. .................................
NASDAQ Composite Index ..........
NASDAQ Biotechnology Index ...
Ticker
ARDX
IXIC
NBI
$
$
$
June 19, 2014
June 30, 2014
100.00
100.00
100.00
$
$
$
113.18
101.12
102.62
64
Dividend Policy
We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future
earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the
foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors.
Use of Proceeds from Registered Securities
On June 24, 2014 we closed our IPO, in which we sold an aggregate of 4,928,900 shares of common stock at a price to the
public of $14.00 per share. The aggregate offering price for shares sold in the offering was $69.0 million. The offer and sale of all of
the shares in the IPO were registered under the Securities Act pursuant to the registration statement on Form S-1 (File No. 333-
196090). After deducting underwriting discounts, commissions and offering expenses paid or payable by us, the net proceeds from the
offering were approximately $61.2 million.
There has been no material change in the planned use of proceeds from our IPO as described in the registration statement on
Form S-1 (File No. 333-196090). We invested the proceeds from the IPO in money market funds.
Recent Sale of Unregistered Securities
There were not any sales of unregistered securities by us for the period covered by this Annual Report on Form 10-K that have
not been otherwise reported on a Quarterly Report on Form 10-Q or Current Report on Form 8-K.
Issuer Purchases of Equity Securities
None.
65
Item 6. Selected Financial Data.
The data set forth below is not necessarily indicative of the results of future operations and should be read in conjunction with
the financial statements and the notes included elsewhere in this annual report on Form 10-K and also with “Item 7. Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the related notes included
in this Annual Report on Form 10-K.
Year Ended December 31,
2013
(in thousands, except share and per share amounts)
2014
2012
Revenue:
Licensing revenue ................................................ $
Collaborative development revenue .....................
Total revenue .................................................................
Operating expenses:
Research and development ...................................
General and administrative ..................................
Total operating expenses ...............................................
Loss from operations .....................................................
Other income (expense), net ..........................................
Change in fair value of preferred stock warrant
liability ......................................................................
Loss before provision for income taxes .........................
Provision for income taxes ............................................
Net loss and comprehensive loss ................................... $
Net loss per common share, basic and diluted( ................ $
Shares used to compute net loss per common share,
$
18,394
13,229
31,623
8,063 $
20,865
28,928
25,900
7,287
33,187
(1,564)
10
(1,593)
(3,147)
(67)
(3,214) $
(0.31) $
28,093
3,700
31,793
(2,865 )
(52 )
(3,506 )
(6,423 )
(141 )
(6,564 ) $
(5.82 ) $
3,182
2,228
5,410
10,184
4,031
14,215
(8,805)
(30)
(950)
(9,785)
—
(9,785)
(11.32)
basic and dilute .........................................................
10,248,337
1,127,948
864,020
2014
As of December 31,
2013
(in thousands)
2012
Balance Sheet Data:
Cash and cash equivalents ..................................... $
Total assets ............................................................
Deferred revenue ...................................................
Convertible preferred stock warrant liability ........
Convertible preferred stock ...................................
Accumulated deficit ..............................................
Total stockholders’ equity (deficit) .......................
107,286
113,414
$
47,053
—
—
(71,867)
60,682
34,435 $
42,904
40,298
6,456
56,155
(68,653 )
(63,479 )
32,903
37,884
32,662
2,950
56,155
(62,089)
(57,392)
66
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with the section of
this report entitled “Selected Financial Data” and our financial statements and related notes included elsewhere in this report. This
discussion and other parts of this report contain forward-looking statements that involve risk and uncertainties, such as statements of
our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-
looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the
section of this report entitled “Risk Factors.”
Overview
We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal, or GI, tract to treat cardio-
renal, GI and metabolic diseases. We have developed a proprietary drug discovery and design platform enabling us, in a rapid and
cost-efficient manner, to discover and design novel drug candidates. Utilizing our platform, we discovered and designed our lead
product candidate, tenapanor, which in clinical studies has demonstrated the ability to improve the symptoms of constipation-
predominant irritable bowel syndrome, or IBS-C, and to reduce the absorption of both dietary sodium and phosphorus, which are key
factors in the progression of kidney disease.
In October 2012, we entered into a collaboration partnership with AstraZeneca AB, or AstraZeneca, for the worldwide
development and commercialization of tenapanor. AstraZeneca is responsible for all development and commercialization costs for
tenapanor and we have retained an option to co-promote in the United States. Together with AstraZeneca, we have completed a Phase
2b clinical trial evaluating tenapanor in patients with IBS-C. Results from the study demonstrated statistically significant and
clinically meaningful improvements for IBS-C patients compared to patients receiving placebo, and at the 50 mg dose, the study met
its primary endpoint. We, and AstraZeneca, have also completed a Phase 2b clinical trial evaluating tenapanor in treating
hyperphosphatemic patients with chronic kidney disease on dialysis, or CKD-5D, and the study met its primary endpoint of lowering
serum phosphate. In this study, the rate of diarrhea and the discontinuation rate due to diarrhea at the highest doses were higher than
expected based on previous clinical trials. Higher discontinuations rates due to diarrhea were observed primarily in the 30mg once
daily and 30mg twice daily dose groups. We plan to announce results of a Phase 2a trial in patients with late-stage chronic kidney
disease during the second quarter of 2015.
Through our participation with AstraZeneca on a development collaboration committee, we are involved in the management and
oversight of the development of tenapanor and participation will continue until all of Phase 2 clinical trials with tenapanor have been
completed. In addition, we are directly responsible for the conduct of certain specified clinical trials being conducted with tenapanor.
AstraZeneca reimburses us for our internal and external costs related to those development efforts, and any other development efforts
that may be assigned to us by the development collaboration committee.
Under the terms of the agreement with AstraZeneca, we received a $35.0 million upfront payment and we are eligible to receive
up to $237.5 million in development milestones, of which we have received $40.0 million through December 31, 2014.
The $40.0 million in development milestones consists of a payment of $15.0 million that we received in December 2013 and a
payment of $25.0 million that we received in May 2014 as a result of the dosing of the first patient in the Phase 2b ESRD clinical trial
in hyperphosphatemia in April 2014. In addition to the $237.5 million in total development milestones, we are also eligible to receive
up to $597.5 million in sales and launch milestones. Through December 31, 2014, we also received $34.2 million in reimbursement
for our development efforts provided under the agreement. We are also eligible to receive incremental tiered royalties based on
aggregate annual net sales of each licensed product starting in the high single digits and increasing to high teen percentages as annual
net sales increase, subject to an increase related to our co-fund election, if we decide to make such an election.
67
We have identified the deliverables within the arrangement as a license to the technology, the initial supply of the compound of
the licensed product for use in development, and ongoing development activities through completion of all Phase 2 clinical trials to be
conducted with tenapanor, which are accounted for as a single unit of accounting. We have concluded that the license is not a separate
unit of accounting. It does not have stand-alone value to AstraZeneca, separable from the development services to be performed
pursuant to the agreement, as AstraZeneca is unable to use the license for its intended purpose without our performance of the
development services, which included the initial supply of the compound of the licensed product. We recognize revenue from the
$35.0 million up-front payment on a straight-line basis over the period from the effective date of the agreement through the
completion of the Phase 2b CKD trials to be conducted with tenapanor, which we currently estimate to be December 2017. During the
third quarter of 2014, we extended the estimated period of performance from December 2016 to December 2017 due to the extension
of the estimated completion date of the Phase 2 CKD clinical trials. The expected period of performance is reviewed quarterly and
adjusted, as needed, to reflect our current assumptions regarding the timing of clinical studies. In addition, we recognize revenue from
the $15.0 million and the $25.0 million development milestone payments on a straight-line basis over the same estimated completion
date.
In February 2014, we entered into an option and license agreement with Sanofi under which we granted Sanofi an exclusive
worldwide license to conduct research utilizing our program evaluating small molecule NaP2b inhibitors for the treatment of
hyperphosphatemia in CKD-5D patients. In addition, Sanofi has the option to obtain an exclusive license to develop, manufacture and
commercialize our NaP2b inhibitors. Sanofi is advancing this program towards first-in-human clinical trials. Under our arrangement,
Sanofi is responsible for all of the costs and expenses for research and preclinical activities and, should it exercise its option, for the
development and commercialization efforts under the program. Under the License Option and License Agreement, we received a
payment of $1.25 million in March 2014, which was fully recognized as licensing revenue in May 2014 after we completed our
obligation to provide to Sanofi the background know-how, listed patents, and materials described in the License Option and License
Agreement. We have the potential to earn future development, regulatory and commercial milestone payments of up to
$196.75 million if Sanofi continues to advance the program into development and through commercialization. If a NaP2b inhibitor is
commercialized by Sanofi as a result of this program, we will receive tiered royalties ranging from the mid-single digits into the low
double digits. As part of our agreement with Sanofi, we retain an option to co-promote licensed products in the United States.
Our revenue to date has been generated from collaboration and license revenue pursuant to our license agreements with
AstraZeneca, and Sanofi. We have not generated any commercial product revenue. As of December 31, 2014, we had an accumulated
deficit of $71.9 million. We have incurred significant losses in the past and may continue to incur significant losses in the future as we
advance our unpartnered preclinical programs. The significance of future losses will be dependent in part on whether AstraZeneca
continues to develop and advance tenapanor, and whether Sanofi exercises its option to obtain an exclusive license to develop,
manufacture and commercialize our NaP2b inhibitors, which in either case would result in milestone payments to us. There can be no
assurance that we will receive additional collaboration revenue in the future.
Initial Public Offering
On June 18, 2014, our registration statement on Form S-1 (File No. 333-196090) relating to the IPO of our common stock was
declared effective by the SEC and the IPO closed on June 24, 2014. We sold 4,928,900 shares of our common stock, which included
642,900 shares of common stock purchased by the underwriters upon the full exercise of their option to purchase additional shares of
common stock, and we received cash proceeds of $61.2 million from the IPO, net of underwriting discounts and commissions and
expenses paid by us.
Financial Operations Overview
Revenue
Our revenue to date has been generated from non-refundable license payments and reimbursements for research and
development expenses under our license agreements. We recognize revenue from upfront payments ratably over the term of our
estimated period of performance under the agreement which we consider to be licensing revenue. In addition to receiving upfront
payments, we may also be entitled to milestone and other contingent payments upon achieving predefined objectives. Such payments
are recorded as revenue when we achieve the underlying milestone if it is deemed to be a substantive milestone at the date the
arrangement is entered into. To the extent that non-substantive milestones are achieved and we have remaining performance
obligations, milestones are deferred and recognized as revenue over the estimated remaining period of performance. Reimbursements
from AstraZeneca for development costs incurred under our license and collaboration agreement with them are classified as
collaborative development revenue.
68
We expect that any revenue we generate will fluctuate from year to year as a result of the timing and amount of milestones and
other payments from our collaboration partnerships with AstraZeneca, Sanofi, and any future collaboration partners, and as a result of
the fluctuations in the research and development expenses we incur in the performance of assigned activities under our license
agreement with AstraZeneca. We also expect revenue we generate from AstraZeneca to fluctuate based on changes to clinical
timelines or strategy that determine the recognition period of upfront/milestone payments.
Research and Development Expenses
Research and development expenses represent costs incurred to conduct research, such as the discovery and development of our
unpartnered product candidates, as well as the development of product candidates pursuant to our license agreement with
AstraZeneca. We recognize all research and development costs as they are incurred.
Research and development expenses consist of the following:
(cid:121)
(cid:121)
(cid:121)
external research and development expenses incurred under agreements with consultants, third-party contract research
organizations, or CROs, and investigative sites where a substantial portion of our clinical studies are conducted, and with
contract manufacturing organizations, or CMOs, where our clinical supplies are produced;
employee-related expenses, which include salaries, benefits and stock-based compensation; and
facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities,
depreciation and amortization expense and other supplies.
Prior to the execution of our license agreement with AstraZeneca in October 2012, we incurred $18.0 million in research and
development expenses related to tenapanor. Following the execution of the license agreement and through December 31, 2014, we
incurred $35.4 million in research and development expenses related to tenapanor, all of which are reimbursed by AstraZeneca under
the license agreement. The reimbursements are recognized in collaborative development revenue in the Statement of Operations and
Comprehensive Loss.
The following table summarizes our research and development expenses during the years ended December 31, 2014, 2013 and
2012:
Discovery research expense ............................................ $
Clinical development expense—tenapanor ....................
Total unpartnered expense ....................................
AstraZeneca collaboration development expense ...........
Total research and development expenses ...................... $
Year Ended
December 31,
2013
(in thousands)
7,746 $
—
7,746
20,347
28,093 $
2014
12,734
—
12,734
13,166
25,900
$
$
2012
6,311
1,961
8,272
1,912
10,184
We expect our unpartnered research and development expenses will increase in the future as we progress our internal product
candidates, advance our discovery research projects into the preclinical stage and continue our early stage research. The process of
conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. We or our
collaboration partners may never succeed in achieving marketing approval for any of our product candidates. The probability of
success of each of the product candidates may be affected by numerous factors, including preclinical data, clinical data, competition,
manufacturing capability and commercial viability.
Most of our product development programs are at an early stage; therefore, the successful development of our product
candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly
for each product candidate and are difficult to predict. Given the uncertainty associated with clinical trial enrollment and the risks
inherent in the development process, we are unable to determine the duration and completion costs of current or future clinical trials of
our product candidates or if and to what extent we will generate revenues from the commercialization and sale of any of our product
candidates. We anticipate that we and our collaboration partners will make determinations as to which programs to pursue and how
much funding to direct to each program on an ongoing basis in response to the scientific and clinical success of each product
candidate, as well as an ongoing assessment as to each product candidate’s commercial potential. We will need to raise additional
capital or may seek additional collaboration partnerships in the future in order to complete the development and commercialization of
our product candidates.
69
General and Administrative
General and administrative expenses include personnel costs, travel expenses and other expenses for outside professional
services, including legal, human resources, audit and accounting services. Personnel costs include salaries, bonus, benefits and stock-
based compensation. We have incurred, and expect to continue to incur, additional expenses as a result of being a public company
following the completion of our IPO in June 2014, including expenses to comply with the rules and regulations applicable to
companies listed on a national securities exchange and costs related to compliance and reporting obligations pursuant to the rules and
regulations of the SEC, as well as increases in expenses for additional insurance, investor relations activities and other administration
and professional services.
Change in Fair Value of Convertible Preferred Stock Warrant Liability
Change in fair value of convertible preferred stock warrant liability was the fair value remeasurement of our liability related to
our convertible preferred stock warrants. We recorded adjustments to the estimated fair value of the convertible preferred stock
warrants until they were net exercised in connection with our IPO. At that time, the convertible preferred stock warrant liability was
reclassified to additional paid-in capital and we no longer record any related periodic fair value adjustments.
Provision for Income Taxes
We did not record a provision for income taxes for the year ended December 31, 2012. Our deferred tax assets continue to be
fully offset by a valuation allowance.
Provision for income taxes for the years ended December 31, 2014 and 2013 consist of California state income taxes as we are
required to pay Alternative Minimum Tax for the upfront and milestone payments received from AstraZeneca.
Critical Accounting Polices and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our financial
statements, which have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. The
preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and
liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue
generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various
other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these
estimates under different assumptions or conditions.
Revenue Recognition
Research Activities
Revenue from research activities made under collaboration partnership agreements are recognized as the services are provided
and when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and
collectability is reasonably assured. Revenue generated from research and license agreements typically includes up-front signing or
license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments, and royalties on future licensees’
product sales.
Multiple-Element Arrangements
For revenue agreements with multiple-element arrangements, such as license and development agreements, we allocate revenue
to each non-contingent unit of accounting based on the relative selling price of each unit. When applying the relative selling price
method, we determine the selling price for each deliverable using vendor-specific objective evidence or third-party evidence. If neither
exists, we use the best estimate of selling price for that deliverable. Revenue allocated is then recognized when the four basic revenue
recognition criteria are met for each unit. Our obligations under the agreements may include the transfer of intellectual property rights
in the form of licenses, obligations to provide research and development services and obligations to participate on certain development
committees with the collaboration partner. We make judgments that affect the period over which we recognize revenue. On a quarterly
basis, we review our estimated period of performance for our license revenue based on the progress under the arrangement and
account for the impact of any changes in estimated periods of performance on a prospective basis.
70
Cost Reimbursement
We recognize cost reimbursement revenue under collaboration partnership agreements as the related research and development
costs for services are rendered. Deferred revenue represents the portion of research or license payments received that have not been
earned.
Milestone
A milestone is considered substantive when the consideration earned from the achievement of the milestone (i) is commensurate
with either our performance to achieve the milestone or the enhancement of value of the item delivered as a result of a specific
outcome resulting from our performance to achieve the milestone, (ii) relates solely to past performance and (iii) is reasonable relative
to all deliverables and payment terms in the arrangement. Such payments that are contingent upon the achievement of a substantive
milestone are recognized entirely as revenue in the period in which the milestone is achieved. To the extent that non-substantive
milestones are achieved and we have remaining performance obligations, milestones are deferred and recognized as revenue over the
estimated remaining period of performance. If there were no remaining performance obligations, we recognize the revenue in the
period it is earned.
Research and Development Expense and Accruals
Research and development expenses include employee-related expenses, clinical trial costs, consultant fees, supplies,
manufacturing costs for research and development programs and allocations of corporate costs. All such costs are charged to research
and development expense as incurred. These expenses result from our independent research and development efforts as well as efforts
associated with collaborations. Our expense accruals for clinical trials are based on estimates of the services received from clinical
trial centers and clinical research organizations. If possible, we obtain information regarding unbilled services directly from service
providers. However, we may be required to estimate these services based on information available to our product development or
administrative staff. If we underestimate or overestimate the activity associated with a study or service at a given point in time,
adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities
have approximated actual expense incurred.
Stock-Based Compensation
We recognize compensation costs related to stock options granted to employees based on the estimated fair value of the awards
on the date of grant, net of estimated forfeitures. We estimate the grant date fair value, and the resulting stock-based compensation
expense, using the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is generally recognized on
a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. Stock-based
compensation expense was $1.7 million, $0.4 million and $0.5 million for the years ended December 31, 2014, 2013 and 2012,
respectively.
The Black-Scholes option-pricing model requires the use of highly subjective assumptions which determine the fair value of
stock-based awards. These assumptions include:
Expected Term—The expected term represents the period that stock-based awards are expected to be outstanding. We used the
simplified method to determine the expected term, which is calculated as the average of the time-to-vesting and the contractual
life of the options.
Expected Volatility— Prior to our initial public offering in June 2014, we were privately held and thus have limited trading
history for our common stock. Accordingly, the expected volatility was estimated based on the average volatility for comparable
publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. We will
continue to apply this process until a sufficient amount of historical information regarding the volatility of our stock price
becomes available.
Risk-Free Interest Rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of
grant for periods corresponding with the expected term of option.
Expected Dividend—We have never paid dividends on our common stock and have no plans to pay dividends on our common
stock. Therefore, we used an expected dividend yield of zero.
71
In addition to the Black-Scholes assumptions, we estimate our forfeiture rate based on an analysis of our actual forfeitures and
will continue to evaluate the adequacy of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover
behavior, and other factors. The impact from any forfeiture rate adjustment would be recognized in full in the period of adjustment
and if the actual number of future forfeitures differs from our estimates, we might be required to record adjustments to stock-based
compensation in future periods.
Prior to our IPO in June 2014, our board of directors, with the assistance of management and independent consultants,
performed fair value analyses for the valuation of our common stock. For grants made on dates for which there was no
contemporaneous valuation to utilize in setting the exercise price of our common stock, and given the absence of an active market for
our common stock prior to our IPO in June 2014, our board of directors determined the fair value of our common stock on the date of
grant based on several factors, including:
• progress of our research and development efforts;
• our operating results and financial condition, including our levels of available capital resources;
• rights and preferences of our common stock compared to the rights and preferences of our other outstanding equity
securities;
• material risks related to our business;
• equity market conditions affecting comparable public companies;
• the likelihood of achieving a liquidity event for the shares of common stock, such as an initial public offering given
prevailing market and biotechnology sector conditions; and
• that the grants involved illiquid securities in a private company.
For valuations after the completion of our initial public offering on June 18, 2014, our board of directors determined the fair
value of each share of underlying common stock based on the closing price of our common stock as reported on the date of grant.
Estimated Fair Value of Convertible Preferred Stock Warrants
Freestanding warrants for shares that were contingently redeemable were classified as a liability on the balance sheet at their
estimated fair value. At the end of each reporting period, the change in estimated fair value during the period was recorded in change
in fair value of convertible preferred stock warrant liability in the statement of operations and comprehensive loss. We estimated the
fair values of these warrants using their intrinsic value in 2012 given their low exercise price. Beginning in 2013, we estimated the fair
value of the warrant liability using a hybrid of the options pricing method, or OPM, and the probability-weighted return method, or
PWERM. The hybrid method applied the PWERM utilizing the probability of two exit scenarios, going public or being acquired, and
the OPM was utilized in the remaining private scenario. The scenarios were weighted based on our estimate of the assigned
probability. We continued to adjust the carrying value of the warrants until the completion of our initial public offering in June 2014,
at which time the liability was reclassified to additional paid-in capital and is no longer subject to remeasurement.
72
Results of Operations
Comparison of the Years Ended December 31, 2014 and 2013
Revenue
Revenue:
Licensing revenue ................................................. $
Collaborative development revenue ......................
Total revenue .................................................................. $
18,394
13,229
31,623
$
$
8,063 $
20,865
28,928 $
10,331
(7,636)
2,695
Year Ended December 31,
2013
2014
Dollar Change
(in thousands)
Licensing revenue for the year ended December 31, 2014 was $18.4 million, an increase of $10.3 million, or 128%, compared to
$8.1 million for the year ended December 31, 2013. The increase was primarily due to the amortization of deferred revenue from the
$15.0 million development milestone payment we received in December 2013 related to the amendment to the AstraZeneca agreement
and the $25.0 million development milestone payment we received in May 2014 related to the dosing of the first patient in the Phase
2b ESRD clinical trial in hyperphosphatemia in April 2014, which are both being recognized ratably over our expected period of
performance under the agreement. The estimated period of performance is based on the completion of all of the Phase 2 clinical trials
for tenapanor, which we currently estimate will be December 2017. This estimated period was extended during the third quarter of
2014 from December 2016 to December 2017 due to the extension of the estimated completion date of the remaining Phase 2 clinical
trials. The expected period of performance is reviewed quarterly and adjusted, as needed, to reflect our current assumptions regarding
the timing of clinical studies. The remaining increase was due to the $1.25 million we recognized in May 2014 pursuant to the Option
and License Agreement with Sanofi upon the completion of our performance obligations.
Collaborative development revenue consists of our development expenses that are reimbursable to us by AstraZeneca as part of
our license agreement. Collaborative development revenue for the year ended December 31, 2014 was $13.2 million, a decrease of
$7.6 million, or 37%, compared to $20.9 million for the year ended December 31, 2013. The decrease was due to a decrease in our
development activities primarily related to the clinical trials that are a part of the AstraZeneca agreement.
Research and Development
Research and development ............................................. $
25,900
$
28,093 $
(2,193)
Year Ended December 31,
2013
2014
Dollar Change
(in thousands)
Research and development expenses were $25.9 million for the year ended December 31, 2014, a decrease of $2.2 million, or
8%, compared to $28.1 million for the year ended December 31, 2013. The change was due to a decrease in AstraZeneca collaboration
development expense of $7.2 million which was primarily driven by the decrease in development activities related to tenapanor
conducted by us under the license agreement with AstraZeneca. The decrease was offset by a $5.0 million increase in discovery
research expenses primarily due to an increase in our personnel costs of $1.2 million, an increase in our stock-based compensation
expense of $1.2 million primarily driven by the acceleration of stock option vesting related to the separation agreement with Dr.
Charmot, an increase in CRO consultant service fees and other temporary consultant fees of $0.9 million, and an increase in lab supply
expenses from increased research activities for unpartnered programs of $0.8 million.
General and Administrative
General and administrative ............................................. $
7,287
$
3,700 $
3,587
Year Ended December 31,
2013
2014
Dollar Change
(in thousands)
General and administrative expenses were $7.3 million for the year ended December 31, 2014, an increase of $3.6 million, or
97%, compared to $3.7 million for the year ended December 31, 2013. The increase was due to an increase in operational costs of $2.1
million as a result of being a public company, including professional services and legal services, an increase personnel related
expenses of $0.7 million, and an increase of $0.8 million due to office related and travel expenses.
73
Change in Fair Value of Preferred Stock Warrant Liability
Change in fair value of preferred stock warrant liability .. $
(1,593) $
(3,506 ) $
1,913
Year Ended December 31,
2013
2014
Dollar Change
(in thousands)
Change in fair value of preferred stock warrant liability was $1.6 million for the year ended December 31, 2014 compared to
$3.5 million for the year ended December 31, 2013. The amounts recorded in each of 2014 and 2013 were due to increases in the fair
value of our convertible preferred stock as compared with the prior year. The smaller amount recorded in 2014 was due to a smaller
increase in the value of the underlying stock as compared with the prior year. The preferred stock warrants were net exercised upon
the completion of the IPO and are no longer subject to remeasurement.
Provision for Income Taxes
Provision for income taxes ............................................. $
(67) $
(141 ) $
74
Year Ended December 31,
2013
2014
Dollar Change
(in thousands)
Provision for income taxes was $0.1 million for the years ended December 31, 2014 and 2013, and was due to California state
income taxes for Alternative Minimum Tax.
Comparison of the Years Ended December 31, 2013 and 2012
Revenue
Revenue:
Licensing revenue ................................................. $
Collaborative development revenue ......................
Total revenue .................................................................. $
8,063
20,865
28,928
$
$
3,182 $
2,228
5,410 $
4,881
18,637
23,518
Year Ended December 31,
2012
2013
Dollar Change
(in thousands)
Licensing revenue for the year ended December 31, 2013 was $8.1 million, an increase of $4.9 million, or 153%, compared to
$3.2 million for the year ended December 31, 2012. The increase was due to a full year of amortization in 2013 of the AstraZeneca
up-front license payment as compared to a partial period in 2012. In addition, we received an additional payment of $15.0 million in
December 2013 related to the amendment to the AstraZeneca agreement which is also being amortized over the expected period of
performance. The estimated period of performance is based on the completion of all of the Phase 2 clinical trials for tenapanor. We
initially estimated the period of performance to be through June 2015. In connection with our process of evaluating the progress of
clinical activities, in the fourth quarter of 2013 we revised our estimate of the period of performance to be through December 2016.
Collaborative development revenue consists of our development expenses that are reimbursable to us by AstraZeneca as part of
our license agreement. Collaborative development revenue for the year ended December 31, 2013 was $20.9 million, an increase of
$18.6 million, compared to $2.2 million for the year ended December 31, 2012. The increase was due to a full year of development
activities related to the AstraZeneca agreement.
Research and Development
Research and development ............................................. $
28,093
$
10,184 $
17,909
Year Ended December 31,
2012
2013
Dollar Change
(in thousands)
74
Research and development expenses were $28.1 million for the year ended December 31, 2013, an increase of $17.9 million, or
176%, compared to $10.2 million for the year ended December 31, 2012. The increase was primarily driven by increased development
activities, including our ongoing Phase 2 clinical trials, as part of our license agreement with AstraZeneca for the research,
development, and commercialization of tenapanor. AstraZeneca reimburses us for our internal and external development-related costs
associated with our license agreement. These development-related costs are mainly comprised of external research and development
expenses incurred under agreements with consultants and third-party contract research organizations.
General and Administrative
General and administrative ............................................. $
3,700
$
4,031 $
(331)
Year Ended December 31,
2012
2013
Dollar Change
(in thousands)
General and administrative expenses were $3.7 million for the year ended December 31, 2013, a decrease of $0.3 million, or
8%, compared to $4.0 million for the year ended December 31, 2012. The decrease was primarily due to a decrease in consulting and
legal fees of $0.5 million related to negotiation costs incurred in 2012 in connection with the AstraZeneca agreement, partially offset
by an increase in salary expenses as a result of increased headcount in 2013.
Change in Fair Value of Preferred Stock Warrant Liability
Change in fair value of preferred stock warrant liability .. $
(3,506) $
(950 ) $
(2,556)
Year Ended December 31,
2012
2013
Dollar Change
(in thousands)
Change in fair value of preferred stock warrant liability was $3.5 million for the year ended December 31, 2013 compared to
$1.0 million for the year ended December 31, 2012. The increase was due to an increase in the fair value of our convertible preferred
stock.
Provision for Income Taxes
Provision for income taxes ............................................. $
(141) $
— $
(141)
Provision for income taxes was $0.1 million for the year ended December 31, 2013 compared to zero for the year ended
December 31, 2012. The increase is primarily due to California state income taxes for Alternative Minimum Tax.
Year Ended December 31,
2012
2013
Dollar Change
(in thousands)
Liquidity and Capital Resources
As of December 31, 2014, we had cash and cash equivalents totaling $107.3 million. In connection with our IPO, we received
cash proceeds of $61.2 million, net of underwriters’ discounts and commissions and expenses paid by us. Prior to the IPO, we funded
our operations primarily with cash flows from the sales of our convertible preferred stock in private placements and from the upfront
payments and other collaboration related payments received from our collaboration partners AstraZeneca and Sanofi.
Our primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash used to fund
operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts
payable and accrued expenses.
75
We believe that our existing capital resources as of December 31, 2014 will be sufficient to meet our projected operating
requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could
utilize our available capital resources sooner than we currently expect. Further, our operating plan may change, and we may need
additional funds to meet operational needs and capital requirements for clinical trials and other research and development
expenditures. We currently have no credit facility or committed sources of capital other than potential milestones receivable under our
current collaboration partnerships. Because of the numerous risks and uncertainties associated with the development and
commercialization of our product candidates and the extent to which we may enter into additional collaboration partnerships with third
parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays
and operating expenditures associated with our current and anticipated clinical studies. Our future funding requirements will depend
on many factors, including the following:
(cid:121) our decision whether or not to exercise our right to co-fund the first Phase 3 clinical development program for tenapanor,
in which we may invest $20.0 million, $30.0 million or $40.0 million to acquire an increase of 1%, 2% or 3%,
respectively, in the royalties payable to us by AstraZeneca on net sales of tenapanor;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
the achievement of development and regulatory milestones resulting in the payment to us from our collaboration partners
of contractual milestone payments and the timing of the receipt of such payments, if any;
the decision of AstraZeneca whether or not to continue the development of tenapanor or exercise its right of termination
under the agreement to return the program to us;
the progress, timing, scope, results and costs of our preclinical studies and clinical trials for our product candidates that
have not been licensed, including the ability to enroll patients in a timely manner for clinical trials;
the time and cost necessary to obtain regulatory approvals for our product candidates that have not been licensed and the
costs of post-marketing studies that could be required by regulatory authorities;
(cid:121) our ability and the ability of our collaboration partners to successfully commercialize and/or co-promote our product
candidates;
(cid:121)
the manufacturing, selling and marketing costs associated with product candidates, including the cost and timing of
building our sales and marketing capabilities;
(cid:121) our ability to establish and maintain collaboration partnerships, in-license/out-license or other similar arrangements and
the financial terms of such agreements;
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
(cid:121)
the timing, receipt, and amount of sales of, or royalties on, our future products, if any;
the sales price and the availability of adequate third-party reimbursement for our product candidates;
the cash requirements of any future acquisitions or discovery of product candidates;
the number and scope of preclinical and discovery programs that we decide to pursue or initiate;
the time and cost necessary to respond to technological and market developments; and
the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property
rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of
infringement brought by others in connection with the development, manufacture or commercialization of our product
candidates.
The following table summarizes our cash flows for the periods indicated (in thousands):
Cash provided by operating activities ............................. $
Cash used in investing activities .....................................
Cash provided by (used in) financing activities ..............
$
13,397
(1,856)
61,310
1,811 $
(278 )
(1 )
21,980
(128)
270
2014
Year Ended December 31,
2013
2012
76
Cash Flows from Operating Activities
Cash provided by operating activities for the year ended December 31, 2014 was $13.4 million, consisting of net loss of $3.2
million, which was offset by non-cash charges of $0.3 million for depreciation and amortization expense, $1.7 million for stock-based
compensation, and $1.6 million for the change in the fair value remeasurement of our convertible preferred stock warrant liability.
The change in our net operating assets and liabilities was primarily due to a $6.8 million increase in deferred revenue which was
mainly driven by the $25.0 million payment received in May 2014 in connection with our agreement with AstraZeneca offset by
amortization of $18.4 million that was recognized as license revenue, a $3.9 million decrease in our accounts receivable due to the
timing of payments received from AstraZeneca for reimbursable costs incurred under our licensing agreement, a $0.8 million increase
in accounts payable due to timing of payments, as well as a $0.7 million increase in accrued compensation and benefits due to an
increase in compensation costs.
Cash provided by operating activities for the year ended December 31, 2013 was $1.8 million, consisting of a net loss of $6.6
million, which was offset by non-cash charges of $0.4 million for stock-based compensation, $0.6 million for depreciation and
amortization expense, and $3.5 million for the change in the fair value remeasurement of our convertible preferred stock warrant
liability. The change in our net operating assets and liabilities was due primarily to a $7.6 million increase in deferred revenue as a
result of the $15.0 million payment received in 2013 under our license agreement with AstraZeneca, offset by $8.1 million in
amortization of revenue and a $1.1 million increase in our accounts payable due to the timing of payments. Our accounts receivable
increased by $3.4 million due to the timing of payments received from AstraZeneca for reimbursable costs incurred under our license
agreement.
Cash provided by operating activities for the year ended December 31, 2012 was $22.0 million, consisting of a net loss of $9.8
million which was offset by non-cash charges of $0.5 million for stock-based compensation, $0.7 million for depreciation and
amortization expense, and $1.0 million for the change in the fair value remeasurement of our convertible preferred stock warrant
liability. The change in our net operating assets and liabilities was due primarily to a $32.7 million increase in deferred revenue which
was mainly driven by the $35.0 million up-front payment received in connection with our agreement with AstraZeneca, net of the
amortization to revenue of $3.2 million. The remaining difference was an increase in reimbursable expenses included in deferred
revenue of $0.9 million that related to reimbursements received for prepaid development expenses. Our accounts receivable increased
by $3.1 million due to the recognition of reimbursable development costs and related timing of payments received from AstraZeneca.
Cash Flows from Investing Activities
Cash used in investing activities for the years ended December 31, 2014, 2013 and 2012 was related to our acquisition of
property and equipment of $1.9 million, $0.3 million and $0.1 million. Purchases of property and equipment are primarily related to
expansion of our laboratory and related equipment.
Cash Flows from Financing Activities
Cash provided by financing activities for the year ended December 31, 2014 was due to the net proceeds from our initial
public offering of $61.2 million and proceeds from the issuance of common stock upon the exercise of stock options of $0.1 million.
Cash provided by financing activities for the years ended December 31, 2012 was related to proceeds from the issuance of
common stock upon the exercise of stock options of $0.3 million.
Contractual Obligations and Other Commitments
The following table summarizes our contractual obligations as of December 31, 2014 (in thousands):
Contractual Obligations:
Less than
1 year
Payments Due by Period
4 to 5
Years
More Than
5 Years
1 to 3
Years
Total
Purchase commitments ............................................................ $
Operating leases (1) ...................................................................
Capital expenditures .................................................................
Total contractual obligations .................................................... $
$
651
843
1,233
$
2,727
— $
1,763
—
$
1,763
— $
1,574
—
1,574 $
— $
—
—
— $
651
4,180
1,233
6,064
(1) Operating leases include total future minimum rent payments under non-cancelable operating lease agreements.
77
Off-Balance Sheet Arrangements
As of December 31, 2014, we did not have any off-balance sheet arrangements or any holdings in variable interest entities.
Recent Accounting Pronouncements
In July 2013, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU 2013-11,
Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit
Carryforward Exists. The ASU concludes an unrecognized tax benefit should be presented as a reduction of a deferred tax asset when
settlement in this manner is available under the law. We adopted this amendment as of January 1, 2014, which did not have a
significant impact on the balance sheet.
In May 2014, the FASB issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers, or ASU 2014-
09, which converges the FASB and the International Accounting Standards Board standards on revenue recognition and will replace
nearly all existing revenue recognition under U.S. GAAP. The core principle of ASU 2014-09 is that an entity should recognize
revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity
expects to be entitled in exchange for those goods or services. This guidance is effective for the fiscal years and interim reporting
periods beginning after December 15, 2016, at which time we may adopt the new standard under the full retrospective method or the
modified retrospective method. Early adoption is not permitted. We have not yet selected a transition method nor have we determined
the impact of the new standard on our financial statements and related disclosures.
In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-15, Disclosure of
Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to
evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote
disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under today’s
guidance. ASU 2014-15 is effective for us in the first quarter of 2016 with early adoption permitted. We do not believe the impact of
adopting ASU 2014-15 on our financial statements will be material.
JOBS Act Accounting Election
We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under
the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the
enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail
ourselves of this exemption from new or revised accounting standards, and, therefore, are subject to the same new or revised
accounting standards as other public companies that are not emerging growth companies.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
We are exposed to market risks in the ordinary course of our business. These risks primarily include risk related to interest rate
sensitivities. We had cash and cash equivalents of $107.3 million as of December 31, 2014, which consist of bank deposits and money
market funds. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income
have not been significant. We had no outstanding debt as of December 31, 2014.
78
Item 8. Financial Statements and Supplementary Data.
ARDELYX, INC.
INDEX TO FINANCIAL STATEMENTS
Report of Independent Registered Public Accounting Firm ..............................................................................................................
Page
80
Balance Sheets ...................................................................................................................................................................................
Statements of Operations and Comprehensive Loss ..........................................................................................................................
Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) ................................................................................
Statements of Cash Flows .................................................................................................................................................................
Notes to Financial Statements ...........................................................................................................................................................
81
82
83
84
85
79
Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
Ardelyx, Inc.
We have audited the accompanying balance sheets of Ardelyx, Inc. (the Company) as of December 31, 2014 and 2013, and the related
statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity (deficit), and cash flows for
each of the three years in the period ended December 31, 2014. These financial statements are the responsibility of the Company’s
management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of
material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our
audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate
in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over
financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by
management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our
opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Ardelyx, Inc.
at December 31, 2014 and 2013, and the results of its operations and its cash flows for each of the three years in the period ended
December 31, 2014, in conformity with U.S. generally accepted accounting principles.
/s/ Ernst & Young LLP
Redwood City, California
March 5, 2015
80
Ardelyx, Inc.
Balance Sheets
(In thousands, except share and per share amounts)
Assets
Current assets:
Cash and cash equivalents ................................................................................................... $
Accounts receivable .............................................................................................................
Prepaid expenses and other current assets ...........................................................................
Total current assets ....................................................................................................
Property and equipment, net .........................................................................................................
Other assets ...................................................................................................................................
Restricted cash ..............................................................................................................................
Total assets ................................................................................................................. $
Liabilities, convertible preferred stock, and stockholders’ equity (deficit)
Current liabilities:
Accounts payable................................................................................................................. $
Accrued compensation and benefits ....................................................................................
Accrued and other liabilities ................................................................................................
Deferred revenue, current portion........................................................................................
Total current liabilities ...............................................................................................
Other long-term liabilities .............................................................................................................
Deferred revenue, non-current ......................................................................................................
Convertible preferred stock warrant liability ................................................................................
Liabilities related to early exercise of options ...............................................................................
Total liabilities ...........................................................................................................
Commitments and contingencies (Note 12)
Convertible preferred stock, $0.0001 par value per share—no shares and 108,829,748 shares
authorized as of December 31, 2014 and 2013, respectively; no shares and
11,517,222 shares issued and outstanding as of December 31, 2014 and 2013,
respectively ..........................................................................................................................
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 5,000,000 shares and no shares authorized as of
December 31, 2014 and 2013, respectively; no shares issued and outstanding as of
December 31, 2014 and 2013 .........................................................................................
Common stock, $0.0001 par value per share—300,000,000 and 130,360,121 shares
authorized as of December 31, 2014 and 2013, respectively; 18,589,245 and
1,225,481 shares issued and outstanding as of December 31, 2014 and 2013,
respectively .....................................................................................................................
Additional paid-in capital ....................................................................................................
Accumulated deficit .............................................................................................................
Total stockholders’ equity (deficit) ...............................................................................................
Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) ........................... $
See accompanying notes.
December 31,
2014
2013
107,286 $
2,584
1,209
111,079
2,131
104
100
113,414 $
3,129 $
1,648
780
15,979
21,536
122
31,074
—
—
52,732
—
—
34,435
6,436
965
41,836
530
358
180
42,904
2,284
927
100
13,828
17,139
—
26,470
6,456
163
50,228
56,155
—
2
132,547
(71,867)
60,682
113,414 $
—
5,174
(68,653)
(63,479)
42,904
81
Ardelyx Inc.
Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
Year Ended December 31,
2014
2013
2012
18,394 $
13,229
31,623
25,900
7,287
33,187
(1,564 )
10
(1,593 )
(3,147 )
(67 )
(3,214 ) $
(0.31 ) $
$
8,063
20,865
28,928
3,182
2,228
5,410
28,093
3,700
31,793
(2,865)
(52)
(3,506)
(6,423)
(141)
(6,564) $
(5.82) $
10,184
4,031
14,215
(8,805)
(30)
(950)
(9,785)
—
(9,785)
(11.32)
864,020
10,248,337
1,127,948
Revenue:
Licensing revenue ........................................................................................... $
Collaborative development revenue ................................................................
Total revenue ............................................................................................................
Operating expenses:
Research and development ..............................................................................
General and administrative ..............................................................................
Total operating expenses ...........................................................................................
Loss from operations ................................................................................................
Other income (expense), net .....................................................................................
Change in fair value of preferred stock warrant liability ..........................................
Loss before provision for income taxes ....................................................................
Provision for income taxes ........................................................................................
Net loss and comprehensive loss .............................................................................. $
Net loss per common share, basic and diluted .......................................................... $
Shares used to compute net loss per common share, basic and diluted ....................
See accompanying notes.
82
Ardelyx, Inc.
Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(In thousands, except share amounts)
Convertible
Preferred Stock
Common Stock
Additional
Paid-In
Capital
4,049 $
Accumulated
Deficit
(52,304) $
Total
Stockholders’
Equity
(Deficit)
Amount
Balance as of January 1, 2012 ................... 11,517,222 $ 56,155
Shares
Shares
659,485
Amount
— $
Exercise of stock options and vesting
of early exercised stock options,
net of repurchases ..........................
Stock-based compensation .................
Net loss ...............................................
—
—
—
Balance as of December 31, 2012 .............. 11,517,222
—
—
—
56,155
342,131
—
—
1,001,616
175
—
473
—
—
—
— 4,697
—
—
(9,785)
(62,089)
(48,255)
175
473
(9,785)
(57,392)
Exercise of stock options and vesting
of early exercised stock options,
net of repurchases ..........................
Stock-based compensation .................
Net loss ...............................................
—
—
—
Balance as of December 31, 2013 .............. 11,517,222 $ 56,155
—
—
—
223,865
—
—
1,225,481
—
—
—
— $
125
352
—
5,174 $
—
—
(6,564)
(68,653) $
125
352
(6,564)
(63,479)
Conversion of convertible preferred
stock to common stock in
connection with initial public
offering .......................................... (11,517,222)
(56,155) 11,517,222
1
56,154
—
56,155
Net exercise and conversion of
preferred stock warrants to
common stock in connection with
initial public offering .....................
Exercise of stock options and vesting
of early exercised stock options,
net of repurchases ..........................
Issuance of common stock in
connection with initial public
offering, net of offering costs ........
Issuance of common stock for
services .........................................
Stock-based compensation .................
Net loss ...............................................
Balance as of December 31, 2014 ..............
—
—
—
—
—
—
— $
—
571,244
— 8,049
—
8,049
—
336,398
—
238
—
238
— 4,928,900
1
61,240
—
61,241
10,000
—
—
—
—
—
— 18,589,245 $
—
208
— 1,484
—
—
2 132,547 $
—
—
(3,214)
(71,867) $
208
1,484
(3,214)
60,682
See accompanying notes.
83
Ardelyx, Inc.
Statements of Cash Flows
(In thousands)
Operating activities
Net loss ...................................................................................................................... $
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization expense ............................................................
Stock-based compensation ...............................................................................
Change in fair value of preferred stock warrant liability ..................................
Changes in operating assets and liabilities:
Accounts receivable ................................................................................
Prepaid expenses and other assets ..........................................................
Accounts payable ....................................................................................
Accrued compensation and benefits .......................................................
Accrued and other liabilities ..................................................................
Deferred revenue ....................................................................................
Other long-term liabilities .......................................................................
Net cash provided by operating activities ..................................................................
Investing activities
Purchases of property and equipment ........................................................................
Net cash used in investing activities ..........................................................................
Financing activities
Proceeds from issuance of common stock upon initial public offering, net ..............
Proceeds from issuance of common stock from exercise of options, including early
exercise of stock options .......................................................................................
Repurchase of unvested common stock .....................................................................
Net cash provided by (used in) financing activities ...................................................
Net increase in cash and cash equivalents .................................................................
Cash and cash equivalents at beginning of period .....................................................
Cash and cash equivalents at end of period ............................................................... $
Year Ended December 31,
2013
2014
2012
(3,214 ) $
(6,564) $
(9,785)
302
1,692
1,593
3,852
96
831
721
647
6,755
122
13,397
(1,856 )
(1,856 )
592
352
3,506
(3,364)
(438)
1,138
(38)
(1,009)
7,636
—
1,811
(278)
(278)
675
473
950
(3,072)
(790)
(105)
760
212
32,662
—
21,980
(128)
(128)
61,241
—
—
71
(2 )
61,310
72,851
34,435
107,286 $
1
(2)
(1)
1,532
32,903
34,435 $
290
(20)
270
22,122
10,781
32,903
Supplementary disclosure of cash flow information
Income taxes paid ...................................................................................................... $
— $
160 $
Supplementary disclosure of non-cash financing information:
Services settled through the issuance of common stock ............................................ $
Reclassification of convertible preferred warrant liability to additional paid-in
208 $
capital .................................................................................................................... $
8,049 $
Conversion of convertible preferred stock to common stock at closing of initial
public offering ....................................................................................................... $
56,155 $
— $
— $
— $
—
—
—
—
See accompanying notes.
84
Ardelyx, Inc.
Notes to Financial Statements
1. Organization and Basis of Presentation
Ardelyx, Inc. (the “Company”) is a clinical stage biopharmaceutical company focused on the discovery, development and
commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to
treat cardio-renal, gastrointestinal and metabolic diseases. The Company has developed a drug discovery and design platform enabling
it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. The Company was incorporated in Delaware on
October 17, 2007, under the name Nteryx and changed its name to Ardelyx, Inc. in June 2008.
The Company operates in only one business segment, which is the development of biopharmaceutical products.
Reverse Stock Split
On June 18, 2014, the Company’s Amended and Restated Certificate of Incorporation became effective resulting in a reverse
split of the Company’s common stock and convertible preferred stock at a 1-for-9 ratio (the “Reverse Stock Split”). The par value and
the authorized shares of the common stock and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. All
issued and outstanding common stock, convertible preferred stock, warrants for preferred stock, options for common stock and per
share amounts contained in the financial statements have been retroactively adjusted to reflect this Reverse Stock Split for all periods
presented.
Initial Public Offering
On June 18, 2014, the Company’s registration statement on Form S-1 (File No. 333-196090) relating to the initial public
offering (the “IPO”) of its common stock was declared effective by the SEC, and the IPO closed on June 24, 2014. The Company sold
4,928,900 shares of its common stock, which included the exercise in full by the underwriters of the IPO of their option to purchase
642,900 additional shares of the Company’s common stock, and the Company received cash proceeds of $61.2 million from the IPO,
net of $7.8 million underwriting discounts and commissions and expenses paid by the Company.
On June 24, 2014, prior to the closing of the IPO, all outstanding shares of convertible preferred stock converted into
11,517,222 shares of common stock with the related carrying value of $56.2 million being reclassified to common stock and additional
paid-in capital. In addition, all convertible preferred stock warrants were net exercised and the related convertible preferred stock
warrant liability was reclassified to additional paid-in capital.
On June 24, 2014, the Company’s Amended and Restated Certificate of Incorporation became effective and the number of
shares of capital stock the Company is authorized to issue was increased to 305,000,000 shares, of which 300,000,000 shares may be
common stock and 5,000,000 shares may be preferred stock. Both the common stock and preferred stock have a par value of $0.0001
per share. There are no shares of preferred stock outstanding at December 31, 2014.
2. Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires
management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes.
On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical trial accruals,
income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-
specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from
those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments purchased with an original maturity date of 90 days or less on the date of
purchase to be cash equivalents. The Company invests its cash in bank deposits and money market accounts.
85
Restricted Cash
The Company is required to guarantee the credit limit on its corporate credit card with a certificate of deposit of $0.1 million.
The collateral will be released upon the cancellation of the corporate credit card.
Concentration of Credit Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash
equivalents, and certificates of deposit. Cash and cash equivalents, as well as certificates of deposit held with financial institutions,
may exceed the Federal Deposit Insurance Corporation insurance limits. The Company is exposed to credit risk in the event of default
by the financial institutions holding its cash and cash equivalents to the extent of the amounts on its balance sheets. The Company has
not experienced any losses on its cash, cash equivalents and certificates of deposit during the years ended December 31, 2014, 2013
and 2012.
Accounts receivable are unsecured and are concentrated with one collaboration partner in the pharmaceutical industry,
AstraZeneca AB (“AstraZeneca”). Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical
companies or specific to the license and collaboration agreement with AstraZeneca. To date the Company has not experienced any
losses related to its receivables.
Fair Value of Financial Instruments
Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized
at fair value in the financial statements on a recurring basis (at least annually).
Property and Equipment
Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the
straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are
amortized over the lesser of the estimated useful lives or the related remaining lease term.
Impairment of Long-Lived Assets
The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in
business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist,
an impairment loss would be recognized when estimated, undiscounted future cash flows expected to result from the use of the asset
and its eventual disposition are less than its carrying amount. The impairment charge is determined based upon the excess of the
carrying value of the asset over its fair value, with fair value determined based upon an estimate of discounted future cash flows or
another appropriate measure of fair value. The Company has not recorded any impairment of long-lived assets during any of the
periods presented.
Income Taxes
The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and
liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are
measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation
allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Revenue Recognition
Revenue from research activities made under collaboration partnership agreements are recognized as the services are provided
and when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and
collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes up-front signing or
license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments, and royalties on future licensees’
product sales.
86
For revenue agreements with multiple-element arrangements, such as license and development agreements, the Company
allocates revenue to each unit of accounting based on the relative selling price of each unit. When applying the relative selling price
method, the Company determines the selling price for each deliverable using vendor-specific objective evidence or third-party
evidence. If neither exists, the Company uses its best estimate of selling price for that deliverable. Revenue allocated is then
recognized when the four basic revenue recognition criteria are met for each deliverable.
The Company recognizes revenue from upfront payments ratably over the term of its estimated period of performance under the
agreement which is recorded as licensing revenue. Reimbursements for development costs incurred under the Company’s license
agreement with AstraZeneca are classified as collaborative development revenue. The Company recognizes cost reimbursement
revenue under collaboration partnership agreements as the related research and development costs for services are rendered. Deferred
revenue represents the portion of research or license payments received which has not been earned.
Revenues from milestones, if they are nonrefundable and deemed substantive, are recognized upon successful accomplishment
of the milestones. To the extent that non-substantive milestones are achieved and the Company has remaining performance
obligations, milestones are deferred and recognized as revenue over the estimated remaining period of performance. The Company
will recognize revenue associated with the non-substantive milestones upon achievement of the milestone if there are no undelivered
units and it has no remaining performance obligations. The Company will account for sales-based milestones as royalties that will be
recognized as revenue upon achievement of the milestone.
Stock-Based Compensation
The Company measures its stock-based payment awards made to employees and directors based on the estimated fair values of
the awards and recognizes the compensation expense over the requisite service period. The Company has selected the Black-Scholes
option-pricing model to estimate the fair value of its stock-based awards. Stock-based compensation expense is recognized using the
straight-line method. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is
ultimately expected to vest. As such, the Company’s stock-based compensation is reduced for the estimated forfeitures at the date of
grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
The Company accounts for compensation expense related to stock options granted to non-employees based on the fair values
estimated using the Black-Scholes model. Stock options granted to non-employees are remeasured at each reporting date until the
award is vested.
Research and Development Costs
Research and development expenditures are expensed as incurred. Major components of research and development expenses
consist of personnel costs, materials and supplies, and allocations of facilities-related costs, as well as fees paid to consultants and
third parties that conduct certain research and development activities on the Company’s behalf. Payments made to other entities are
under agreements that are generally cancelable by the Company. Nonrefundable advance payments for goods or services to be
rendered in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are
expensed as the related goods are delivered or the services are performed.
Convertible Preferred Stock Warrant Liability
The Company accounts for freestanding warrants to purchase shares of convertible preferred stock that were contingently
redeemable as liabilities in the balance sheets at their estimated fair value. Convertible preferred stock warrants are subject to
remeasurement at each balance sheet date, and any change in fair value is recognized as a component of other expense, net in the
statements of operations and comprehensive loss. The Company continued to adjust the carrying value of the warrants until the closing
of the IPO, at which time the warrants were net exercised for shares of the Company’s common stock and the liability was reclassified
to stockholders’ equity (deficit).
Comprehensive Loss
Comprehensive loss is composed of two components: net loss and other comprehensive loss. Other comprehensive income
(loss) refers to gains and losses that under GAAP are recorded as an element of stockholders’ equity (deficit), but are excluded from
net loss. The Company did not record any transactions within other comprehensive income (loss) in the periods presented and,
therefore, the net loss and comprehensive loss were the same for all periods presented.
87
Net Loss per Share
Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares
outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share in the periods
presented is the same as basic net loss per common share, since the effects of potentially dilutive securities are antidilutive.
Recent Accounting Pronouncements
In July 2013, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update (“ASU”) 2013-11,
Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit
Carryforward Exists. The ASU concludes an unrecognized tax benefit should be presented as a reduction of a deferred tax asset when
settlement in this manner is available under the law. The Company adopted this amendment as of January 1, 2014, which did not have
a significant impact on the balance sheet.
In May 2014, the FASB issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers (“ASU 2014-
09”), which converges the FASB and the International Accounting Standards Board standards on revenue recognition and will replace
nearly all existing revenue recognition under U.S. GAAP. The core principle of ASU 2014-09 is that an entity should recognize
revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity
expects to be entitled in exchange for those goods or services. This guidance is effective for the fiscal years and interim reporting
periods beginning after December 15, 2016, at which time the Company may adopt the new standard under the full retrospective
method or the modified retrospective method. Early adoption is not permitted. The Company has not yet selected a transition method
nor has the Company determined the impact of the new standard on its financial statements and related disclosures.
In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-15, Disclosure of
Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to
evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote
disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under today’s
guidance. ASU 2014-15 is effective for the Company in the first quarter of 2016 with early adoption permitted. The Company does
not believe the impact of adopting ASU 2014-15 on its financial statements will be material.
3. Fair Value Measurements
Pursuant to the accounting guidance for fair value measurement and its subsequent updates, fair value is defined as the price that
would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market
participants at the measurement date. The accounting guidance establishes a hierarchy for inputs used in measuring fair value that
minimizes the use of unobservable inputs by requiring the use of observable market data when available. Observable inputs are inputs
that market participants would use in pricing the asset or liability based on active market data. Unobservable inputs are inputs that
reflect the assumptions market participants would use in pricing the asset or liability based on the best information available in the
circumstances.
The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:
Level 1
– Valuations are based on quoted prices in active markets for identical assets or liabilities and readily
accessible by us at the reporting date. Examples of assets and liabilities utilizing Level 1 inputs are certain
money market funds, U.S. Treasuries and trading securities with quoted prices on active markets.
Level 2 – Valuations based on inputs other than the quoted prices in active markets that are observable either directly
or indirectly in active markets. Examples of assets and liabilities utilizing Level 2 inputs are U.S.
government agency bonds, corporate bonds, commercial paper, certificates of deposit and over-the-counter
derivatives.
Level 3
– Valuations based on unobservable inputs in which there is little or no market data, which require us to
develop our own assumptions.
88
The following table sets forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis by
level within the fair value hierarchy:
Total
Level 1
Level 2
Level 3
December 31, 2014
(in thousands)
Assets:
Money market funds ............................................... $
Certificates of deposit .............................................
Total ........................................................................ $
105,410
100
105,510
Assets:
Money market funds ............................................... $
Certificates of deposit .............................................
Total ........................................................................ $
Liabilities:
Convertible preferred stock warrant liability .......... $
Total ........................................................................ $
Total
32,472
180
32,652
6,456
6,456
$
$
$
$
$
$
105,410
—
105,410
$
$
— $
100
100 $
December 31, 2013
Level 1
Level 2
Level 3
(in thousands)
32,472
—
32,472
$
$
— $
180
180 $
—
—
—
—
—
—
— $
— $
— $
— $
6,456
6,456
Where quoted prices are available in an active market, securities are classified as Level 1. The Company classifies money
market funds as Level 1. When quoted market prices are not available for the specific security, then the Company estimates fair value
by using benchmark yields, reported trades, broker/dealer quotes, and issuer spreads. The Company classifies certificates of deposit as
Level 2. In certain cases where there is limited activity or less transparency around inputs to valuation, securities are classified as
Level 3. There were no transfers between Level 1 and Level 2 during the periods presented.
Level 3 liabilities that were measured at fair value on a recurring basis consist of the preferred stock warrant liability, which was
measured using the probability weighted expected return method that calculated the probability of the Company going public or being
acquired, and the option-pricing method for remaining private in the near to mid-term. The fair value of the preferred stock warrant
liability as of December 31, 2013 was estimated using such scenarios that were weighted based on the Company’s estimate of the
probability of each scenario: 20% for IPO; 10% for merger and 70% for stay private as of December 31, 2013. At the end of each
reporting period, the change in estimated fair value during the period is recorded in change in fair value of convertible preferred stock
warrant liability in the statements of operations and comprehensive income (loss). Generally, increases or decreases in the fair value of
the underlying convertible preferred stock would result in a directionally similar impact in the fair value measurement of the warrant
liability. The preferred stock warrant liability was remeasured prior to the net exercise of the warrants using the IPO price. The
preferred stock warrants were net exercised and converted to common stock upon the completion of the IPO and are no longer subject
to remeasurement.
The following table sets forth a summary of the changes in the estimated fair value of the Company’s preferred stock
warrants which were measured at fair value on a recurring basis (in thousands):
Preferred Stock
Warrant Liability
(in thousands)
Balance at December 31, 2012 ............................................................... $
Net increase in fair value of warrant liabilities upon revaluation ..
Balance at December 31, 2013 ............................................................... $
Net increase in fair value of warrant liabilities upon revaluation ..
Reclassification of warrant liability to additional paid-in capital
upon completion of IPO ...........................................................
Balance at December 31, 2014 ............................................................... $
2,950
3,506
6,456
1,593
(8,049 )
—
89
4. Property and Equipment
Property and equipment consist of the following:
December 31,
2014
2013
Laboratory equipment ........................................................... $
Office equipment and furniture .............................................
Construction in progress .......................................................
Leasehold improvements ......................................................
Property and equipment, gross ....................................
Less: accumulated depreciation and amortization ................
Total property and equipment, net ..................... $
$
(in thousands)
3,039
229
362
2,135
5,765
(3,634)
2,131
$
2,315
91
—
1,456
3,862
(3,332 )
530
Depreciation and amortization expense totaled $0.3 million, $0.6 million and $0.7 million for the years ended December 31,
2014, 2013 and 2012.
5. Collaboration and Licensing agreements
AstraZeneca AB
In October 2012, the Company entered into a license agreement (the “License Agreement”) pursuant to which the Company and
AstraZeneca collaborate to research, develop, and commercialize the Company’s small molecule NHE3 inhibitors program, which
includes the Company’s lead product candidate, tenapanor, as well as back-up compounds. Pursuant to the agreement, the Company
granted a worldwide exclusive right and license to exploit such licensed compounds solely for development and commercialization
purposes.
The Company is currently responsible for certain development activities from the effective date of the agreement through
completion of the chronic kidney disease (“CKD”) Phase 2a clinical trial. AstraZeneca reimburses the Company for its internal and
external development-related costs. The Company is also obligated to participate on a Development Collaboration Committee through
the completion of all Phase 2 clinical trials for tenapanor. As part of the transaction, the Company has an option to co-promote the
product in the United States, subject to agreed limitations.
Upon product sales, the Company is eligible to receive royalties that adjust depending on sales volume with tiered royalty
percentage ranges starting in the high single digits and moving into double digits in mid-teens as net sales increase, subject to
reductions in certain specified circumstances.
Under the License Agreement, the Company has the option to participate in the funding of the first Phase 3 clinical development
program for the first indication of tenapanor by investing a co-funding amount of $20.0 million, $30.0 million or $40.0 million to
acquire an increase of 1%, 2% or 3%, respectively, in the royalties payable to us by AstraZeneca on net sales of tenapanor at all tiers.
The selected co-funding amount would be paid ratably over the estimated period of the Phase 3 clinical development program. The
Company may exercise this right only for a limited period of 60 days following AstraZeneca’s determination to proceed to the first
Phase 3 clinical development program for tenapanor for a specific indication.
The Company identified the deliverables within the arrangement as a license to the technology, the initial supply of the
compound of the licensed product for use in development, and ongoing development activities through completion of all Phase 2
clinical trials for tenapanor, which are accounted for as a single unit of accounting. The Company concluded that the license is not a
separate unit of accounting. It does not have stand-alone value to AstraZeneca, separable from the development services to be
performed pursuant to the agreement, as AstraZeneca is unable to use the license for its intended purpose without the Company’s
performance of the development services, which included the initial supply of the compound. As a result, the Company will recognize
revenue from the up-front payment on a straight-line basis over the period from the effective date of the agreement through the
completion of all Phase 2 clinical trials for tenapanor (the estimated period of performance).
90
Under the License Agreement, AstraZeneca paid the Company an up-front license fee of $35.0 million in October 2012. In
December 2013, AstraZeneca and the Company entered into an amendment to the License Agreement to acknowledge the intention of
AstraZeneca to commence development of tenapanor for the treatment of hyperphosphatemia in CKD-5D patients, and to provide
additional clarification for the payment of certain development milestones (the “License Amendment”). The License Amendment was
not deemed to be a material modification to the arrangement since there were no changes in the total arrangement consideration or key
provisions, only a change in the allocation of payments. AstraZeneca made a payment of $15.0 million in December 2013 pursuant to
the amendment. The payment was combined with the unamortized upfront payment and is being recognized as revenue on a straight-
line basis over the estimated period of performance.
In May 2014, the Company received from AstraZeneca a $25.0 million payment as a result of the dosing of the first patient in
the Phase 2b clinical trial in hyperphosphatemia. As the $25.0 million did not meet the criteria to be considered the achievement of a
substantive milestone for accounting purposes, the amount was recorded as deferred revenue when received and is being recognized as
revenue on a straight-line basis over the remaining estimated period of performance under the AstraZeneca collaboration partnership
agreement.
The estimated period of performance is currently estimated to be December 2017, which was changed during the quarter ended
September 30, 2014 from December 2016 due to the extension of the estimated completion date of the Phase 2 CKD clinical trials.
The expected period of performance is reviewed quarterly and adjusted, as needed, to reflect our current assumptions regarding the
timing of clinical studies.
AstraZeneca reimburses the Company for its internal and external development-related costs. These reimbursements are
recognized as collaborative development revenue when the development-related costs are incurred.
As of December 31, 2014, the Company was eligible to receive future contingent payments up to a total of $795.0 million,
which is comprised of future development milestones up to an additional $197.5 million and launch, commercialization, and sales
milestones up to an additional $597.5 million. The contingent payments are triggered upon the activities expected to be undertaken by
AstraZeneca. Revenue from milestones, if they are nonrefundable and deemed substantive, are recognized upon successful
accomplishment of the milestone. The Company will recognize revenue associated with non-substantive milestones upon achievement
of the milestones if there are no undelivered units and it has no remaining performance obligation. To the extent that non-substantive
milestones are achieved and the Company has remaining performance obligations, milestones are deferred and recognized as revenue
over the estimated remaining period of performance.
For the years ended December 31, 2014, 2013 and 2012, the Company recognized revenue of $18.4 million, $8.1 million and
$3.2 million, respectively, related to amortization of the up-front and other license fees, and $13.2 million, $20.9 million and $2.2
million, respectively, for collaborative development services. As of December 31, 2014, the Company had total deferred revenue of
$47.1 million related to the AstraZeneca license agreement.
Sanofi SA
In February 2014, the Company entered into a License Option and License Agreement with Sanofi SA (“Option and License
Agreement”) for its phosphate transport NaP2b inhibitor program. NaP2b is an intestinal phosphate transporter whose activity
accounts for a significant portion of dietary phosphate absorption in humans. The inhibition of NaP2b is believed to have utility for the
treatment of hyperphosphatemia (elevated serum phosphate) in patients with CKD-5D. Under the Option and License Agreement, the
Company granted Sanofi an exclusive worldwide license to conduct research utilizing the Company’s small molecule NaP2b
inhibitors. In addition, Sanofi has the option to obtain an exclusive license to develop, manufacture and commercialize the Company’s
NaP2b inhibitors. Sanofi is advancing this program towards first-in-human clinical trials. Under the Option and License Agreement,
Sanofi is responsible for all of the costs and expenses for research and preclinical activities and, should it exercise its option, for the
development and commercialization efforts under the program. Under the Option and License Agreement, the Company received a
payment of $1.25 million and is responsible for up to $0.2 million of patent costs after which any additional patent costs will be fully
reimbursed to the Company by Sanofi.
The Company received the payment of $1.25 million in March 2014, which was fully recognized as licensing revenue in May
2014 after the Company completed its obligation to provide to Sanofi the background know-how, listed patents, and materials
described in the License Option and License Agreement.
91
The Company has the potential to earn future development, regulatory and commercial milestone payments of up to $196.8
million if Sanofi continues to advance the program into development and through commercialization. If a NaP2b inhibitor is
commercialized by Sanofi as a result of this program, the Company will receive tiered royalties ranging from mid-single digits into the
low double digits. As part of the arrangement with Sanofi, the Company retains an option to participate in co-promotional activities in
the United States. Future potential milestone payments do not meet the criteria to be considered substantive milestones, and therefore
will be treated as other contingent consideration and recognized as revenue as they are achieved as the Company has no performance
obligations under the License Option and License Agreement. No milestones have been received since the inception of the agreement.
6. Convertible Preferred Stock
On June 24, 2014, prior to the closing of the IPO, all outstanding shares of convertible preferred stock converted into
11,517,222 shares of common stock with the related carrying value of $56.2 million reclassified to common stock and additional paid-
in capital.
Convertible preferred stock as of December 31, 2013 consisted of the following:
Convertible Preferred Stock:
Shares
Authorized
Shares
Issued and
Outstanding
Net
Carrying
Value
Aggregate
Liquidation
Preference
(In thousands, except share data)
Series A ....................................................................
Series B ....................................................................
Total convertible preferred stock ....................
25,231,213
83,598,535
108,829,748
2,803,462
8,713,760
11,517,222
$
$
25,957 $
30,198
56,155 $
28,764
30,310
59,074
7. Preferred Stock Warrants
In connection with the closing of the Series B financing in August 2011, the Company issued warrants for the purchase of
574,953 shares of Series B convertible preferred stock. The exercise price of the warrants was $0.09 per share. The preferred stock
warrant liability was measured at fair value on a recurring basis. Changes in fair value were recorded in change in fair value of
preferred stock warrant liability in the Statements of Operations and Comprehensive Loss. As a result of the low exercise price for the
warrants, the Company used the intrinsic value of the warrants as a proxy for the fair value for financial reporting purposes. The
Company revalued the warrants as of December 31, 2012 using their intrinsic value given their low exercise price. As of
December 31, 2013 and for the period in 2014 up to the IPO date, the Company revalued the warrants using a hybrid of the option
pricing method and the probability-weighted expected return method. The hybrid methodology was applied to reflect two exit
scenarios, IPO and merger using a market approach and the income approach was used in the stay private scenario. The scenarios
were weighted based on the Company’s estimate of the probability of each scenario: 20% for IPO; 10% for merger and 70% for stay
private for the year ended December 31, 2013. As of December 31, 2013, the fair value of this convertible preferred stock warrant
liability amounted to $6.5 million. Just prior to the IPO close date of June 24, 2014, the preferred stock warrant liability was
remeasured prior to the net exercise of the warrants using the IPO price. The preferred stock warrants were net exercised.
8. Equity Incentive Plans
2008 Plan
The Company granted options under its 2008 Stock Incentive Plan (the “2008 Plan”) until June 2014 when it was terminated as
to future awards, although it continues to govern the terms of options that remain outstanding under the 2008 Plan. The 2008 Plan
provided for the granting of incentive and nonstatutory stock options, and stock purchase rights to employees, directors and
consultants at the discretion of the Board of Directors. Stock options granted generally vest over a period of four years from the date
of grant. In connection with the Board of Directors and stockholders approval of the 2014 Plan, all remaining shares available for
future award under the 2008 Plan were transferred to 2014 Plan, and the 2008 Plan was terminated.
92
2014 Plan
The 2014 Equity Incentive Award Plan (“2014 Plan”) became effective on June 18, 2014, immediately prior to the time the
Company’s Registration Statement on Form S-1 became effective. Under the 2014 Plan, 1,419,328 shares of common stock were
initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation
rights, or SARs, restricted stock awards, restricted stock unit awards, deferred stock awards, deferred stock unit awards, dividend
equivalent awards, stock payment awards and performance awards. In addition, 35,221 shares that had been available for future
awards under the 2008 Plan as of June 18, 2014, were added to the initial reserve available under the 2014 Plan, bringing the total
reserve upon the effective date of the 2014 Plan to 1,454,549. The number of shares initially reserved for issuance or transfer pursuant
to awards under the 2014 Plan will be increased by (i) the number of shares represented by awards outstanding under 2008 Plan on
June 18, 2014, that are either forfeited or lapse unexercised or that are repurchased for the original purchase price thereof, up to a
maximum of 1,153,279 shares, and (ii) if approved by the Administrator of the 2014 Plan, an annual increase on the first day of each
fiscal year ending in 2024, equal to the lesser of (A) four percent (4.0%) of the shares of stock outstanding (on an as converted basis)
on the last day of the immediately preceding fiscal year and (B) such smaller number of shares of stock as determined by our board of
directors; provided, however, that no more than 10,683,053 shares of stock may be issued upon the exercise of incentive stock options.
Effective January 1, 2015, the 2014 Plan share reserve was increased by 743,569 shares.
Stock Plan Activity
The following table summarizes activity under the 2008 Plan and the 2014 Plan, including grants to nonemployees and
restricted stock issued:
Options Issued and
Outstanding
Shares
Available for
Grant
Number of Shares
Weighted- Average
Exercise Price per
Share
Aggregate
Intrinsic Value
(in thousands)
Balances at December 31, 2011 .........................
Options authorized ....................................
Options granted .........................................
Options exercised .....................................
Options canceled .......................................
Balance at December 31, 2012 ...........................
Options granted .........................................
Options exercised .....................................
Options canceled .......................................
Balance at December 31, 2013 ...........................
Options authorized ....................................
Options granted .........................................
Options exercised .....................................
Options canceled .......................................
Options repurchased .................................
Issuance of common stock for services ....
Balance at December 31, 2014 ...........................
Vested and expected to vest at December 31,
2014 ...............................................................
Vested at December 31, 2014 ............................
19,798
114,428
(81,233)
—
43,848
96,841
(99,552)
—
6,625
3,914
1,452,661
(188,888)
—
4,084
3,511
(10,000)
1,265,282
$
$
$
1,598,513
—
81,233
(342,131)
(43,848)
1,293,767
99,552
(223,865)
(6,625)
1,162,829
—
188,888
(336,398)
(4,084)
(3,511)
—
1,007,724
$
990,889
$
643,217 $
0.57
3.46
0.52
0.52
0.77
3.42
0.56
2.23
1.03
24.41
0.71
2.21
0.55
—
5.51 $
5.27 $
1.21 $
14,839
14,746
11,376
The weighted-average grant-date estimated fair value of options granted during the years ended December 31, 2014, 2013 and
2012 was $18.53, $2.68 and $2.56 per share. The aggregate intrinsic value was calculated as the difference between the exercise price
of the options and the estimated fair value of the Company’s common stock of $18.89 per share as of December 31, 2014.
93
2014 Employee Stock Purchase Plan
The Company adopted the 2014 Employee Stock Purchase Plan (ESPP) and initially reserved 202,762 shares of common stock
as of its effective date of June 18, 2014. If approved by the Administrator of the ESPP, on the first day of each calendar year, ending
in 2024, the number of shares in the reserve will increase by an amount equal to the lesser of (i) one percent (1.0%) of the shares of
common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of common stock as
determined by the board of directors; provided, however, no more than 2,230,374 shares of our common stock may be issued under
the ESPP. Effective January 1, 2015, the ESPP share reserve was increased by 185,892. Under the ESPP, participants are offered the
option to purchase shares of the Company’s common stock at a discount during a series of successive offering periods normally
commencing on March 1 and September 1 of each year. The initial offering period commenced on September 1, 2014 and will end on
February 27, 2015.
As of December 31, 2014, no shares of common stock have been issued to employees participating in the ESPP and 202,762
shares were available for issuance under the ESPP.
The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in
determining the fair value of ESPP purchase rights granted to employees:
Expected term (years) ....................................................
Volatility .......................................................................
Risk-free interest rate ....................................................
Dividend yield ...............................................................
Year Ended
December 31, 2014
0.5
73 %
0.05 %
— %
Liability for Early Exercise of Stock Options
As of December 31, 2014 and 2013, there were zero and 286,217 shares of common stock outstanding, respectively, subject to
the Company’s right of repurchase at prices ranging from $0.27 to $1.08 per share. As of December 31, 2014 and 2013, the Company
recorded zero and $0.2 million, respectively, as liabilities associated with shares issued with repurchase rights.
Modification of Stock Awards
During September 2014, the Company entered into a Transition and Separation Agreement with its Chief Scientific Officer,
Dominique Charmot, under which certain restricted shares that were subject to vesting and repurchase by the Company have become
fully vested as of Dr. Charmot’s separation from the Company as an employee and director on December 23, 2014. This resulted in
the acceleration of the vesting for 58,969 shares of restricted stock. As a result of the acceleration, the Company has recorded a stock-
based compensation charge of $0.8 million during the year ended December 31, 2014 to reflect the revised service period for the
restricted stock and related vesting of shares that would otherwise not have vested.
Stock-based Compensation
Total stock-based compensation recognized was as follows (in thousands):
Research and development ............................................. $
General and administrative .............................................
Total stock-based compensation ........................... $
1,376
316
1,692
$
$
200 $
152
352 $
221
252
473
2014
Year Ended December 31,
2013
(in thousands)
2012
As of December 31, 2014, there was $3.2 million of unrecognized stock-based compensation expense, net of estimated
forfeitures, related to unvested share options with a weighted-average remaining recognition period of 2.3 years.
94
In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and
assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.
Expected Term— The Company’s expected term represents the period that the Company’s stock-based awards are expected to
be outstanding. The Company used the simplified method to determine the expected term, which is calculated as the average of
the time-to-vesting and the contractual life of the options.
Expected Volatility— The Company was privately held prior to its IPO in June 2014 and thus a sufficient trading history does
not exist for the Company’s common stock. The expected volatility was estimated based on the average volatility for
comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants.
When selecting comparable publicly traded biopharmaceutical companies on which it has based its expected stock price
volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles,
position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based
awards. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the
equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process
until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.
Risk-Free Interest Rate— The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of
grant for periods corresponding with the expected term of option.
Expected Dividend— The Company has never paid dividends on its common stock and has no plans to pay dividends on its
common stock. Therefore, the Company used an expected dividend yield of zero.
The fair value of stock option awards to employees was estimated at the date of grant using a Black-Scholes option-pricing
model with the following weighted-average assumptions:
Expected term (years) ....................................................
Volatility ........................................................................
Risk-free interest rate .....................................................
Dividend yield ...............................................................
5.97
94%
1.79%
—%
6.07
98 %
1.35 %
— %
5.73
97%
0.79%
—%
2014
Year Ended December 31
2013
2012
The weighted-average, estimated grant-date fair value of employee stock options granted during the years ended December 31,
2014, 2013 and 2012 was $18.57, $2.68 and $2.56 per share, respectively.
Options Granted to Nonemployees
The Company has granted options to purchase shares of common stock to consultants in exchange for services performed.
The Company granted options to purchase 10,000 and 3,333 shares with average exercise prices of $20.77 and $3.43 per share,
respectively, during the years ended December 31, 2014 and 2013, respectively. These options vest upon grant or various terms up to
three years. The Company recognized non-employees stock compensation expense of $0.1 million, $2,000 and zero during the years
ended December 31, 2014, 2013 and 2012, respectively. The fair value of non-employees’ options was measured using the Black-
Scholes option-pricing model reflecting the same assumptions as applied to employee options in each of the reported years, other than
the expected life, which is assumed to be the remaining contractual life of the option.
Issuance of Common Stock for Services
During the year ended December 31, 2014, the Company issued 10,000 shares of common stock to consultants in exchange for
services performed. The shares issued were valued at $0.2 million based on the fair value of the common stock on the date of grant.
95
9. Income Taxes
The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate:
Expected income tax provision at the federal statutory
rate ............................................................................
State taxes, net of federal benefit ...................................
Change in valuation allowance ......................................
Nondeductible expenses ................................................
Tax credits .....................................................................
Other ..............................................................................
Income tax provision .....................................................
2014
Year Ended December 31,
2013
2012
35.0%
4.6
(17.9)
(20.6)
—
(3.2)
(2.1)%
35.0 %
(1.4 )
(22.6 )
(20.8 )
7.3
0.3
(2.2 )%
35.0%
—
(38.6)
(5.2)
4.4
4.4
—%
Significant components of the Company’s deferred tax assets are as follows:
Deferred tax assets:
Net operating loss carryforwards .......................................... $
Deferred revenue ...................................................................
Research credits ....................................................................
Other .....................................................................................
Gross deferred tax assets .......................................................
Valuation allowance .............................................................
Total deferred tax assets .......................................................
Deferred tax liabilities ..........................................................
Net deferred tax assets .......................................................... $
December 31,
2014
2013
(in thousands)
$
11,262
11,099
1,260
1,201
24,822
(24,741)
81
(81)
— $
13,069
9,723
1,734
475
25,001
(25,001 )
—
—
—
Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which are uncertain.
Accordingly, the deferred tax assets have been fully offset by a valuation allowance. The valuation allowance decreased by $0.3
million for the year ended December 31, 2014. The valuation allowance increased by $1.5 million for the year ended December 31,
2013.
At December 31, 2014, the Company had net operating loss carryforwards for federal income tax purposes of approximately
$28.0 million that expire beginning in 2028 if not utilized, and federal research and development tax credit carryforwards of
approximately $2.1 million that expire beginning in 2029 if not utilized. In addition, the Company had net operating loss
carryforwards for state income tax purposes of approximately $25.6 million that expire beginning in 2018 if not utilized, and state
research and development tax credit carryforwards of approximately $2.3 million, which do not expire.
The future utilization of the net operating loss and tax credit carryforwards and credits may be subject to an annual limitation,
pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that may have occurred previously or that
could occur in the future. Due to the existence of the valuation allowance, future changes under Sections 382 and 383 will not impact
the Company’s effective tax rate.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
2014
December 31,
2013
(in thousands)
2012
Balance at beginning of year .......................................... $
Additions based on tax positions related to prior year ....
Additions based on tax positions related to current year ..
Balance at end of year .................................................... $
96
1,411
$
405
999
2,815
$
1,064 $
—
347
1,411 $
807
—
257
1,064
The unrecognized tax benefits, if recognized and in absence of full valuation allowance, would impact the income tax provision
by $2.8 million, $1.4 million and $1.1 million as of December 31, 2014, 2013 and 2012, respectively.
The Company has elected to include interest and penalties as a component of tax expense. During the years ended December 31,
2014, 2013 and 2012, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. Although the
timing and outcome of income tax audit is highly uncertain, the Company does not anticipate that the amount of existing unrecognized
tax benefits will significantly change during the next 12 months.
The Company files income tax returns in the U.S. federal and California tax jurisdictions. Due to the Company’s net operating
loss and tax credit carryforwards, the income tax returns remain open to U.S. federal and California state tax examinations. The
Company is not currently under examination in any tax jurisdiction.
10. Net Loss per Share
Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during
the period, less shares subject to repurchase, and excludes any dilutive effects of share-based awards and warrants. Diluted net loss per
common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of
stock options, and unvested restricted common stock and stock units. As the Company had net losses for the years ended
December 31, 2014, 2013 and 2012, all potential common shares were determined to be anti-dilutive.
The following table sets forth the computation of net loss per common share (in thousands, except share and per share amounts):
Numerator:
Net loss ................................................................. $
(3,214) $
(6,564 ) $
(9,785)
2014
December 31,
2013
2012
Denominator:
Weighted average number of shares
outstanding—basic and diluted ........................
10,248,337
1,127,948
Net loss per share—basic and diluted ............................. $
(0.31) $
(5.82 ) $
864,020
(11.32)
Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive
were as follows:
Convertible preferred stock ............................................
Options to purchase common stock ................................
Warrants to purchase convertible preferred stock ..........
Total ................................................................................
2014
—
1,007,724
—
1,007,724
December 31,
2013
11,517,222
1,162,829
574,953
13,255,004
2012
11,517,222
1,293,767
574,953
13,385,942
11. Related Party Transactions
As part of the consulting arrangement with the spouse of an executive of the Company to provide research and development
services related to clinical operations, the Company incurred expenses of $0.2 million for services rendered during each of the years
ended December 31, 2014 and 2013, and $0.1 million for services rendered during the year ended December 31, 2012, respectively.
12. Commitments and Contingencies
The Company has a lease agreement for a facility in Fremont, California that was amended in December 2012 to extend the
lease agreement to September 2016. In September 2014, the Company signed the second amendment to its facility lease agreement in
Fremont, California to add space and to extend the lease term through September 2019. In addition, the amended lease agreement
provides for a tenant improvement allowance of up to $0.6 million. The extended lease has rent escalation clauses through the lease
term. Rent increases, including the impact of a rent holiday and leasehold improvement allowance from the landlord, will be
recognized as deferred rent and amortized on a straight-line basis over the term of the lease.
97
Under the terms of the lease agreement, the Company provided the lessor with a security deposit in the amount of $0.1 million.
The lessor shall be entitled to draw on the security deposit in the event of any uncured default by the Company under the terms of the
lease.
The future minimum payments under the noncancelable operating lease at December 31, 2014, are as follows (in thousands):
Year ending December 31,
2015........................................................................................ $
2016........................................................................................
2017........................................................................................
2018........................................................................................
2019........................................................................................
Total .............................................................................. $
Amounts
843
868
895
921
653
4,180
Rent expense under operating leases was $0.6 million, $0.5 million and $0.4 million for the years ended December 31, 2014,
2013 and 2012, respectively.
The Company entered into a series of purchase commitments for research and development equipment at December 31, 2014
totaling $0.7 million, all of which will be due within the next year. The Company has capital expenditure commitments for $1.2
million related to expansion of office space.
Guarantees and Indemnifications
As permitted under Delaware law and in accordance with the Company’s bylaws, the Company indemnifies its officers and
directors for certain events or occurrences while the officer or director is or was serving in such capacity. The maximum amount of
potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This
insurance allows the transfer of the risk associated with the Company’s exposure and may enable it to recover a portion of any future
amounts paid. The Company may terminate the indemnification agreements with its officers and directors upon a 90-day written
notification, but termination will not affect claims for indemnification related to events occurring prior to the effective date of
termination. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not
recorded any liabilities associated with these indemnification agreements as of December 31, 2014 or 2013.
13. Selected Quarterly Financial Data (Unaudited)
Selected quarterly financial results from operations for the years ended December 31, 2014 and 2013 are as follows (in
thousands, except per share amounts):
2014 Quarter End
March 31,
June 30
Total revenue ............................................................ $
Operating expenses ..................................................
Net income (loss) .....................................................
Net income (loss) per share:
Basic ......................................................
Diluted ...................................................
8,550 $
9,014
(3,071)
(2.44)
(2.44)
March 31,
June 30
Total revenue ............................................................ $
Operating expenses ..................................................
Net loss .....................................................................
Basic and diluted net loss per common share ...
6,556 $
6,966
(470)
(0.45)
14. Subsequent Events
None.
98
September 30 December 31
6,338
7,598 $
10,270
7,517
(3,970)
74
9,137 $
6,386
3,753
0.20
0.18
—
—
(0.21)
(0.21)
2013 Quarter End
September 30 December 31
8,488
6,593 $
9,206
7,479
(4,269)
(934 )
(3.53)
(0.81 )
7,291 $
8,142
(891)
(0.81)
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
None.
Item 9A. Controls and Procedures.
Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures
As of December 31, 2014, management, with the participation of our Chief Executive Officer and Chief Financial Officer,
performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules
13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required
to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the
time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and
communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions
regarding required disclosures.
Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the
desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible
controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of
December 31, 2014, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.
Management’s Annual Report on Internal Control Over Financial Reporting
This Annual Report on Form 10-K does not include a report of management’s assessment regarding internal control over
financial reporting due to a transition period established by rules of the Securities and Exchange Commission for newly public
companies.
Attestation Report of the Registered Public Accounting Firm
This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm due to an
exemption established by the JOBS Act for “emerging growth companies.”
Item 9B. Other Information.
None.
99
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
Information required by this item will be contained in our definitive proxy statement to be filed with the Securities and
Exchange Commission on Schedule 14A in connection with our 2015 Annual Meeting of Stockholders (the “Proxy Statement”),
which will be filed not later than 120 days after the end of our fiscal year ended December 31, 2014, under the headings “Executive
Officers,” “Election of Directors,” “Corporate Governance,” and “ Section 16(a) Beneficial Ownership Reporting Compliance,” and is
incorporated herein by reference.
We have adopted a Code of Business Conduct and Ethics that applies to our officers, directors and employees which is available
on our website at www.ardelyx.com. The Code of Business Conduct and Ethics is intended to qualify as a “code of ethics” within the
meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K. In addition, we intend to promptly
disclose (1) the nature of any amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer,
principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any
waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name
of such person who is granted the waiver and the date of the waiver on our website in the future.
Item 11. Executive Compensation.
The information required by this item regarding executive compensation will be incorporated by reference to the information set
forth in the sections titled “Executive Compensation” in our Proxy Statement.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The information required by this item regarding security ownership of certain beneficial owners and management will be
incorporated by reference to the information set forth in the section titled “Security Ownership of Certain Beneficial Owners and
Management” and “Equity Compensation Plan Information” in our Proxy Statement.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
The information required by this item regarding certain relationships and related transactions and director independence will be
incorporated by reference to the information set forth in the sections titled “Certain Relationships and Related Party Transactions” and
“Election of Directors”, respectively, in our Proxy Statement.
Item 14. Principal Accounting Fees and Services.
The information required by this item regarding principal accountant fees and services will be incorporated by reference to the
information set forth in the section titled “Principal Accountant Fees and Services” in our Proxy Statement.
100
PART IV
Item 15. Exhibits, Financial Statement Schedules.
(a) The following documents are filed as part of this report:
1.
Financial Statements
See Index to Financial Statements at Item 8 herein.
2.
Financial Statement Schedules
All schedules are omitted because they are not applicable or the required information is shown in the financial
statements or notes thereto.
3.
Exhibits
See the Exhibit Index immediately following the signature page of this Annual Report on Form 10-K.
101
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Date: March 5, 2015
By: /s/ Michael Raab
Ardelyx, Inc.
Michael Raab
President Chief Executive Officer and Director
(Principal Executive Officer)
POWER OF ATTORNEY
Each person whose individual signature appears below hereby authorizes and appoints Michael Raab and Mark Kaufmann, and
each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful
attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person,
individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the
same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing,
ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully
do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons
on behalf of the registrant and in the capacities and on the dates indicated.
Signature
/s/ Michael Raab
Michael Raab
/s/ Mark Kaufmann
Mark Kaufmann
/s/ Narani Arasaratnam
Narani Arasaratnam
/s/ David Mott
David Mott
/s/ Gordon Ringold
Gordon Ringold, Ph.D.
/s/ Richard Rodgers
Richard Rodgers
/s/ Peter Schultz, Ph.D.
Peter Schultz, Ph.D.
Title
President, Chief Executive Officer and Director
(Principal Executive Officer)
Chief Financial Officer
(Principal Financial Officer)
VP, Corporate Controller
(Principal Accounting Officer)
Date
March 5, 2015
March 5, 2015
March 5, 2015
Chairman of the Board of Directors
March 5, 2015
Director
Director
Director
March 5, 2015
March 5, 2015
March 5, 2015
102
Exhibit Index
Exhibit
Number
3.1
3.2
4.1
4.2
Exhibit Description
Amended and Restated Certificate of Incorporation.
Amended and Restated Bylaws.
Reference is made to exhibits 3.1 and 3.2.
Form of Common Stock Certificate.
10.1(a)†
License Agreement, dated as of October 4, 2012, by and among
AstraZeneca AB and Ardelyx, Inc.
Incorporated by Reference
Form
Date
Number
Filed
Herewith
8-K
6/24/2014
8-K
6/24/2014
3.1
3.2
S-1/A 6/18/2014
4.2
S-1/A
6/5/2014
10.1(a)
10.1(b)† Amendment Number One to License Agreement, dated as of
S-1/A
6/5/2014
10.1(b)
December 23, 2013, by and between AstraZeneca AB and Ardelyx, Inc.
10.2†
10.3
License and Option Agreement, dated February 21, 2014, by and between
Sanofi and Ardelyx, Inc.
S-1/A
6/5/2014
10.2
Amended and Restated Investor’s Rights Agreement dated June 23, 2011,
by and among Ardelyx, Inc. and the investors listed therein.
S-1
5/19/2014
10.3
10.4(a)
Lease, dated August 8, 2008, by and between 34175 Ardenwood Venture,
LLC and Ardelyx, Inc.
S-1
5/19/2014
10.4(a)
10.4(b)
Amendment to Lease, dated December 20, 2012, by and between 34175
Ardenwood Venture, LLC and Ardelyx, Inc.
S-1
5/19/2014
10.4(b)
10.4(c)
Second Amendment to Lease, dated September 5, 2014, by and between
Ardelyx, Inc. and 34175 Ardenwood Venture, LLC.
8-K
9/9/2014
10.1
10.5(a)# Ardelyx, Inc. 2008 Stock Incentive Plan, as amended.
S-1
5/19/2014
10.5(a)
10.5(b)#
Form of Stock Option Grant Notice and Stock Option Agreement under the
2008 Stock Incentive Plan, as amended.
S-1
5/19/2014
10.5(b)
10.5(c)#
Form of Restricted Stock Purchase Grant Notice and Restricted Stock Purchase
Agreement under the 2008 Stock Incentive Plan, as amended.
S-1
5/19/2014
10.5(c)
10.6(a)#
Ardelyx, Inc. 2014 Equity Incentive Award Plan.
S-8
7/14/2014
99.3
10.6(b)#
Form of Stock Option Grant Notice and Stock Option Agreement
under the 2014 Equity Incentive Award Plan.
S-1/A 6/18/2014
10.6(b)
10.6(c)#
Form of Restricted Stock Award Agreement and Restricted Stock
Unit Award Grant Notice under the 2014 Equity Incentive Award Plan.
S-1/A 6/18/2014
10.6(c)
10.7#
Form of Indemnification Agreement for directors and officers.
S-1/A
6/9/2014
10.7
10.8#
10.9#
Amended and Restated Executive Employment Agreement, dated
June 6, 2014, by and between Ardelyx, Inc. and Michael Raab.
S-1/A
6/9/2014
10.8
Amended and Restated Change in Control Severance Agreement,
dated June 6, 2014, by and between Ardelyx, Inc. and Mark Kaufmann.
S-1/A
6/9/2014
10.15
103
Exhibit
Number
10.10#
10.11#
10.12#
10.13#
10.14#
10.15#
10.16#
10.17#
10.18#
10.19#
10.20#
10.21#
10.22#
10.23#
Exhibit Description
Amended and Restated Change in Control Severance Agreement,
dated June 6, 2014, by and between Ardelyx, Inc. and Elizabeth Grammer,
Esq.
Incorporated by Reference
Form
Date
Number
Filed
Herewith
S-1/A
6/9/2014
10.16
Amended and Restated Change in Control Severance Agreement,
dated June 6, 2014, by and between Ardelyx, Inc. and Jeffrey Jacobs, Ph.D.
S-1/A
6/9/2014
10.17
Amended and Restated Change in Control Severance Agreement,
dated June 6, 2014, by and between Ardelyx, Inc. and George Jue.
S-1/A
6/9/2014
10.18
Amended and Restated Change in Control Severance Agreement,
dated June 6, 2014, by and between Ardelyx, Inc. and David Rosenbaum,
Ph.D.
S-1/A
6/9/2014
10.19
Transition and Separation Agreement dated September 4, 2014, by and
between
Ardelyx, Inc. and Dominique Charmot, Ph.D.
8-K
9/9/2014
10.2
Offer Letter, dated August 11, 2011, by and between Ardelyx, Inc. and Mark
Kaufmann.
S-1/A
6/9/2014
10.10
Offer Letter, dated May 21, 2008, by and between Ardelyx, Inc. and George
Jue.
S-1/A
6/9/2014
10.11
Offer Letter, dated May 2, 2008, by and between Ardelyx, Inc. and Jeff
Jacobs, Ph.D.
S-1/A
6/9/2014
10.12
Offer Letter, dated December 28, 2009, by and between Ardelyx, Inc. and
David Rosenbaum, Ph.D.
S-1/A
6/9/2014
10.13
Offer Letter, dated November 21, 2012, by and between Ardelyx, Inc. and
Elizabeth Grammer, Esq.
S-1/A
6/9/2014
10.14
Offer Letter, dated October 15, 2014, by and between Ardelyx, Inc. and
Narani Arasaratnam.
Change in Control Severance Agreement, dated November 26, 2014, by and
Between Ardelyx, Inc. and Narani Arasaratnam.
Offer Letter, dated November 21, 2014, by and between Ardelyx, Inc. and
Jeremy S. Caldwell, Ph.D.
Change in Control Severance Agreement, dated December 19, 2014, by and
between Ardelyx, Inc. and Jeremy S. Caldwell, Ph.D.
10.24#
Ardelyx, Inc. 2014 Employee Stock Purchase Plan.
S-8
7/14/2014
99.6
10.25#
Non-Employee Director Compensation Program.
S-1/A
6/9/2014
10.21
23.1
Consent of Ernst & Young LLP, Independent Registered Public
Accounting Firm
104
X
X
X
X
X
Exhibit Description
Incorporated by Reference
Form
Date
Number
Filed
Herewith
Exhibit
Number
31.1
31.2
32.1
Certification of Principal Executive Officer Required Under Rule 13a-14(a)
and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
Certification of Principal Financial Officer Required Under Rule 13a-14(a) and
15d-14(a) of the Securities Exchange Act of 1934, as amended.
Certification of Principal Executive Officer and Principal Financial Officer
Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as
amended, and 18 U.S.C §1350.
101.INS
XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Taxonomy Extension Label Linkbase Document
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
X
X
X
X
X
X
X
X
X
†
#
Confidential treatment granted as to portions of this Exhibit. The confidential portions of this Exhibit have been omitted and
are marked by asterisks.
Indicates management contract or compensatory plan.
105
CERTIFICATION
Exhibit 31.1
I, Michael Raab, certify that:
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10-K of Ardelyx, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the
periods presented in this report;
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the small business issuer, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;
(b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and
(c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons
performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial
information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting.
Date: March 5, 2015
By:
/s/ Michael Raab
Name
Michael Raab
President Chief Executive Officer and Director
(Principal Executive Officer)
Exhibit 31.2
I, Mark Kaufmann, certify that:
CERTIFICATION
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10-K of Ardelyx, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the
periods presented in this report;
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the small business issuer, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;
(b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and
(c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons
performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial
information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting.
Date: March 5, 2015
By:
/s/ Mark Kaufmann
Name
Mark Kaufmann
Chief Financial Officer
(Principal Financial Officer)
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32.1
In connection with the Annual Report of Ardelyx, Inc. (the “Company”) on Form 10-K for the period ending December 31,
2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Michael Raab, President and Chief
Executive Officer of the Company, and Mark Kaufmann, Chief Financial Officer of the Company, respectively, do each hereby
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of
operations of the Company.
Date: March 5, 2015
Date: March 5, 2015
By:
By:
/s/ Michael Raab
Name
Michael Raab
President Chief Executive Officer and Director
(Principal Executive Officer)
/s/ Mark Kaufmann
Name
Mark Kaufmann
Chief Financial Officer
(Principal Financial Officer)
[THIS PAGE INTENTIONALLY LEFT BLANK]
[THIS PAGE INTENTIONALLY LEFT BLANK]